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Abstract 
 
Colorectal cancer (CRC) is the fourth most common cancer in the United Kingdom. For 
males and females combined, it is the second most common cause of cancer death in the UK. 
The majority of CRC develops as a result of malignant transformation of adenomas via the 
adenoma-carcinoma sequence. Firm evidence exists that bowel screening, colonoscopy, and 
polypectomy results in a reduction of CRC incidence and death. An understanding of the 
association between both adenoma-specific and host characteristics, on the incidence and 
recurrence of colorectal neoplasia, is necessary to target finite colonoscopy resources, 
enhance post-polypectomy surveillance guidelines and reduce CRC incidence. An improved 
understanding of the host mechanisms underpinning the early and pre-malignant stage of 
CRC could encourage the development of targeted intervention strategies aimed at reducing 
the primary incidence, post-polypectomy recurrence, and progression of colorectal 
adenomas to cancer. Notably, bowel screening is now understandably an integral part of the 
strategy to reduce CRC incidence and mortality, mainly by intervention at the pre-malignant 
stage. However, it must be ensured that several inherent risks of screening are considered, 
especially in the era of CT colonography (CTC), where the entire abdomen is imaged, 
resulting in the identification of extracolonic findings.  
Chapter 1 presents an overview of CRC, including the risk factors, treatment, and 
determinants of prognosis and outcome. This is followed by an outline of the process, 
evidence for, risks, benefits, and outcomes of CRC screening in Scotland. Finally, a detailed 
summary of the potential risk factors, natural history, management, and surveillance 
strategies relating to colorectal adenomatous polyps is presented.  
Chapter 2 presents findings from a systematic review and meta-analysis using pooled, raw 
data with regards to post-polypectomy colorectal adenoma recurrence. The work found that 
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age ≥60 years, OR 1.56 [95% CI; 1.13-2.14, p<0.01], male sex, OR 1.58 [95% CI; 1.42-
1.76, p<0.001] and BMI ≥25, OR 1.35 [95% CI; 1.14-1.58, p<0.001] were associated with 
post-polypectomy adenoma recurrence. The work concluded that these host factors could be 
considered for inclusion in post-polypectomy surveillance guidelines. 
Chapter 3 presents original data from the Scottish Bowel Screening Programme (SBoSP). 
An examination was undertaken of the association between adenoma-specific and host 
characteristics, on subsequent adenoma recurrence post-polypectomy in intermediate and 
high-risk bowel screening patients. The work reported that in high-risk groups, 50% of 
patients were found to have adenoma recurrence at follow-up, and a third of these patients 
harbour advanced adenomas. The work also demonstrates that although host characteristics, 
other than male sex, were not associated with adenoma recurrence, a higher baseline 
adenoma number was associated with the finding of subsequent adenomas at follow-up (OR 
2.23 [95% CI; 1.53-3.25, p<0.001] and 4.19 [9% CI; 2.53-6.97, p<0.001], for 3–4 and ≥5 vs. 
1–2 adenomas at baseline respectively). While elevated adenoma number at baseline did not 
increase the risk of subsequent advanced adenomas at follow-up, the presence of advanced 
adenomas at baseline was itself a risk for subsequent advanced adenomas, OR 2.34 [95% 
CI; 1.18-4.61, p<0.05]. This chapter concluded that adenoma-specific factors are superior to 
host characteristics in predicting future risk for bowel screening patients. On that basis, 
additional work is required to explore the adenoma further at a genetic level, while additional 
adenoma-specific factors, other than solely size, should be considered for inclusion in post-
polypectomy surveillance guidelines. 
Chapter 4 presents original, prospectively collected data, from patients attending for 
colonoscopy as part of the SBoSP. In contrast to Chapter 2 and Chapter 3, which focussed 
on secondary prevention (post-polypectomy) of colorectal adenomas, Chapter 4 focussed 
on primary prevention. The association between host characteristics, systemic inflammation, 
and colorectal neoplasia incidence at bowel screening was examined.  The work reported 
 4 
 
that obesity, adjusted OR 2.72 [95% CI; 1.35–5.49, p<0.01], smoking, OR 2.26 [95% CI; 
1.33-3.84, p<0.01] and aspirin use, OR 2.59 [95% CI; 1.15-5.86, p<0.05] were associated 
with a systemic inflammatory response. Despite this, none of the host factors were associated 
with an increased risk of incident colorectal neoplasia, while aspirin was associated with 
reduced risk, OR 0.51 [95% CI; 0.29–0.89, p<0.05] when adjusting for age, sex and 
smoking. The work concluded that while several host factors are associated with systemic 
inflammation, a direct link between these host factors, systemic inflammation and incident 
colorectal neoplasia remains unclear. It also concluded that BMI might be an inferior 
measure with which to study the effects of adiposity on colorectal neoplasia incidence, and 
suggested more precise measures of body composition could be used to explore the 
relationship further. 
Chapter 5 presents original data collected from patients undergoing CTC as part of the 
SBoSP. The association between CT derived body composition and colorectal neoplasia 
incidence was examined. The work concludes that; similar to Chapter 4, BMI was not useful 
in predicting the risk of colorectal neoplasia, but the presence of visceral obesity was 
strongly associated with neoplasia incidence, adjusted OR 2.79 [95% CI; 1.48-5.25, p<0.01]. 
In addition, no association was found between the presence of sarcopenia and early, largely 
pre-malignant disease. The chapter concluded that targeted interventions specifically for 
visceral obesity, and further investigation into the mechanism for its association with 
neoplastic findings should be sought. Moreover, a further examination into the role of 
sarcopenia and its development between the pre-malignant and malignant stage of CRC is 
required. 
Chapter 6 presents original data collected from patients undergoing CTC as part of the 
SBoSP with a focus on the risks of bowel screening, where CTC is increasingly being 
utilised. Original data are reported on the incidence, risk factors for, cost and implications 
of both colorectal (CRF) and incidental extracolonic findings (ECF) at CTC conducted as 
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part of the SBoSP. The work reported that ECFs were very common in the bowel screening 
cohort (62% of patients) and that the subsequent additional yield of useful CRF (11%) from 
completion CTCs was lower than the incidence of important ECFs (15%). The majority of 
ECFs that required further investigation were subsequently benign (63%), and as a result of 
the investigation process, there was an additional estimated cost of £45 per CTC. The work 
concluded that while CTC remains a useful adjunct for screening programmes, it should be 
utilised with caution. Both the clinician and patient must have an awareness of the additional 
risk, cost and implications of a test designed to investigate the colon and rectum, which may 
have a higher yield of ECFs than important CRFs. 
Chapter 7 summarises the main findings presented in the thesis, provides a relevant update 
on newly published work during the thesis preparation period and suggests some 
recommendations for future study.
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1  INTRODUCTION 
1.1 Colorectal cancer 
1.1.1 Epidemiology 
Cancer is common, with 17 million new cases and 9.6 million deaths worldwide per year 
(1). Over 1.8 million new colorectal cancer (CRC) cases are estimated to occur each year, 
with 880,000 deaths (2). CRC is most common in the developed world with the highest 
incidence in Europe, North America, New Zealand and Australia (3). 
CRC is the fourth most common cancer in the United Kingdom (UK), with around 20,000 
new cases each year[Figure 1.1] (1). It accounts for 12% of all UK cancer cases (1). It is the 
third most common cancer in males after prostate and lung and similarly in females after 
breast and lung cancer (1).  
Figure 1.1: The 20 most common cancers in the UK 
 
 
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
Reproduced with permission from Cancer Research UK (1) 
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CRC is predominantly a disease of older age with a steep rise in incidence from around 50–
54 years, the highest rates being in those aged 85–89 years (1). 
The overall Incidence of CRC in the UK is 70 per 100,000 people (1), it is more common in 
males than females, with an incidence of 85 and 57 cases per 100,000, respectively (1). Over 
the last decade, CRC incidence rates combined for males and females, have stabilised and 
are projected to fall in the UK by 11% from 2014–2035, with a steeper fall in males [Figure 
1.2]. A similar pattern has been observed in other developed countries such as the United 
States of America (USA), Australia, New Zealand, and some Western European countries. 
Although the reason for this trend is not entirely apparent, it likely multifactorial while 
reflecting a move towards early and pre-malignant diagnosis through screening, 
colonoscopy and polypectomy (4). 
In a similar manner to incidence, CRC mortality for males and females combined has fallen 
by 14% over the last decade with a more significant decline in males than females (17% and 
12% respectively) [Figure 1.3] (1).  
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Figure 1.2: Observed and projected age-standardised rate (ASR) for colorectal cancer 
incidence by sex in the UK from 1979-2035 
 
 
Reproduced with permission from Cancer Research UK (1) 
 
Figure 1.3: Mortality rate per 100,000 population in the UK from 1971-2016 
 
 
Reproduced with permission from Cancer Research UK (1)
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1.1.2 Risk factors 
CRC develops through genetic mutations that accumulate over a prolonged period of time. 
The majority of CRCs arise sporadically and develop through a complex interaction of 
genetic, host and environmental factors. In contrast to other cancers, such as lung cancer, no 
single risk factor accounts for the majority of cases. Nevertheless, a number of modifiable 
and non-modifiable risk factors have been identified through epidemiological studies. Each 
is associated with a varying degree of risk. Risk factors can be grouped into four main 
categories: 
1. Socioeconomic and sociodemographic factors 
2. Medical factors 
3. Lifestyle factors 
4. Dietary factors 
 
As a general rule, sociodemographic factors are non-modifiable, such as age and sex. 
However, lifestyle, dietary, and some medical factors can be modified to minimise cancer 
incidence. 
1.1.2.1 Socioeconomic and sociodemographic factors 
Advancing age 
As outlined in Section 1.1.1, CRC is a disease predominantly of older age with the steepest 
rise in those aged between 50–54 years and peaking at 85–89 years (1). 
Male sex  
As mentioned in Section 1.1.1, CRC has a male preponderance, although the incidence is 
falling at a higher rate than in females (1). Both advancing age and male sex are risk 
factors that cannot be modified, yet the mechanism by which these factors increase CRC 
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incidence, if identified, could be modifiable. Thus it is plausible that non-modifiable risk 
factors, in effect, could become modifiable. 
Socioeconomic deprivation 
Several definitions of socioeconomic deprivation exist. In short, deprivation is present when 
a population lacks the type of clothing, housing, diet, educational, and working conditions 
that are customary or could be expected in a reasonable society (5). Recent evidence has 
shown that deprivation is associated with increased CRC risk. Interestingly, this trend may 
be more pronounced in males. A study in the West of Scotland reported that males who were 
least deprived had a 20% lower incidence of CRC than males classed in the most deprived 
categories (6). 
The explanation for this is not entirely clear and again, likely to be multifactorial. It is 
plausible that deprivation may increase greater exposure to some modifiable risk factors such 
as cigarette smoking, higher alcohol intake and poor diet (6).  
1.1.2.2 Medical conditions, drugs and inflammation 
Family history 
It is generally accepted that CRC is associated with a family history in around a quarter of 
cases, indicating a likely heritable component (7). The distinction between heritable and 
hereditary or inherited is important. Heritability refers to the magnitude with which a 
person's genetic makeup affects their risk of CRC (8). Twin studies are often used to quantify 
the heritable effect, where identical and non-identical twins who may or may not be exposed 
to the same environmental factors can be compared. Using this concept, a study in the New 
England Journal of Medicine in 2000 concluded that the development of CRC has a 
significant heritable component of approximately 35% (8).  
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Hereditary refers to CRC that is associated with specific inherited genetic abnormalities 
leading to syndromes such as familial adenomatous polyposis (FAP) and Hereditary Non 
Polyposis Colorectal Cancer (HNPCC), also known as Lynch syndrome. It is believed that 
up to 5% of CRC cases are related to hereditary syndromes (9). These syndromes are 
discussed further in Section 1.1.3.  
Furthermore, having a first degree relative with CRC (sibling, child, parent), for whatever 
reason, more than doubles the risk of a person being diagnosed subsequently with CRC (10). 
The risk is elevated further if a person with a first degree relative with the disease has more 
than one affected relative or a relative who was diagnosed at a younger age (11). 
Inflammatory bowel disease 
Inflammatory bowel disease (IBD) refers mainly to ulcerative colitis (UC) and Crohn’s 
disease. Only 1% of all cases of CRC are diagnosed in patients with UC. Thus, although UC 
does not contribute excessively to CRC incidence, it is a significant sequela of the disease 
and accounts for one-sixth of all deaths in UC patients (12). In comparison to age-matched 
controls, UC is associated with a five to ten-fold increase in CRC (13). The risk appears to 
be cumulative with the duration of disease, higher in patients extensive colitis, and in those 
with co-existing primary sclerosing cholangitis (13, 14). For a patient with UC, the risk of 
CRC is around 2% after 10 years, 8% after 20 years, and 18% after 30 years from diagnosis 
(12). The risk is similar in patients with Crohn’s colitis (15). 
The association between CRC and IBD is likely related to chronic inflammation. IBD-related 
and sporadic CRCs are similar in that both have a dysplasia-cancer progression that requires 
multiple mutations to progress to invasive malignancy (14). However, in IBD, the genetic 
and molecular mutations required in this sequence occur at a faster rate. It is likely that 
colitis-associated inflammation results in a cascade of abnormal epithelial proliferation with 
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early mutation of the p53 gene, whereas this is a later event in sporadic CRC (Section 
1.1.3.1) (14). 
The British Society of Gastroenterology (BSG) initially published guidelines in 2002, which 
have been updated in 2010, for CRC screening and surveillance for those in moderate to 
high-risk groups such as IBD (15). The BSG recommended that all patients with UC or 
Crohn’s colitis should undergo a screening colonoscopy approximately 10 years after the 
onset of colitis symptoms. Thereafter, screening colonoscopies are recommended at one, 
three, or five-yearly intervals, depending on endoscopic findings and other associated risk 
factors (15). Patients with IBD who also have active extensive colitis, primary sclerosing 
cholangitis, or a family history of CRC, are higher risk and should undergo colonoscopy at 
shorter intervals [Figure 1.4] (15). 
Figure 1.4: Surveillance guidelines for follow-up bowel screening in patients with 
inflammatory bowel disease-associated colitis 
 
Reproduced from Cairns et al. 2010 (15) (with permission from BMJ Publishing Group LTD) 
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Diabetes mellitus 
Epidemiological studies suggest that diabetes mellitus, especially type 2, is associated with 
an increased risk of several cancers, including CRC. A recent umbrella review of meta-
analyses determined that CRC, along with breast and endometrial cancer, were associated 
with type 2 diabetes (16). 
Infective risk factors 
Common bacterial and viral infections have been investigated as risk factors for CRC.  
Helicobacter pylori infection 
The bacterial pathogen Helicobacter pylori (H. pylori) is passed from human to human and 
colonises the gastric mucosa. The bacterium induces chronic inflammation that can lead to 
chronic gastritis, peptic ulcer disease, gastric adenocarcinoma, and mucosa-associated 
lymphoid tissue (MALT) lymphoma (17). For this reason, studies on the oncogenicity of H. 
pylori have been conducted to examine its role in the development of other gastrointestinal 
cancers.  
At present, studies have found only a statistical association between H. pylori infection and 
colorectal neoplasia, including CRC (18, 19). The risk appears to be modest, and the reports 
above note that bias cannot be excluded. At present, definitive proof of causality is not 
established; however, it is plausible from experimental data, that H. pylori could be 
responsible for the induction and perpetuation of inflammatory responses, the result of which 
may contribute to tumour formation (19, 20). 
Viral infection 
Studies have assessed the association between CRC and common viruses such as human 
papillomavirus (HPV), and human herpesvirus, including a recent systematic review, 
conducted to assess the strength of the evidence (21).  
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The majority of studies included in the review focussed on HPV, where samples of colorectal 
tumours, adjacent tissue, adenomas, and healthy controls were examined for the presence of 
HPV. With the exception of one study, the prevalence of HPV was significantly higher in 
tumour samples than adjacent non-cancerous tissue. Odds ratios (OR) in the studies ranged 
from 1.7 [95% CI; 0.9–3.3] to 12.8 [95% CI; 3.7–43.7] (21). 
The above systematic review concluded that although a role for viral infection in the 
aetiology of CRC is biologically plausible, the evidence is limited (21). Nonetheless, this 
possible association should remain under consideration given the rollout of an HPV vaccine 
as prophylaxis against cervical cancer. 
Medications 
Chemoprevention strategies for CRC have been of interest, and research is ongoing. Several 
of the most common strategies are outlined below. 
Hormone replacement therapy 
Colorectal adenomas and tumours are more prevalent in males than females. This 
observation, combined with some pre-clinical and clinical studies, has led to speculation that 
female hormones, in particular oestrogen, acting at oestrogen receptor β, could provide a 
protective benefit with respect to CRC (22). Consequently, several extensive 
epidemiological studies examining the association between female hormone replacement 
therapy (HRT) and CRC incidence have been conducted. A 2012 meta-analysis showed that 
current use of oestrogen therapy, and current or previous use of combined oestrogen and 
progesterone therapy, decreased CRC risk by 20–30% (23). In addition, a recent study in 
Denmark, recruiting one million women reported that the use of HRT was associated with a 
15% reduction in CRC risk (24). Nevertheless, additional extensive studies have not 
supported these findings (25). The associated risks of long-term HRT in relation to 
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gynaecological cancers, and venous thrombosis, may limit its application as a primary 
prevention medication for CRC in any case. 
Aspirin use 
Aspirin use has been proposed as a chemo protective agent for both colorectal adenomas and 
CRC. It is plausible that the effect is mediated by aspirin’s inhibitory action on the enzyme, 
cyclooxygenase-2 (COX-2). Two COX isoforms exist. COX-1 is an enzyme expressed in 
most mammalian tissues, and COX-2 is an enzyme that acts as a catalyst in the reaction that 
produces prostaglandins from arachidonic acid (26). COX-2 is induced by growth factors, 
oncogenes, tumour promoters, and inflammatory cytokines (27), while it displays up-
regulation in human colonic adenocarcinoma (28). It is plausible that inhibition of this pro-
inflammatory, pro-tumour state by the action of aspirin, on the function of COX-2, reduces 
neoplasia formation. In addition to localised actions in the tumour microenvironment and 
colorectal epithelium, the effects of aspirin are believed to elicit a tumour inhibitory effect 
on a systemic level (27). 
A significant volume of observational and clinical trial data have reported that regular aspirin 
ingestion reduces CRC risk (27, 29); however, there is no uniform agreement, and some 
studies have reported that there is no effect of aspirin on CRC incidence (30, 31). In some 
cases, randomised controlled trial (RCT) data have been extracted from trials that were 
primarily designed to examine cardiovascular disease prevention, and they may lack the 
optimal design with which to investigate CRC incidence (27). At present, there is not a 
consensus on an optimal duration or dose of aspirin as a chemo protective agent. Large 
studies concluded that at least 300 mg daily was required for a duration of around 5 years to 
reduce CRC risk with a latency of 10 years (29). Furthermore, this is a significantly larger 
dose than that used in cardiovascular disease prevention and may put patients at a higher risk 
of aspirin-associated complications. 
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In 2007 the United States Preventative Services Task Force (USPSTF) recommended against 
the routine use of aspirin for the prevention of CRC. However, this guidance was updated in 
2016 (32). The USPSTF now recommends low-dose aspirin for the prevention of 
cardiovascular disease and CRC, but only in adults fitting the following criteria. 
1. Aged 50–59 years 
2. A 10% or higher, 10-year cardiovascular disease risk (Framingham score) (33) 
3. Are not at increased risk of bleeding 
4. Have a life expectancy of at least 10 years 
5. Are willing to take low dose aspirin for at least 10 years 
 
The USPSTF recommendations reflect recent studies with longer follow-up, which report a 
more consistent effect of aspirin on CRC (34). Crucially the USPSTF does not endorse 
aspirin use for the sole purpose of CRC prevention; however, they do suggest the 
“additional” benefit of aspirin use for CRC prevention may be favourable in those at higher 
risk of cardiovascular disease. 
In any case, the routine use of aspirin for chemoprevention in patients aged <50 years in the 
USA and the general population in the UK is not recommended. However, an exception 
could be made for patients at risk of hereditary CRC related to conditions such as FAP and 
HNPCC. Robust RCT evidence suggests there is a chemoprophylaxis benefit of aspirin in 
reducing polyp load in patients with FAP (35) and cancer incidence in HNPCC (35). 
Aspirin chemoprevention remains a topic of interest, and ongoing research, specifically, the 
ASAMET (Aspirin and Metformin) trial is yet to conclude. The ASAMET trial is a 
randomised, double-blind, placebo-controlled study examining the use of aspirin and 
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metformin, and their effect on recurrence, prognosis and second primary cancer incidence 
of patients post-CRC surgery (36). 
Nonsteroidal anti-inflammatory drugs 
A large systematic review, including 44 studies, investigating the effect of nonsteroidal anti-
inflammatory drugs (NSAIDs) on colorectal neoplasia risk was published in 2010 (37). The 
study was concerned with patients at high risk for CRC, such as those with a strong family 
history, FAP, or HNPCC. The work concluded that NSAID use could reduce the polyp 
burden, such as size and number, in patients with FAP (37). In individuals with a history of 
previous adenomas, the meta-analysis concluded that there was a 34% reduction in adenoma 
recurrence, relative risk (RR), 0.66 [95% CI; 0.60–0.72] and a 55% reduction in advanced 
adenoma incidence, RR 0.45 [95% CI; 0.35–0.58]. Nonetheless, there is insufficient 
evidence to recommend the use of NSAIDs for CRC or adenoma prevention in the general, 
average-risk population (37). It is noteworthy that a majority studies in the above review 
focussed on the use of the COX-2 inhibitors due to their perceived lower risk of 
gastrointestinal toxicity. Nevertheless, these are no longer in routine clinical use due to 
concerns regarding cardiovascular toxicity.  
Statins 
Statins are a class of lipid-lowering medications known as hydroxymethylglutaryl-CoA 
(HMG-CoA) reductase inhibitors. HMG-CoA reductase is an enzyme which aids in the 
synthesis of mevalonate, which is included in a chain of molecules that end in the production 
of cholesterol. Interest in statins for chemoprevention is based on reports that they may 
promote apoptosis while inhibiting angiogenesis and cell proliferation (38). Clinical studies 
have explored the effect of statins on CRC risk and reached disparate conclusions prompting 
a meta-analysis (39). Approximately two million pooled patients from observational studies 
and RCTs, primarily undertaken to investigate cardiovascular risk reduction, were included 
in the above study. The summary results supported a very modest reduction in CRC risk of 
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around 9% with statin use, RR 0.91 [95% CI; 0.87–0.96, p<0.001]. On this basis, there is 
insufficient evidence to recommend the use of statins for CRC chemoprevention, yet it may 
be a welcome, albeit modest, benefit for those already on long-term therapy. 
Angiotensin-converting enzyme inhibitors  
Angiotensin-converting enzyme (ACE) inhibitors are a class of anti-hypertensive drugs that 
inhibit the conversion of angiotensin-1 to angiotensin-2. Angiotensin-2 is an active mediator 
controlling the release of aldosterone from the adrenal cortex while raising arterial blood 
pressure by vasoconstriction. In addition to its cardiovascular effects, experimental studies 
have shown that angiotensin-2 also acts as a growth factor and stimulates both 
neovascularisation and cell replication (40). Furthermore, it has been demonstrated that ACE 
is differentially expressed in CRC tumour cells, whereas surrounding non-neoplastic tissue 
rarely expresses it (41). It has also been demonstrated that colorectal adenomas, as precursors 
of CRC, exhibit a similar expression of ACE to CRC tumour cells (41). The above 
observations would suggest that ACE may play a role in tumour formation, and its inhibition 
may provide a chemoprevention effect against CRC. 
A large observational study of 5,200 patients attending a West of Scotland blood pressure 
clinic for 15 years was conducted where the researchers examined all cancer incidence 
during the follow-up period and found both the incidence and cancer-specific death rates, to 
be 28% [RR 0.72, 95% CI; 0.55–0.92] and 35% [RR 0.65, 95% CI; 0.44–0.93] lower 
respectively, for those taking ACE inhibitors compared with controls (40). Nevertheless, 
other large studies (n=18,000) have failed to replicate these results (42), including a meta-
analysis (43). 
These studies were concerned with all cancer incidence. In considering CRC specifically, 
studies using bowel screening patients have reported a reduction in advanced neoplasia 
incidence for those taking ACE inhibitors (44). In one study, the use of ACE inhibitors 
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reduced the incidence of advanced adenoma by 41% over a 3–5 year period, but direct 
evidence of an effect specifically on CRC has yet to be established (45). 
Inflammation and cancer 
Links between cancer and inflammation were first proposed in the 19th century, arising from 
the observation that tumour samples were often found to harbour inflammatory cells within 
the tumour microenvironment. Researchers also noted that many tumours arose at sites of 
chronic inflammation (46). There is now a general acceptance that inflammation and cancer 
are linked.  
Hanahan and Weinberg proposed the six hallmarks and acquired capabilities of cancer 
[Figure 1.5] in their paper outlining the multistep processes of tumorigenesis (47). It has 
since been proposed that cancer-related inflammation is the seventh hallmark of cancer; 
however, the mechanisms that link inflammation and cancer are multiple and complex (48). 
It is believed that inflammation mediates the progression of healthy cells to malignancy 
through pro-inflammatory cytokine and free radical pathways (49). In addition, activation of 
signalling pathways common to both inflammation and carcinogenesis, such as the nuclear 
factor kappa-beta (NF-κβ) are likely to play a role. NF-κβ controls DNA transcription and 
regulates the cellular immune response to infection, and incorrect regulation is linked to 
carcinogenesis.   
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Figure 1.5: The six hallmarks and acquired capabilities of cancer 
 
 
Reproduced (with permission) from Hanahan and Weinberg 2000 (47) 
 
 
 
Although it is accepted that the tumour microenvironment harbours an inflammatory 
component, often described as an ongoing “smouldering” inflammation (46), there is a 
recognition that a general systemic inflammatory response could play a regulatory role in 
cancer development and progression. C-reactive protein (CRP), is an acute-phase protein 
and marker of systemic inflammation  produced in the liver in response to interleukin-6 (IL-
6) secretion by inflammatory cells, namely macrophages and T-cells (50). It is elevated in 
response to infection, trauma, surgery, immune-mediated inflammatory conditions, and 
cancer, amongst other conditions (50). 
In some cases, a prolonged inflammatory response can be raised as a reaction to specific 
agents or conditions, the effect of which is a state of chronic, low-grade, systemic 
inflammation, that may encourage the progression to, and progression of, malignant 
processes (51). 
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This hypothesis is supported by epidemiological studies whereby elevated CRP, as a marker 
of systemic inflammation, in otherwise healthy individuals, is associated with an increased 
risk of cancer (51). Allin and colleagues (2009) investigated a large cohort of 10,000 
individuals from a Danish population with a baseline CRP measurement (51). The 
researchers observed the cohort for up to 16 years and found that individuals with baseline 
CRP in the 5th quintile were 30% more likely to develop cancer of any type, than those in 
the 1st quintile. Crucially, when CRC was explicitly examined in another epidemiology study 
(52), and a recent meta-analysis (53), the above associations with CRP remained. Certainly, 
unravelling the links between cancer and inflammation is desirable with a view that cancer 
related inflammation may be an intervention target (46). 
1.1.2.3 Lifestyle factors 
The World Cancer Research Fund (WCRF) publishes a continuous update on cancer 
prevention and survival in relation to diet, nutrition, and physical activity, from all over the 
world. Worldwide scientific research is continually added to the database, where it is 
systematically reviewed by a team at Imperial College London (54). It is now clear that a 
variety of dietary and lifestyle factors can affect an individual’s risk of CRC (54).  
Tobacco smoking 
Tobacco smoking is associated with a modestly increased CRC risk. Meta-analyses and 
cohort studies have shown that current smokers vs. never smokers have an approximately 
20% increased risk, with the association stronger in males than females (55, 56). The risk is 
thought to increase with the number of cigarettes smoked per day (10% increase per ten 
cigarettes) (55). 
Excessive alcohol consumption 
There is convincing evidence that high alcohol consumption is associated with an increased 
risk of CRC (54). While meta-analysis data concluded that there was no significant risk from 
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low intake levels of up to 20g per day, consumption above 20g per day was found to increase 
CRC risk per additional 10g consumed per day (54). In real terms, one standard drink (one 
can of beer, 100ml wine, or one measure of spirits) contains 10g of ethanol.  
The mechanism of potential carcinogenesis is not well understood, however it is believed 
that ethanol can initiate oxidative stress on tissues, which in turn may elicit a carcinogenic 
effect (57). Furthermore, it has been suggested that ethanol carcinogenesis could be mediated 
by its direct breakdown product, acetaldehyde (58). Acetaldehyde is a known carcinogen 
and is thought to interfere with DNA synthesis and repair (58). It is produced by oxidation 
of ethanol in the liver and by bacterial activity in the colonic mucosa. Significant 
concentrations of acetaldehyde have been measured in saliva and colonic contents following 
moderate alcohol consumption, thus essentially bathing of the colonic mucosa in this 
compound could be carcinogenic (58). 
Obesity and metabolic syndrome 
There is robust evidence that obesity, or being overweight, increases the risk of a number of 
cancers, including CRC. A study of 5.24 million adults in the UK published in The Lancet 
in 2014, concluded that elevated body mass index (BMI, kg/m2) was associated with 17 of 
the 22 most common cancers in the UK (59). The researchers reported that colonic cancer 
risk increased by approximately 10% per 5 unit increase in BMI, with a hazard ratio (HR) 
of 1.10 [95% CI; 1.07–1.13, p<0.001], and rectal cancer by approximately 5%, HR 1.04 
[95% CI; 1.00–1.08, p<0.05] (59).  
The mechanisms linking obesity and CRC are not fully understood and likely multifactorial. 
Obesity, particularly visceral obesity, is associated with metabolic syndrome which is a 
group of interconnected clinical, metabolic, and physiological factors linked to an increased 
risk of cardiovascular disease, type 2 diabetes, and mortality (60). It results in elevated 
concentrations of circulating insulin, which promotes cell growth, proliferation, and limits 
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cellular apoptosis (61). In addition, body “fatness” has been associated with a pro-
inflammatory response, mediated by adipokines, particularly insulin and leptin, which have 
been linked to CRC development (53, 62). 
1.1.2.4 Dietary factors 
High consumption of red and processed meat 
The World Health Organisation’s (WHO) specialist group on cancer: The International 
Agency for Research on Cancer, recently classified red meat as “probably carcinogenic to 
humans”. In addition, they classed processed meat (preserved by salting, curing, smoking, 
or the addition of chemical preservatives) as “carcinogenic to humans” (63). This 
classification is based on large population studies that suggest red and processed meat 
consumption can increase CRC risk by approximately 20% when comparing the highest and 
the lowest intake groups (64). This relationship may also be dose-dependent, with an 
observed 15% increase in CRC risk per 100g of daily consumption (64).  
Nonetheless, more recent studies have downplayed the potential relationship between red 
meat and CRC risk, notably a meta-analysis including 27 studies which reported only a 
weakly elevated summary RR for CRC attributable red meat consumption, RR 1.11 [95% 
CI; 1.03–1.09] (65). The researchers suggested that current epidemiological data concerning 
red meat consumption and CRC risk displays significant heterogeneity and is limited by the 
confounding effects of other dietary and lifestyle factors. Thus, the relationship might be 
best described as a mild to moderate association (65). In summary, it would seem sensible 
to recommend limiting the intake of red and certainly processed meat, but disproportionate 
to recommend total elimination of these. 
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Fruit and vegetables 
Eating a modest to moderate volume of fresh fruit and vegetables might lead to a reduction 
in CRC risk. Meta-analysis results have suggested the risk reduction may be 8% for fruit and 
vegetables combined, RR 0.92 [95% CI; 0.86–0.99] (66). It is thought that vitamins and 
antioxidants found in fruit and vegetables may offer a protective effect against 
carcinogenesis. 
Dietary fibre 
A high intake of dietary fibre is believed to induce a protective effect on colorectal 
carcinogenesis. In a large European study, (EPIC: European Prospective Investigation into 
Cancer and Nutrition) over 500,000 participants from 10 countries participated in a multi-
centre prospective study aiming to investigate the relationship between diet lifestyle, and the 
incidence of several cancers amongst additional outcomes (67). Dietary intake over the 
preceding 12 months was assessed by country-specific questionnaires. The results 
demonstrated an approximate 20% reduction in the risk of CRC for those with the highest 
fibre intake (mean 35g/day) vs. the lowest intake (mean 15g/day) when adjusting for folate 
(67). More recently, a meta-analysis of prospective observational studies performed by the 
WCRF reported a 10% dose-dependent reduction of CRC risk per 10g of daily dietary fibre 
(54). 
The protective effect of fibre might result from faster faecal transit, and it is plausible that 
this would reduce the time for potential faecal based carcinogens to act on colonic mucosa. 
In addition, the breakdown of fibre results in the production of short-chain fatty acids, 
particularly butyrate, which has an anti-proliferative effect. 
Fish intake 
Limited evidence exists that the consumption of fish reduces the risk of CRC. The EPIC 
study of 500,000 Europeans mentioned previously reported a 31% decrease in CRC risk 
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when in excess of 80g/day of fish was consumed, independent of the levels of red and 
processed meat consumed (67). However, competing studies have reported non-significant 
or inconsistent results (54). It is postulated that long-chain fatty acids found in fish may 
provide a chemoprotective effect. 
Calcium and vitamin D 
Anti-tumorigenic effects of calcium and vitamin D have been demonstrated in experimental 
studies to limit cellular proliferation, inducing apoptosis, and stimulating cellular 
differentiation (68). Epidemiological studies report an approximate 20–30% risk reduction 
in CRC and adenomatous polyps when comparing high and low-intake groups (68). 
Unfortunately, both calcium and vitamin D are inextricably linked; therefore, it is difficult 
to ascertain their independent effects. Furthermore, there is a lack of consistency or 
consensus between studies regarding the optimal dosage as a dietary supplement (68).  
A more recent systematic review and meta-analysis data would support calcium, and to a 
lesser extent, vitamin D supplementation for chemoprevention in those who wish to self-
treat (54). As of yet, there is insufficient evidence to recommend supplementation as a 
population-based chemoprevention strategy. 
1.1.2.5 Risk factor summary  
In the UK, approximately 50% of CRCs may be attributable to modifiable risk factors. The 
risk and preventative factors outlined above, and the relative strength of associations are 
summarised in Table 1.1.  
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Table 1.1: Summary of factors associated with increased or decreased risk of colorectal 
cancer 
Risk Factor Risk of CRC 
 
Modifiable 
   
Sociodemographic factors   
 
Advancing age 
 
 
↑↑↑ No 
Male sex 
 
↑↑ No 
Socioeconomic deprivation 
 
↑ Yes 
Medical factors   
 
Family history 
 
 
↑↑ 
 
No 
Inflammatory bowel disease 
 
↑↑ Potentially with colectomy 
Diabetes mellitus 
 
↑ No- Type-1, Yes type-2 
Helicobacter pylori 
 
(↑) Yes 
Viral infections 
 
(↑) Yes 
Hormone replacement therapy 
 
↓ Females only 
Aspirin 
 
↓ Yes 
Statins 
 
(↓) Yes 
Systemic inflammation 
 
↑ Yes 
Lifestyle factors   
 
Smoking 
 
 
↑ Yes 
Excessive alcohol consumption 
 
↑ 
Yes 
Obesity 
 
↑ Yes 
Physical activity 
 
↓ Yes 
Dietary factors   
   
Red and processed meat ↑↑ Yes 
   
Dietary fibre ↓ Yes 
   
Fish 
 
(↓) Yes 
Calcium and vitamin D intake ↓ Yes 
 
 
 
Adapted from Brenner et al. 2014 (7) 
 
↑↑↑      Very strong risk increase 
↑↑        Strong risk increase 
↑          Moderate risk increase 
↓          Moderate risk reduction 
( ) ( )    probable association
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1.1.3 Aetiology 
1.1.3.1 The molecular basis of colorectal carcinogenesis 
Chromosomal instability 
The vast majority (>90%) of invasive colorectal carcinomas develop from a pre-malignant 
precursor in the form of an adenomatous polyp (69). This process is known as the adenoma-
carcinoma sequence and is characterised by the stepwise transition, via genetic mutations, 
of normal colonic mucosa to adenomatous tissue and eventually adenocarcinoma. 
Initially, changes in the tumour suppressor gene, Adenomatous Polyposis Coli (APC) results 
in a loss of its function and is considered a very early step in the process. APC changes are 
identified in approximately 80% of adenomas and carcinomas (69). In a simplified version 
of events, APC mutations are followed by mutations in the KRAS gene, resulting in a loss of 
genetic material on chromosome 18q at SMAD4, and deletion of the upper part of 
chromosome 17 (17p), which houses the critical tumour suppressor gene TP53. This 
sequence of events results in carcinoma formation [Figure 1.6] (70, 71). 
Figure 1.6: The adenoma-carcinoma sequence model for chromosomal instability in 
colorectal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced (with permission) from Walther et al. 2009 (70)  
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Chromosomal instability is thought of as the traditional pathway to CRC. However, it is 
acknowledged that this pathway inadequately explains the undoubtedly complex sequences 
involved in the adenoma-carcinoma sequence and some of these steps may be skipped or 
occur in a different order (72). 
What is clear however, is that progression from adenoma to carcinoma may take several 
decades, and usefully, this would provide an opportunity for clinicians to intervene with 
measures such as colonoscopy and polypectomy for the prevention of subsequent CRC (73). 
Microsatellite instability 
Up to 15% of CRCs are characterised by microsatellite instability (MSI) (74). This pathway 
is defined by the inactivation of DNA mismatch repair (MMR) genes. The MMR genes play 
a role in the synthesis of enzymes that identify and correct errors during DNA replication. 
Mutation of MMR genes lead to inactivity that can result in base pair mismatches during 
DNA replication. Microsatellites are small stretches of repetitive DNA that due to their 
repetitive nature, are prone to errors. A defective MMR gene can leave the genome with 
microsatellites that are either longer or shorter than the parent DNA; this is termed MSI and 
can result in carcinogenesis (75). 
As will be discussed later, MSI is the hallmark of cancers arising in patients with HNPCC 
and is present in all cases. However, MSI is not limited to hereditary CRC and is identified 
in sporadic CRCs in approximately 15% of cases. The mechanism that precipitates MSI can 
vary. For example, in sporadic CRC the cause of MSI is epigenetic silencing (prevention of 
gene transcription) MMR genes, whereas in hereditary CRC the cause is a germline mutation 
resulting in defective MMR genes (73). 
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DNA hypermethylation 
Hypermethylation refers to the inappropriate addition of methyl groups to gene promoter 
regions of DNA (75). As a result of methylation, gene transcription of the affected gene is 
downregulated (silenced). Hypermethylation of tumour suppressor genes effectively 
switches them off (72). Up to 20% of CRCs develop via this pathway and are often 
associated with BRAF gene mutations (69). BRAF is a human gene that encodes a protein 
(B-Raf) involved in cell signalling and growth, and mutated versions of it have been 
identified in several human cancers, including CRC (76). 
 
1.1.3.2 Sporadic Colorectal Cancer 
The majority of CRCs are sporadic and arise as a result of progressive genetic alterations or 
interactions between the host and environmental factors (77). Sporadic CRCs are those 
which arise from the colon or rectum without a known genetic cause, family history, or 
diagnosis of IBD. Approximately two-thirds of CRCs fit these criteria. The most common 
route for the development of sporadic CRC is through the adenoma-carcinoma sequence 
(Section 1.1.3.1.) (77). 
1.1.3.3 Hereditary Colorectal Cancer 
Less commonly, CRCs arise where the specific cause is apparent. This could be related to a 
medical or inherited condition that predisposes a patient to CRC. 
Hereditary Non-Polyposis Colorectal Cancer 
HNPCC, first described in the 1960s by Henry Lynch (78), is an autosomal dominant genetic 
condition associated with a higher risk of several cancers such as colorectal, endometrial, 
gastric, small bowel, breast and ovarian (79). HNPCC is the most common of the inherited 
CRC conditions accounting for approximately 3% of all CRCs (80). These type of CRCs 
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arise due to an inherited mutation of MMR genes leading to tumours with MSI, as mentioned 
previously (81). 
HNPCC-associated CRCs are often right-sided and characterised by a young age of onset, 
with a mean age of 45 years, and an elevated risk of synchronous and metachronous cancers 
(79, 81). Although multiple adenomas may be observed in HNPCC, florid polyposis is not 
a feature. Despite this, the majority of HNPCC cancers follow the adenoma-carcinoma 
sequence, which progresses at a faster rate in HNPCC (82). Patients with CRC related to 
HNPCC tend to have a better prognosis with a 10-year survival of 91% (82). 
The disorder can be diagnosed empirically from a detailed family history or by genetic 
testing (83). However, not all MMR mutated tumours are related to HNPCC which presents 
a diagnostic challenge if using genetic testing alone. As such, internationally recognised 
criteria to help identify HNPCC patients, primarily for clinical trials, have been established. 
Namely the Amsterdam Criteria. These were first described in 1990 as the Amsterdam I 
Criteria, and have since been updated to the current Amsterdam II Criteria [Table 1.2] (81). 
Table 1.2: Amsterdam II criteria for the diagnosis of HNPCC 
Amsterdam II criteria 
 
1. At least three relatives with HNPCC-associated cancer (CRC, endometrial, small bowel, ureteric, 
renal pelvis) 
 
2. One should be a first degree relative of the other two 
 
3. At least two successive generations must be affected 
 
4. At least one should be diagnosed before the age of 50 years 
 
5. If the case is a CRC, FAP must be excluded 
 
6. Tumours should be verified by pathological examination 
 
In addition, the Bethesda Guidelines were devised in order to identify CRCs from patients 
that should undergo additional immunohistochemistry and MSI testing. This is to help 
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identify patients who are MMR-gene carriers but do not fit the Amsterdam Criteria. The 
revised Bethesda Guidelines are shown in Table 1.3 (84). 
Table 1.3: Criteria for selection of tumours to be tested for microsatellite instability 
Revised Bethesda Guidelines 
 
1. CRC diagnosed in a patient <50 years 
 
2. Presence of synchronous, metachronous colorectal or other HNPCC-associated tumours, 
regardless of age 
 
3. CRC with MSI diagnosed in a patient <60 years 
 
4. CRC or other HNPCC-associated tumour diagnosed in at least one first degree relative <50 years 
of age 
 
5. CRC or other HNPCC-associated tumour diagnosed in two first or second-degree relatives at any 
age 
 
In patients with HNPCC, the lifetime CRC risk is around 80% (15). As such, routine CRC 
surveillance is warranted. Guidelines published in 2013 recommend patients undergo 
colonoscopy at 1–2 year intervals (85) since there exists an elevated risk of interval cancers 
for patients undergoing three-yearly surveillance (85).  
Familial Adenomatous Polyposis Syndrome 
FAP is an autosomal dominant genetic disorder caused by a mutation and loss of function of 
the APC gene located on chromosome 5q21 (86). The APC gene is primarily involved in 
cellular adhesion but is also a tumour suppressor, and loss of function leads to the clinical 
presentation of the disease (87). This is characterised by the development of multiple (>100) 
adenomas within the colon and rectum and the incidence is approximately 1:5,000–1:10,000 
with an equal male: female split (88). FAP is a less common cause of CRC than HNPCC, 
accounting for under 1% of all CRCs (89). For carriers, there is almost a 100% risk of 
developing CRC by the age of 40 years, so prophylactic colectomy is recommended in the 
teenage years (90). 
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1.1.4 Clinical presentation 
The mode of presentation in CRC varies. Some patients may present with symptoms relating 
to the primary tumour, while others may present at a later stage with symptoms related to 
metastatic disease; but increasingly, asymptomatic patients will be diagnosed as part of a 
national bowel screening programme. 
1.1.4.1 Elective presentation 
Elective presentations are related to symptomatic patients visiting their primary care 
physicians. Symptoms may include one or a combination of three primary symptoms, 
namely: rectal bleeding, change in bowel habit, and abdominal pain (91). Unfortunately, 
these symptoms are also common to benign disease, which can reduce their specificity 
greatly (92). While there is a recognition that many patients with cancer have more than one 
symptom, in the case of CRC, a palpable abdominal or rectal mass, iron deficiency anaemia, 
or weight loss are red flags (93). Nonetheless, a degree of clinical judgment must be 
exercised when deciding on further investigations for suspected CRC. 
1.1.4.2 Emergency presentation 
Despite screening and efforts to improve referral guidelines in primary care, up to 30% of 
patients with CRC present to the surgical department as an emergency (94). The presenting 
condition may be one of large bowel obstruction, perforation or rectal bleeding.  
Unfortunately, surgery performed to relieve acute obstruction in the emergency setting 
results in significantly higher morbidity and mortality (95). Furthermore, the prognosis is 
poorer in patients who present as an emergency, even if emergency surgery is not required. 
An early study by McArdle et al. in 2004, included over 3,000 patients who underwent 
surgery for CRC. The researchers reported that those undergoing emergency vs. elective 
CRC surgery for curative intent had higher postoperative mortality (8.2% vs. 2.8%) and 
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lower overall and cancer-specific 5-year survival, (39.1% vs. 57.5%) and (52.9% vs. 70.9%) 
respectively (96).  
1.1.4.3 Metastatic disease at presentation 
Patients may present with symptoms of metastatic disease; and in the USA, up to 20% of 
patients are found to have metastatic disease at presentation (97). Symptoms from metastatic 
disease can vary and are related to the route of disease spread. The most frequent sites of 
metastatic spread are regional lymph nodes, the liver, the lungs, and the peritoneum. 
However, spread to bone and brain are not uncommon. Since the majority of venous drainage 
of the intestinal tract is via the portal system, the liver is often the first site of haematogenous 
spread. The exception to this is distal rectal tumours that may metastasise to the lungs 
initially. This occurs since venous drainage via the inferior rectal veins enters the systemic 
circulation rather than the portal system via the inferior vena cava, thus bypassing the liver. 
As such, symptoms from metastatic disease can be wide and varied depending on the 
location and extent of the metastases.  
1.1.4.4 Bowel screening presentation 
Bowel screening is discussed in Section 1.2. As a mode of presentation, screening provides 
a significant gateway for cancer detection. Mansouri et al. in 2016, published data from the 
Greater Glasgow and Clyde (GGC) Health Board in relation to the Scottish Bowel Screening 
Programme (SBoSP). During the study period, a total of 1,129 CRCs were diagnosed. Of 
these, 421 (37%) were screen-detected which indicates the majority of cancers are still 
diagnosed outside of the screening programme. Although the results may be explained when 
considering only half (52%) of those eligible for screening accepted the offer (98).  
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1.1.5 Diagnosis and investigations 
The diagnosis of CRC must be confirmed by histological analysis, and in the majority of 
cases, this occurs prior to any intervention. However, this ideal situation is not always 
possible. For example, in the emergency setting, if a patient presents with colonic perforation 
and faecal peritonitis primary surgery would need to be undertaken on an emergency basis. 
Thereafter, histological confirmation from the resected specimen would follow. In cases 
where a patient presents with metastatic disease found incidentally on a radiological scan, a 
search for the primary tumour may be undertaken using a combination of endoscopic 
investigations, blood sampling for tumour markers, and tissue biopsy using image-guided 
techniques. 
1.1.5.1 Diagnostic tests 
Colonoscopy 
Colonoscopy is the gold standard for investigating the colon and rectum. It is used both as a 
diagnostic and a therapeutic tool. This procedure can localise lesions and enable biopsies to 
be taken. It has high sensitivity and specificity for CRC (99), but there are a number of 
drawbacks, such as a small but not insignificant risk of perforation, in the order of 1:1,000 
(0.1%) (100, 101). This increases with age (101). In addition, the requirement for 
intravenous sedation is not without risk; formal bowel preparation is unpleasant for 24 hours 
prior to the colonoscopy, and the procedure can cause discomfort. Other down sides include 
a failure to complete the investigation. In order to ensure an adequate standard of 
colonoscopy, practitioners must aim for a minimum 90% caecal intubation rate for all 
colonoscopies and 95% for a screening colonoscopy (102). Despite this target, incomplete 
colonoscopy rates can vary from 4–25% (102), which is often related patient discomfort, 
technical difficulty (e.g. looping of the colon, tight colonic angulation, diverticular disease), 
or inadequate bowel preparation. 
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Flexible sigmoidoscopy 
Flexible sigmoidoscopy affords direct visualisation of the colon and rectum without the need 
for intravenous sedation or full bowel preparation. In this regard, it offers an advantage over 
colonoscopy, especially in frail patients. Flexible sigmoidoscopy would be expected to 
detect 70% of all cancers since the majority occur distal to the splenic flexure (103). 
Drawbacks include a failure to examine the colon proximal to the splenic flexure, and 
variability in the view of this area limited by bowel preparation. In addition, synchronous 
tumours of the colon are present in up to 5% of cases  and thus, diagnosing a tumour via 
flexible sigmoidoscopy would warrant a full colonoscopy subsequently (104). 
Barium enema 
A double-contrast barium enema is performed by the insufflation of air into the rectum in 
combination with radio-opaque barium. The barium and air contrast on subsequent X-rays 
are used to identify mucosal lesions. The use of this diagnostic test has dwindled with the 
increasing availability and superiority of colonoscopy and Computed Tomography (CT) 
scanning. 
Computed tomography colonography 
Computed tomography colonography (CTC), also referred to as virtual colonoscopy, allows 
3D imaging of the colon and rectum. The test was first introduced clinically in 1994 (105). 
CTC is significantly less invasive than a colonoscopy, and only minimal bowel preparation 
is required. The procedure is carried out with the patient in the lateral decubitus position, 
and the colon is distended using room air or carbon dioxide via a small enema tip in the 
rectum (105). CT scanning is undertaken, and the resulting 2D and 3D images are reviewed 
by a radiologist using specialised imaging software. Discomfort is minimal and limited to 
the gaseous distension of the colon, with many patients reporting less discomfort than 
colonoscopy (105). 
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Several studies comparing CTC and colonoscopy have been conducted. In general, CTC is 
regarded as an acceptable alternative to colonoscopy. A 2013 systematic review concluded 
that CTC is less sensitive than colonoscopy overall, but for larger lesions (e.g. ≥1cm), 
sensitivity is comparable (91.2% CTC vs. 92.9% colonoscopy) (106).  
There are a number of drawbacks of CTC such as the need to visualise directly, biopsy or 
remove any detected lesions which require a colonoscopy, resulting in a two-stage 
procedure. In addition, the dose of radiation received in a screening CTC, although lower 
than standard CT must be considered (107). 
A debatable topic, which may be thought of as either a drawback or an advantage, is the 
detection of extracolonic findings (ECF) at CTC.  While ECFs from CTC are common, and 
the majority are insignificant, one study reported just over a third (37%) are of intermediate 
or high significance (108). Despite this, only 1% of patients included in the above study 
required surgical or medical intervention as a result of ECFs. This report implies that there 
may be a significant degree of work-up and investigation required for what subsequently 
turns out to be benign disease. This could be viewed negatively by patients in terms of 
anxiety or discomfort from further invasive investigations, and similarly a health economics 
standpoint given the cost to a health service of investigating ECFs for minimal health gain. 
These concerns must be balanced with the potential benefit of diagnosing an important 
clinical condition such as an aortic aneurysm or solid organ tumour that would otherwise 
have gone unnoticed. 
Blood tests 
There are no blood tests that can diagnose CRC; however as previously discussed, the 
presence of iron deficiency anaemia is an indicator of occult blood loss in the gastrointestinal 
tract; and as such, it is used as a prompt for endoscopic examination. Carcinoembryonic 
Antigen (CEA) is a blood test utilised as a tumour marker in patients with CRC. It has a 90% 
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specificity for CRC, but sensitivity is poor at approximately 40–75% (109) rendering it 
unhelpful for diagnostic purposes. Its main use is as a prompt for further investigation to 
detect occult disease recurrence, and it has some value in monitoring the response to 
chemotherapy (110). 
1.1.5.2 Colorectal cancer staging at presentation 
The principles of staging 
Following histological confirmation of CRC, further investigation is undertaken in order to 
stage the disease which is useful as a prognostic indicator (Section 1.1.7), facilitates 
management decisions, and aids in clinical research (111). The Association of 
Coloproctology of Great Britain and Ireland (ACPGBI) recommend three areas are assessed 
for staging purposes (112). 
1. Assessment of local disease relating to the primary tumour 
2. Assessment for metastatic disease  
3. Assessment for synchronous colonic disease 
 
Modalities used for staging 
Local disease is examined by CT scanning of the abdomen and pelvis in order to collect 
information on the size of the tumour, local spread, or lymph node involvement while 
assessing for invasion of the abdominal wall or other organs. 
For tumours of the rectum (tumour within 15cm of the dentate line during rigid 
sigmoidoscopy), Magnetic Resonance Imaging (MRI) is used for local staging; and 
crucially, this modality can estimate the risk of circumferential resection margin (CRM) 
involvement. A clear CRM is one in which normal tissue is >1mm from malignant tissue. 
Detailed staging of rectal cancers is essential as it determines the feasibility and timing of 
potentially curative surgery. An additional modality for rectal tumour staging is endoluminal 
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ultrasound, whose value is realised in patients where MRI is contraindicated, or where local 
excision of a small primary tumour is being considered (113). 
In addition to the above, CT scanning of the thorax to look for metastatic disease in the lung 
or pleura is routinely conducted for staging purposes, while suspicious liver lesions can be 
further assessed by MRI. Positron Emission Tomography CT (PET-CT) scanning can be 
used to investigate suspicious lesions seen on CT or MRI. However, its real preoperative 
value lies in the detection of occult disease in patients being considered for surgical 
management of liver or lung metastases (112). PET-CT is a nuclear imaging modality where 
patients are injected with radioactive tracers that label molecules such as glucose with 
positron-emitting radionuclides. The most commonly used being 18-Fluoro-deoxy-glucose 
(18FDG). Since malignant cells have an elevated glucose uptake, the PET-CT scanner can 
detect “hot spots” of high metabolic activity, suggesting malignancy (114). Drawbacks of 
PET-CT include diagnostic uncertainty, where tissue with inherently high physiological 
activity such as the brain and heart; or the kidneys, where 18FDG is excreted, light up as hot 
spots. Nonetheless, PET-CT has great value in cases where occult malignancy, such as 
disease recurrence, are suspected but modalities such as CT fail to pick up convincing 
abnormalities. 
Synchronous cancers occur in up to 5% of patients and must be excluded during the initial 
diagnostic colonoscopy (104). If synchronous disease has not been excluded (e.g. a diagnosis 
made with flexible sigmoidoscopy), then a full colonoscopy or CTC should be arranged 
(112). 
Systems and classification of staging 
The Tumour, Node, Metastasis (TNM) system is the most commonly used classification and 
staging system worldwide. It was developed in 1992 by the American Joint Committee on 
Cancer (AJCC). In this system, CRCs are classified according to the tumour itself (T), the 
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degree of regional lymph node involvement (N) and the presence or absence of distal organ 
metastasis (M). The 7th edition of the AJCC TNM staging system for CRC is displayed in 
Table 1.4. This will be superseded for clinical use in 2018 by the 8th edition. 
In the preoperative setting, the TNM classification is based on clinical, biopsy and 
radiological findings and would be allocated a “c” prefix, (e.g. cT1N2M0). After surgical 
resection, re-classification is conducted, and the prefix “p” is given to indicate the updated 
pathological classification. Pathological staging is superior to clinical as it enables a verified 
result. The combined TNM classification is subsequently used to stage a patient from I to 
IV. Stage II and III have subdivisions; however, a simplified outline is presented below. 
• Stage I: A patient with a T1 or T2 tumour who is lymph node and distant metastases 
negative 
• Stage II: A patient with a T3 or T4 tumour who is lymph node and distant metastases 
negative 
• Stage III: Varied stage of tumour and lymph node-positive but no distant 
metastases are present 
• Stage IV: Metastatic spread 
 
In the UK, an alternative system is still in use called Dukes’ staging system, with the 
Turnbull modification (115). This system allocates stage A–D, and similar to the TNM 
system, it accounts for local tumour extent, lymph node involvement, and the presence or 
otherwise of distant metastatic disease [Table 1.5].  
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Table 1.4: TNM staging for CRC: American Joint Committee on Cancer, 7th Edition 
Primary tumour (T) T Criteria 
 
Tx 
 
 
Primary tumour cannot be assessed 
T0 
 
No evidence of primary tumour 
Tis 
 
Carcinoma in situ: intraepithelial tumour or invasion of lamina propria 
T1 Tumour invades the submucosa 
 
T2 
 
Tumour invades the muscularis propria 
T3 Tumour invades through the muscularis propria into the peri-colorectal 
tissues 
 
T4a Tumour penetrates the surface of the visceral peritoneum 
 
T4b Tumour directly invades or is adherent to other organs or structures 
  
Regional lymph nodes (N) N Criteria 
 
Nx 
 
 
Regional lymph nodes cannot be assessed 
N0 
 
No regional lymph node metastases 
N1 
 
Metastasis in 1–3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
  
N1b Metastasis in 2–3 regional lymph nodes 
  
N1c Tumour deposits in the subserosa, mesentery, or non-peritonealised 
pericolic or perirectal tissues without regional nodal metastasis 
  
N2 
 
≥4 regional lymph nodes positive 
N2a Metastasis in 4–6 regional lymph nodes 
  
N2b Metastasis in 7 or more regional lymph nodes 
  
Distant metastasis (M) M Criteria 
 
M0 
 
 
No distant metastasis are seen on imaging 
M1 Metastasis to 1 or more distant sites, organs or peritoneal metastasis 
  
M1a Metastasis confined to one organ or site only 
  
M1b Metastasis in more than one organ, site or the peritoneum 
  
 
 
The AJCC: Colon and Rectum, Cancer Staging Manual- 7th Edition (116) 
 
 
 54 
 
Table 1.5: The relationship between Dukes’ stage, TNM stage, and 5-year survival in CRC 
 
 
 
The National Cancer Intelligence Network UK (117) 
 
 
 
 
1.1.6 Management 
1.1.6.1 The multi-disciplinary team 
A key component of the investigation and management process for CRC are multi-
disciplinary team (MDT) meetings. These constitute a regular meeting of healthcare 
professionals, namely: surgeons, radiologists, pathologists, oncologists, and nurse specialists 
all with an interest in CRC (118). Every new cancer case is discussed, the images and 
pathology results are reviewed, and a management approach is agreed. Cases are re-
discussed post-surgery, post-neoadjuvant treatment or if recurrence is suspected. The MDT 
meetings ensure that high-quality care is delivered in an evidence-based approach. Evidence 
exists that these meetings result in improved 5-year survival in CRC, and in rectal cancer, a 
reduction in the rate of CRM involvement (119) (120). 
1.1.6.2 Surgical resection 
The gold standard of treatment for CRC is surgical resection with curative intent. The 
majority of patients will have their surgery on an elective basis, but as discussed previously, 
a proportion of patients will present as an emergency.  
Dukes’ stage TNM stage TNM classification 5-year survival 
(%) 
    
A 
 
I T1–2 N0 M0 93 
B 
 
II T3–4 N0 M0 77 
C 
 
III Tany N1–2 M0 48 
D IV Tany Nany M1 6 
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Elective surgery 
The majority of patients will undergo a planned elective procedure that will, in the vast 
majority of cases, be conducted by a specialist colorectal surgeon. This approach has been 
shown to improve long-term survival (121). 
The primary goal of surgery is to remove the section of bowel containing the tumour. It is 
important to ensure the tumour is removed en bloc with a surrounding margin of healthy 
tissue. It is also critical that the specimen is resected in continuity with its lymphatic drainage 
pathways to ensure lymph node metastases are excised, and to enable staging. 
Rectal cancers are unique in that the surgical decision is made with respect to the 
preservation or otherwise of the anal sphincter complex. For this reason, preoperative 
staging, by clinical examination and in particular, MRI is crucial. Above all, it is important 
to achieve a clear distal resection margin. If a rectal tumour is deemed too low to allow distal 
margin clearance while maintaining a degree of normal rectal function, then a complete 
excision of the anus is warranted with the formation of an end colostomy. This operation is 
called an abdominoperineal resection (APR). Recent thinking has led to a more radical 
approach for some rectal cancers whereby removal of the levator muscles is conducted with 
the patient in the prone or jack-knife position. This is called extra-levator, or cylindrical APR 
and studies have reported good oncological clearance at the CRM (122). 
A key aspect during excision of the rectum is to excise the mesorectal fat plane intact, which 
sits below the peritoneal reflection and envelopes the rectum in a cylindrical fashion. This 
process is described as a total mesorectal excision (TME), and it has been shown to reduce 
the risk of subsequent local recurrence (123). 
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Emergency surgery 
Emergency presentation of CRC was discussed in Section 1.1.4.2. Despite the modern 
practice of bowel screening and early referral to secondary care, a substantial proportion of 
patients still undergo emergency surgery for their oncological resection with the associated 
downsides which include; a lack of preoperative planning, limited staging, and the absence 
of an MDT discussion. 
1.1.6.3 Neoadjuvant therapy 
In simplistic terms, neoadjuvant therapy is designed to shrink tumours and treat involved 
lymph nodes prior to definitive surgical treatment with curative intent. At present, 
neoadjuvant therapy, in the form of radiotherapy with or without chemotherapy, is 
considered in certain rectal cancers but not colonic cancers. As such, distinguishing rectal 
from colonic cancer is vitally important. MRI can often make this distinction, whereby the 
rectum is said to begin at the level of the sacral promontory (124). Rectal cancers inherently 
have a higher risk of local recurrence than colonic cancers due to the absence of serosa and 
their close proximity to other pelvic structures. These features increase the technical 
difficulty in obtaining a clear resection margin (125).  
In order to reduce the risk of local recurrence, T3–4 tumours, those with nodal involvement, 
or threatened CRM are considered for preoperative neoadjuvant therapy to downstage the 
tumour (125). The CRM can be accurately assessed preoperatively by MRI and images are 
then viewed and discussed at the MDT where neoadjuvant therapy is considered (126). 
Neoadjuvant therapy can be delivered in one of two regimens: Long-course preoperative 
chemo radiotherapy (CRT) or short-course preoperative radiotherapy (SCPRT). CRT 
constitutes radiotherapy over a 5-week interval with a dose of at least 45 Gray (Gy) in 25 
fractions with synchronous 5-fluorouracil or oral capecitabine chemotherapy (124). Surgery 
is then delayed for around 6–10 weeks after completion to allow adequate response time. 
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The alternative option is SCPRT, which constitutes a dose of 25Gy in five fractions daily 
for one week, followed by surgery within ten days of completion to minimise the risk of 
post-radiotherapy complications. This regimen is often used in patients who have a moderate 
risk of local recurrence but without mesorectal fascia involvement, or in patients with 
comorbid disease who are less fit for CRT (124). 
1.1.6.4 Adjuvant therapy 
Adjuvant therapy, in the form of systemic chemotherapy, is considered in patients who are 
at higher risk of cancer recurrence after attempted curative resection. The justification for 
this is based on the theory that occult disease left behind during surgery, is most likely 
responsible for subsequent recurrence. Most centres now offer adjuvant chemotherapy to 
patients with stage III (node-positive, or Dukes’ C) colon cancer and rectal cancer, assuming 
they are adequately fit and this intervention has led to improved overall and disease-free 
survival (127). Commonly used chemotherapy agents include 5-fluorouracil, FOLFOX 
(folinic acid, 5-fluorouracil and oxaliplatin), capecitabine or Xelox (capecitabine and 
oxaliplatin). The duration of therapy varies but is typically 6–8 months. The decision for 
adjuvant chemotherapy must be made jointly with the patient and oncologist and include a 
discussion of the risks and benefits (124). In rectal cancers, salvage radiotherapy can be 
carried out postoperatively in cases where a positive resection margin has been obtained 
(124). 
1.1.6.5 Palliative management 
A substantial proportion of patients present with inoperable disease, metastatic disease or a 
significant comorbid burden and are not deemed fit for surgical intervention, leaving 
palliation as the only option. Some patients may choose not to undergo active intervention 
and are given end of life care, where maintaining quality of life while alleviating suffering 
is the primary goal. Palliation can be facilitated by good communication between medical 
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teams including; surgeons, oncologists, nurse specialists, palliative specialists, and other 
carers such as family and primary care physicians. Some patients can be considered for 
palliative chemotherapy. Meta-analyses data of RCTs have reported a 3.7-month median 
survival benefit of palliative chemotherapy when compared with best supportive care (128). 
In the palliative situation, a colonic or rectal obstruction by the tumour can pose a problem; 
as such, diversion of the faecal stream by a defunctioning colostomy is considered. An 
alternative option is the placement of a stent which has rising popularity, although the 
limitations of stenting include the risk of perforation and technical failure (129). 
1.1.7 Postoperative prognosis  
Both tumour and host factors contribute to postoperative prognostic stratification, which is 
important in order to inform patients, and aid decision making for follow-up planning, or 
adjuvant therapy. Section 1.1.5 described the most commonly used staging systems in CRC; 
however, there are a number of other factors to consider when determining prognosis. 
1.1.7.1 Tumour specific factors 
Additional tumour-related prognostic factors not accounted for in TNM staging are worthy 
of considering. 
Tumour grade 
A tumour is graded pathologically depending on the degree of differentiation displayed by 
its cells. Differentiation is the extent to which a tumour cell resembles the cell type expected 
in the tissue of origin under normal circumstances. Colorectal tumours may be classed as 
low-grade (high or moderately differentiated) or high-grade (poorly differentiated), where 
high-grade is associated with a worse prognosis (130). 
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Venous invasion  
The diagnosis of venous invasion is a pathological one. Venous invasion is evident if tumour 
cells are observed within an endothelial lined space, with a rim of smooth muscle, in the 
presence of red blood cells, and is associated with a poorer prognosis (131, 132). 
Perineural invasion 
The invasion of nerve structures, including nerve sheaths, defines perineural invasion, which 
is associated with a poorer prognosis (133). 
Tumour necrosis 
Rapidly growing malignant tumours can outgrow their local blood supply, resulting in self-
induced hypoxia and nutrient deprivation. As a result, necrosis occurs in core regions of the 
tumour (129). In patients undergoing surgery for CRC, tumour necrosis has been associated 
with reduced cancer-specific survival and is a marker of poor prognosis independent of the 
pathological stage (134). 
Lymph node ratio 
The lymph node ratio (LNR) is calculated by dividing the number of positive nodes by the 
total number of nodes provided in the resection specimen. It has been reported that 
examining a greater number of lymph nodes increases the likelihood of correct staging. 
Nevertheless, as a result of surgical technique, variation in the actual number of lymph nodes 
present, and the efficiency of the pathologist, the number reported can vary. This led to the 
development of the LNR prognostic indicator. In a large study of over 25,000 patients, an 
LNR of >0.4 was associated with poorer 5-year survival. The prognostic estimates were 
comparable to that calculated by the more traditional TNM system (135). At present LNR is 
not routinely used in clinical practice. 
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Tumour perforation and peritoneal or margin involvement 
A visible defect in the wall of the bowel while analysing the pathological specimen suggests 
perforation. Both perforation or the presence of visible tumour cells attached to peritoneal 
surfaces, are associated with a poor prognosis (136). Tumour cells <1mm from the 
circumferential or longitudinal resection margin is classed as “an involved margin” and is 
associated with poorer prognosis.  
1.1.7.2 Host factors 
Other than pathological and tumour specific factors, host characteristics have demonstrated 
prognostic value. It is difficult to determine whether the host characteristics influence the 
tumour itself or vice versa, in reality, it is likely there is a complex interplay between the 
host and the tumour. A sizeable body of work has demonstrated that sociodemographic 
factors, systemic inflammation, the local inflammatory response, and aspects of body 
composition have prognostic value. 
Sociodemographic and socioeconomic factors 
Extensive population studies previously carried out in Scotland have shown that older 
patients and those who live in areas with a higher level of socioeconomic deprivation suffer 
poorer overall 5-year survival from CRC when compared to younger and less deprived 
patients (137). The observed associations remain independent of emergency presentation 
and cancer stage, which in themselves are determinants of poor prognosis. The explanation 
for this observation is not clear; however, it may be that those subjected to higher levels of 
deprivation are less likely to engage with healthcare, and this delays presentation leading to 
later stage presentation with associated worse outcomes (138). Evidence for this hypothesis 
was observed in a study by Mansouri et al. (139), where the researchers reported that patients 
exposed to higher levels of deprivation are less likely to engage in population-based 
screening programmes. Screening is associated with earlier stage disease at diagnosis (in 
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those without metastases) (140); therefore it is plausible that those exposed to socioeconomic 
deprivation are more likely to present outside of the screening programme, potentially as an 
emergency, or with later-stage disease. 
The host inflammatory response and prognosis 
As discussed in Section 1.1.2.2, there is an association between inflammation and cancer. 
Whether inflammation is a response to the tumour itself or has merely contributed to 
carcinogenesis is difficult to identify, but in all likelihood, it is a combination of both. In the 
human body, an inflammatory response is a defence mechanism, but it appears to promote 
tumour progression as well as destruction. However, what has become clear is that the 
inflammatory response of the host has prognostic value in CRC. 
Systemic inflammatory response 
A systemic inflammatory response refers to one which is non-specific and occurs in response 
to bodily insult or injury. It is a whole-body response and involves a complex cascade of 
changes in circulating inflammatory cytokines and immune cell activity. As previously 
discussed, circulating CRP is a sensitive, specific, and routinely measured marker of 
systemic inflammation (141). As such, it is an optimal marker in which to study the link 
between systemic inflammation and CRC prognosis. Multiple studies have reported that 
systemic inflammation, as measured by elevated CRP, and CRP-based scoring systems, are 
associated with disease progression and poorer long-term survival independent of tumour 
stage (138, 142, 143). 
In addition to CRP, hypoalbuminaemia, as a marker of systemic inflammation is also 
associated with a poor cancer prognosis (144), and these findings have led to the 
development of combined albumin and CRP scoring systems, notably the Glasgow 
Prognostic Score (GPS). The GPS has subsequently been revised, and the modified Glasgow 
Prognostic Score (mGPS) is now used (143, 145).  
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The mGPS allocates to a patient, a score of 0,1 or 2, where 2 reflects the most marked 
systemic inflammatory response. It is scored as follows: 
 
• mGPS = 0 CRP ≤10mg/l AND albumin ≥35g/l 
• mGPS = 1 CRP >10mg/l  
• mGPS = 2  CRP >10mg/l AND albumin <35g/l 
 
The prognostic power of the mGPS system has been studied extensively in a range of solid 
organ cancers, particularly CRC. Elevated mGPS, as a marker of systemic inflammation, has 
repeatedly been associated with poorer outcomes (143); and in CRC, has been shown to 
predict survival, independent of disease stage (145), emergency presentation (141) and 
comorbidity (146). In addition, an elevated mGPS has been associated with increased 
postoperative complications in patients undergoing surgery for potentially curative CRC 
(147). A recent review paper summarising over 60 studies, including 30,000 patients, 
concluded that elevated GPS and mGPS scores are independently associated with poorer 
survival across several cancer types (148).  
Additional inflammation-based scoring systems have demonstrated similar prognostic value, 
and wide-reaching systemic reviews and meta-analyses have been conducted to validate 
these. They include the neutrophil: lymphocyte ratio (NLR), the platelet: lymphocyte ratio 
(PLR) and the lymphocyte: monocyte ratio (LMR), yet presently, inflammation-based 
prognostic scoring systems are mainly used in clinical research (138, 143, 149, 150). 
The local inflammatory response  
In contrast to the poor prognosis associated with systemic inflammation, a local 
inflammatory cell reaction in the tumour microenvironment is associated with improved 
prognosis, as reported by Roxburgh and McMillan in 2012 (151). The authors noted that in 
order to enhance its clinical relevance, a standardised assessment of the local inflammatory 
 63 
 
infiltrate within the tumour microenvironment was needed. A previously validated system, 
the Klintrup-Makinen criteria was suggested (151). The Klintrup-Makinen criteria is a 
reproducible grading system where a score of 0–3 is awarded depending on the intensity of 
the inflammatory cell reaction at the invasive tumour margin. Subsequently, tumours are 
graded as low-grade (score 0–1) or high-grade (score 2–3), and the authors above previously 
reported that high-grade tumours were associated with an enhanced 5-year survival when 
compared to low-grade tumours (87.6% vs. 47%), in Dukes’ A and B or lymph node-
negative cancers (152). 
Body composition and prognosis 
In a similar fashion to other solid organ tumours, CRC is associated with progressive 
nutritional and functional decline. These factors are associated with disease progression and 
can independently predict poor outcomes (153). In the past, crude measures of nutritional 
decline such as BMI and weight loss have been utilised for prognostic stratification (154). 
An advantage of these measures lies in their ease of use, portability and low cost. BMI is an 
index, and while this enables standardisation of weight for height, it cannot account for the 
contribution specifically of muscle volume, fat volume and the relative distribution of these 
tissue types within the body. In addition, sex and race variations introduce difficulty in 
predicting overall body adiposity from crude measures such as waist circumference or BMI 
(155). As a result, recent interest of the association between CT derived body composition 
and cancer prognosis has evolved. CT scanning makes use of the principle that different 
tissues have a higher or lower radiodensity. Radiodensity is measured by Hounsfield units, 
and thresholds for fat and skeletal muscle can be set such that the area of each tissue type 
can be accurately measured. The measured areas can be standardised for height to develop 
indices such as the subcutaneous fat index, skeletal muscle index, sarcopenia and visceral 
obesity (154, 156).  
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Recent interest has specifically surrounded sarcopenia, which has been described as a marker 
of patient frailty (157) and has been defined as follows: 
“A syndrome characterised by progressive and generalised loss of skeletal muscle mass 
and strength with a risk of adverse outcomes such as physical disability, poor quality of 
life and death” (158). 
Thresholds for skeletal muscle index, such as those developed by Dolan et al., (154) for a 
given BMI, can be used to define patients with radiologically proven sarcopenia. Dolan et 
al. went on to examine a cohort of 650 patients with primary operable CRC and reported 
that sarcopenia was associated with poor cancer-specific and overall survival (154). What is 
not entirely clear however, is the role of body composition in early cancer development or 
adenoma formation and how this may evolve over time. 
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1.2 Screening for colorectal cancer in Scotland 
Principles for mass population screening were first outlined by Wilson and Jungner in 1968 
(159). In general, for a condition to be considered for screening, it must be an important 
health problem, the disease should have a detectable pre-clinical phase, and a better 
prognosis if treated at an earlier stage. In addition, the test used for screening requires 
adequate sensitivity and specificity while remaining acceptable, safe and cost-effective. 
CRC incorporates most of these criteria and is considered a good target for screening (160). 
1.2.1 Evidence underpinning bowel screening 
In Scotland, bowel screening was fully rolled out in 2009. The basic principles are that the 
laboratory detection of occult blood, as a sign of potential CRC, would prompt endoscopic 
visualisation of the colon. Three key trials ensured bowel screening was supported by data. 
In the Minnesota Colon Cancer Study, the researchers randomly assigned 46,000 Americans 
aged 50–80 years to either annual screening for faecal occult blood (FOB), biennial 
screening, or a control group and patients were followed for 13 years. The researchers 
reported that annual FOB screening reduced CRC mortality by 33% compared to control 
groups (161). Similar trials in Nottingham and the Funen trial in Denmark, reported a 
reduction in CRC mortality of 15% and 18% respectively, when participants were 
randomised to biennial FOB testing compared to controls (162) (163).  
1.2.2 The current pathway for the Scottish Bowel Screening Programme 
In Scotland, males and females aged 50–74 years, or those who wish to self-refer at or above 
75 years are invited to take part in biennial screening. An illustration of the current pathway 
for bowel screening in Scotland is represented in Figure 1.7. The Faecal Immunochemical 
Test (FIT) is used for the SBoSP (164). This laboratory test uses antibodies specific to human 
haemoglobin, specifically the globin component, to test for occult blood in the stool. For this 
reason, it does not suffer the disadvantages of its predecessor in Scotland, the guaiac faecal 
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occult blood (gFOB) test. The gFOB test detected the peroxidase activity of haematin in 
faeces. As such, there was a risk that animal blood products, found in raw meat, peroxidase 
rich fruit, and vegetables such as broccoli and cauliflower could illicit false-positive results. 
Since the FIT method detects the globin portion of haemoglobin, which degrades as it 
traverses the gastrointestinal tract, there is a lower chance of detecting occult blood from the 
upper gastrointestinal tract. The FIT screening method measures micrograms of human 
haemoglobin per gram of faeces (µgHb/g). A cut-off of  ≥80µgHb/g is accepted as a positive 
test for screening purposes. The test requires only one sample; thus, it is more 
straightforward and user friendly than its predecessor, which required two samples on three 
separate occasions. It is hoped this will improve uptake by those invited to screening. 
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Figure 1.7: The Scottish Bowel Screening Pathway 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
The National Health Service (NHS) Scotland: The new Scottish bowel screening test (164) 
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1.2.3 Uptake and results in Scotland 
Statistics related to uptake and results of the SBoSP are periodically published by the 
Scottish Government, Information Services Division, as Key Performance Indicator (KPI) 
reports. The KPI report is used to monitor and evaluate the effectiveness of the SBoSP and 
is published at the end of each bowel screening (biennial) round. 
The following information is taken from the latest available report at the time of writing in 
August 2016. This reports data from 2013 to the end of 2015 (165). The KPI report indicates 
that uptake of screening overall was 58%, with males less likely than females to partake 
(54% vs. 61%). There was a significant disparity in uptake depending on the degree of 
socioeconomic deprivation patients were exposed to. Considering Scotland as a whole, in 
the most deprived areas, uptake was 45% compared to 67% in the most affluent areas. These 
results were mirrored when males and females were considered separately. 2% of those who 
took up the invitation had a positive screening test, and 76% went on to have a colonoscopy 
with a 96% completion rate. Females were slightly less likely to have successful completion 
of colonoscopy when compared to males (95% vs. 98%). The KPI reported that 0.5% of 
patients required admission to hospital as a direct result of colonoscopy complications. Of 
those who had a screening test and went on to have a colonoscopy, 7% had CRC detected, 
with a higher incidence in males than females (7% vs. 6%). In those who had a screening 
test result but were negative for cancer, 39% were found to have at least one adenoma, again 
with a higher incidence in males than (45% vs. 30%). 
These results indicate that the SBoSP detects a significant volume of pathology, although 
there is room for improvement in the uptake of invitations. The results of this KPI are related 
to screening rounds where testing was carried out predominantly using the gFOB test. There 
are hopes that the more practical, single sample, FIT method may improve uptake.  
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Data previously published from rounds of the SBoSP have already shown a trend towards 
earlier stage disease, in those without metastases, with the proportion of stage I tumours at 
diagnosis rising from 17% pre-screening to 28% post-screening (p<0.001) (140). 
1.2.4 Screening for high-risk groups. 
Patients who do not fall under the traditional criteria for population screening but who are at 
high risk of CRC as a result of inherited conditions are recommended to undergo screening. 
The ACPGBI in their most recent guidelines recommend that patients diagnosed with 
HNPCC should commence colonoscopy screening at age 25 and undergo annual or biennial 
colonoscopy until age 75 years unless comorbid disease dictates screening should end earlier 
(104). For patients with FAP, colonoscopy surveillance is recommended from age 13–15 
years until 30 years, then 3–5 yearly until the age of 60 years (104). In reality, the majority 
of FAP sufferers, as discussed in Section 1.1.3.3 would undergo subtotal colectomy before 
their fourth decade. 
1.2.5 Risks of bowel screening 
There are a number of disadvantages, drawbacks, and risks of bowel screening. The first is 
cost. The Scottish Government estimated, at the commencement of the SBoSP, that it would 
cost £9 million per year. This is likely to rise with improved uptake and cost of healthcare 
in general (166). Given that less than two-thirds of invitees in Scotland take part in screening, 
despite the estimated £9 million investment, a sizeable proportion of people will not benefit 
from this.  
Although the screening test itself is unlikely to cause any patient complications, the majority 
of the 2% of those with a positive screening result will undergo colonoscopy. The risk of 
serious complications at colonoscopy has been discussed earlier (Section 1.1.5.1), and there 
is a perforation rate of around 1:1,000 (0.1%). This, combined with the 0.5% risk of 
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admission to hospital from screening colonoscopy complications mentioned in Section 
1.2.3, must be balanced against the 7% chance of making a cancer diagnosis. Nonetheless, 
with experienced endoscopists, such as those involved in the SBoSP, the complication rate 
should remain low, since serious complications such as bleeding and perforation are 
associated with low volume endoscopists (167). 
Patient anxiety is another consideration. 600 patients who had undergone gFOB screening 
as part of a screening feasibility study in Denmark were assessed for anxiety related to the 
outcome of the test result prior to any further investigation. Patients with positive gFOB 
results had significantly higher levels of anxiety than those with negative results, and the 
effect persisted for up to three months even after further investigations were negative. 
Nonetheless, anxiety levels returned to baseline by 12 months (168). 
A risk associated with screening that is developing interest, but whose impact has not yet 
been assessed within a bowel screening population, is the risk: benefit ratio of CTC as a 
screening tool. CTC is conducted on screening positive patients who are either deemed unfit 
for a colonoscopy, or have undergone an incomplete colonoscopy. As discussed in Section 
1.1.5.1, there is a high prevalence of ECFs at CTC of around 50–60% (169, 170). The 
majority of which are of no clinical significance. The difficulty lies in whether to investigate 
patients with borderline ECFs further, as this may result in multiple or invasive tests for what 
subsequently turns out to be benign disease (170). This situation could lead to patient anxiety 
during the investigative phase, and there is also an associated monetary and resource cost to 
the health service. 
Furthermore, the problem may be exaggerated depending on the potential yield of positive 
intracolonic findings at CTC. In a situation where the yield of colonic findings is low, but 
the burden of ECFs is high or similar, the implications of ECFs and their possible 
investigation would need to be discussed with the patient. In a previously reported series, 
 71 
 
the yield of important colonic findings was reported as 14% while indeterminate ECFs 
requiring possible investigation was slightly lower at 11% (171). In situations where patients 
are symptomatic, or the referring physician has a higher suspicion of cancer, the potential 
downsides of detecting ECFs may be justified. However, in a publicly funded health system 
with population screening programmes of asymptomatic patients such as the UK, the risk: 
benefit ratio of CTC as a second-line screening tool requires further investigation.
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1.3 Colorectal polyps 
1.3.1 Classification of polyps 
A polyp of the colon or rectum is a protuberance that extends into the gut lumen beyond the 
surrounding mucosa. Adenomatous polyps are of considerable interest and are discussed at 
length in Section 1.4. However, there are a number of non-adenomatous colorectal polyps 
that require consideration. Generally, polyps of the colon or rectum are classified as either 
neoplastic or non-neoplastic types. A neoplasm is a new growth of tissue, whose growth 
continues, despite the absence of conditions for normal cell growth (172), and when a 
neoplastic growth invades adjacent tissues, it is defined as malignant.  
1.3.1.1 Non-neoplastic polyps 
Inflammatory polyps 
These are non-neoplastic projections of the mucosa, which are densely packed with 
inflammatory cells. Morphologically they present as pedunculated (on a stalk) or sessile 
(largely flat). Inflammatory polyps often occur as a result of trauma or surrounding 
inflammatory conditions. Inflammatory pseudopolyps are in fact islands of normal mucosa 
surrounded by ulceration and commonly associated with IBD. Inflammatory polyps 
themselves do not undergo malignant transformation, although, where they are present as 
part of IBD, there is an increased risk of CRC overall for the patient. 
Hamartomatous polyps 
Hamartomatous polyps are formed from cell types that are typically present in the 
gastrointestinal tract, but whose organisation and architecture differ from that normally seen 
in the tissue (173). Examples of hamartomatous polyps in the colon or rectum include 
juvenile polyps, which despite their name, can arise at any age although more common in 
childhood. Juvenile polyps are usually solitary and harbour inflammatory cells, but their 
malignant potential is negligible.  
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There exist several rare and heterogeneous disorders termed “hamartomatous polyposis 
syndromes”. This group of disorders are inherited in an autosomal dominant pattern and are 
characterised by the development of hamartomatous polyps within the gastrointestinal tract 
(173). It is also common for patients to display associated extra-intestinal features. 
Conditions include juvenile polyposis syndrome and Peutz-Jeghers syndrome, amongst 
others. The hamartomatous polyposis syndromes are associated with a significantly 
increased risk of colon cancer as well as other solid organ tumours (174).  
Sessile serrated lesions 
These are a rather heterogeneous classification of polyps which includes hyperplastic polyps, 
serrated adenomas, and serrated adenomas (often synonymous with sessile serrated polyps). 
The classification of serrated lesions is still somewhat debated and evolving (175). 
Hyperplastic polyps are the most common of the non-neoplastic type. They are a type of 
serrated polyp with a characteristic saw-tooth pattern on histological analysis and harbour 
typical cellular components with an absence of dysplasia. Hyperplastic polyps are 
commonly, but not exclusively, small (<5mm) and most readily found in the rectosigmoid 
area (176). A hyperplastic polyp in itself is not believed to have malignant potential. 
Nonetheless, some studies have reported that the presence of hyperplastic polyps in the distal 
colon or rectum are associated with the presence of proximal neoplasia, and in around 5% 
of cases, advanced proximal neoplasia (177). In most circumstances, hyperplastic polyps are 
excised during colonoscopy since it is not always possible to distinguish them from 
adenomatous polyps with certainty. Serrated adenomas differ from hyperplastic polyps in 
that they are usually more prevalent in the proximal colon, likely to be sessile, may have a 
mucous cap, and frequently show signs of dysplasia (178). Sessile serrated polyps are 
thought of as likely precursor lesions to sporadic colon cancer caused by the MSI pathway 
(Section 1.1.3.1) (179). All sessile serrated adenomas should be excised since there is some 
evidence to suggest they result in rapid progression to cancer (180). Whether this is as a 
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result of these lesions being missed previously, due to their sessile nature, or previous 
inadequate removal is unclear. 
1.3.1.2 Neoplastic polyps 
The most common, well known, and widely studied neoplastic polyps of the colon and 
rectum are adenomatous polyps. They are discussed at detail in Section 1.4, but the 
histological characteristics and classification are outlined below. An adenoma is a benign 
tumour, formed from glandular structures in the epithelial lining of organs. Around two-
thirds of colorectal polyps are adenomas, and they are frequently found in the presence of 
synchronous lesions (181, 182). Adenomatous polyps can present as pedunculated, giving 
them a mushroom type appearance, or they can be sessile. Due to their flat nature, sessile 
polyps are frequently harder to identify and excise fully. The official classification for polyp 
morphology is the Paris Classification, which divides adenomas into polypoid and non-
polypoid morphologies (183). 
From a histological perspective, three subclasses of colorectal adenomas are described. Each 
is found with varying frequency in the colon and rectum, and each has a different malignant 
potential. Subtypes include tubular, tubulovillous and villous adenomas [Table 1.6]. Data 
from the National Polyp Study, which examined 3,371 adenomas from 1,867 patients in the 
USA reported some of the earliest data with respect to malignant potential. The researchers 
reported that larger adenoma size and villous architecture were associated with high-grade 
dysplasia (HGD) (p<0.0001), and by inference, harboured a greater malignant potential 
(182). The findings of the National Polyp Study were similar to those presented from a 
10,000 patient database by Nusko et al. [Table 1.7] (184). Nonetheless, the majority of 
adenomas are small at the time of removal and thus have lower malignant potential. Around 
75% of excised adenomas measure less than 1cm in diameter (182). Adenomatous polyps 
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are commonly but not exclusively found distally with approximately two-thirds located in 
the distal colon and rectum (182). 
 
Table 1.6: Histological classification of colorectal adenomas and the risk of malignant 
potential 
 
 
 
  Data from the National Polyp Study, USA (182) 
 
 
 
 
Table 1.7: Adenoma size and the percentage containing invasive carcinoma 
Adenoma size 
(mm) 
Percentage of polyps 
(%) 
Percentage with 
carcinoma (%) 
   
<5 
 
44.9 0 
6-15 
 
31.5 2.2 
16–25 
 
9.4 18.7 
26–35 
 
4.6 42.7 
>35 9.6 75.8 
 
  
 Data reported by Nusko et al. (184) 
 
 
 
 
 
Adenoma subtype Histopathological appearance Presence of HGD 
   
Tubular  
 
 
The majority of the tissue shows a tubular appearance with 
≤25% displaying villous architecture 
Very low (<2%) 
Tubulovillous 
 
 
26–75% of the tissue displays villous architecture Moderate (15%) 
Villous >75% of the tissue has a villous appearance High (30–50%) 
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1.4 Colorectal adenomatous polyps 
1.4.1 Epidemiology 
Colorectal adenomas are common. The reported incidence varies between countries, yet in 
asymptomatic individuals undergoing colonoscopy for varied reasons, an incidence of 
around 25% is reported (185). Amongst bowel screening patients, the incidence is higher. A 
2013 study investigating the early outcomes of the SBoSP reported an adenoma detection 
rate is as high as 47% in those undergoing colonoscopy for a positive screening (139). The 
SboSP reports an adenoma incidence of 0.9% for men and 0.4% for women in those who 
undertook a screening test, regardless of the result (186), which provides an insight into the 
overall prevalence of adenomas in a screening age population. More recent data from the 
SboSP (2013–2015) shows that 39% of patients with a positive screening test who underwent 
colonoscopy, were diagnosed with an adenoma, and 7% with CRC (165). The incidence of 
adenomatous polyps is thus more than five times that of CRC in a screening population. 
1.4.2 Risk factors 
A definite aetiology for primary incident colorectal adenomas has not been identified. 
Potential risk factors are discussed below.  
1.4.2.1 Non-modifiable risk factors 
Demographic factors 
Many of the suggested risk factors for colorectal adenomas bear a resemblance to those for 
CRC. In particular, advancing age and male sex have consistently been associated with 
colorectal adenoma incidence (187, 188).  
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Pre-existing medical conditions 
Diabetes has been reported as a risk factor, and a recent study of 375 patients undergoing 
index colonoscopy in 2014 reported that the risk of colorectal adenomas in younger patients 
aged 40–49 years, with diabetes, was higher than non-diabetics of the same age, OR 3.1 [ 
95% CI; 1.5–6.4, p<0.01] (189). Although UC is a risk factor for the development of CRC, 
studies have reported a lower incidence of dysplastic polyps in these patients compared to 
controls (190, 191). The reason for this is not clear. FAP, as discussed in Section 1.1.3.3, is 
an autosomal dominant genetic disorder caused by a mutation in the APC gene located on 
chromosome five, which results in the formation of hundreds of adenomatous polyps, and 
equates to a 100% lifetime risk of progression to CRC in those left untreated. 
1.4.2.2 Modifiable risk factors 
Lifestyle factors 
Obesity 
Obesity is a growing epidemic, particularly the industrialised world. As discussed in Section 
1.1.2, obesity has been linked to solid organ cancers, including CRC, and several studies 
have linked obesity with colorectal adenoma incidence, albeit with some inconsistent results.  
Three meta-analyses were recently carried out to examine this possible link. The first 
investigated the association between elevated BMI and colorectal adenoma incidence 
reporting that an elevated BMI was associated with a higher risk of incident adenomas, RR 
1.19 [95% CI; 1.13–1.26, p<0.001] per five unit increase, although a high level of 
heterogeneity was displayed between studies (I2=76.8%) (192). The second meta-analysis 
was generally in agreement and concluded that overall, those with BMI ≥25 had a 
significantly increased incidence of colorectal adenomas than those with BMI <25, OR 1.24 
[95% CI; 1.16–1.33, p<0.01], there was moderate heterogeneity between studies (I2=58.9%) 
(193). The third meta-analysis was concerned with abdominal obesity, as measured by waist 
circumference and waist: hip ratio. For colorectal adenoma incidence, the researchers 
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reported a RR of 1.39 [95% CI; 1.13–1.26], when comparing the highest and lowest waist 
circumference, and a RR of 1.22 [95% CI; 1.10–1.35] for the highest vs. the lowest waist: 
hip ratio (194).  
Tobacco smoking 
A recent large study was conducted recruiting 25,000 patients over a 4-year period who 
underwent health screening, including a colonoscopy. The researchers concluded that active 
smoking was an independent risk factor for colorectal adenoma incidence. In women 
specifically, the risk was higher and associated with advanced adenomas (188). 
Alcohol intake 
There is weak evidence that increasing alcohol intake is associated with the incidence of 
advanced adenomas. The aforementioned study of 25,000 participants reported that those 
with higher alcohol use scores were slightly more at risk of colorectal adenomas, OR 1.09 
[95% CI; 1.01–1.18] (188). 
Dietary habits 
Like CRC, red and processed meat has been associated with colorectal adenoma incidence, 
and a recent meta-analysis of 21 studies was conducted (195). The researchers reported a 
summary RR of colorectal adenomas for those with the highest vs. the lowest red meat intake 
of 1.24 [95% CI; 1.12–1.36]. In relation to processed meat, the summary RR was 1.17 [95% 
CI; 1.08–1.26] when comparing the highest vs. the lowest intake; thus it would seem likely 
that higher dietary intake of red or processed meat is associated with a significantly increased 
risk of colorectal adenomas. 
The association between dietary fibre intake and the risk of colorectal adenomas has been of 
interest such that a meta-analysis of case-control and cohort studies was presented in 2014. 
The researchers included 20 studies totalling 10,948 subjects with colorectal adenomas and 
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reported a summary RR for colorectal adenoma incidence of 0.72 [95% CI; 0.63–0.83] when 
comparing high vs. low dietary fibre intake groups (196). 
Despite this perceived benefit in reducing the primary incidence, dietary fibre has not been 
effective in reducing colorectal adenoma recurrence after polypectomy. The Polyp 
Prevention Trial was a multicentre RCT which recruited 2,079 men in North America. 
Participants were included if they had a histologically confirmed colorectal adenoma excised 
within six months of the trial start date. The participants were randomised to either a control 
group or a dietary intervention group, who were assigned to a high fibre, high fruit, low-fat 
diet. The study was unable to demonstrate a significant difference in the adenoma recurrence 
rate between the two groups during a 4-year follow-up (197). When the study period was 
extended for a further 4 years, the results were similar (198). 
1.4.3 Diagnosis and detection 
Colorectal polyps can be diagnosed by radiological imaging such as double-contrast barium 
enema, which has mostly been superseded by CTC. Nevertheless, by far the most common 
method of diagnosis is under direct vision during endoscopic procedures. The majority of 
colorectal polyps are detected incidentally as part of bowel screening or when an endoscopic 
investigation is being undertaken on symptomatic individuals. Confirmation of the polyp 
subtype and whether it is adenomatous can only definitively be made on histological 
examination. However, more recently, interest has centred on the use of narrow-band 
imaging (NBI) during colonoscopy. This technique was first described by Gono et al. in 
2004 (199). It is a technique whereby red light is removed from the endoscopy source by an 
electronic filter and narrowed bandwidths of blue and green light are used preferentially in 
isolation (200). NBI allows enhanced visualisation of the mucosal surface vasculature and 
epithelial pit pattern (201). This affords an advantage over conventional white light as a 
method to enhance the detection of adenomatous polyps and distinguish between neoplastic 
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and non-neoplastic lesions (201). NBI is particularly useful in detecting small flat polyps 
which are notoriously harder to visualise (199). RCTs have reported that trained 
endoscopists, when using NBI, can accurately distinguish small (<5mm) adenomas from 
non-adenomatous polyps (202) under direct vision [Figure 1.8]. Potentially, this would 
allow small lesions that are likely benign and hyperplastic to be left in situ, thus reducing 
the risk of excision and any laboratory processing costs. 
Figure 1.8: Hyperplastic vs. adenomatous polyp on narrow-band imaging 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
                                            A: Hyperplastic polyp in near focus narrow-band endoscopic imaging 
                                          B: An adenomatous polyp in near focus narrow-band imaging at endoscopy 
 
         Figure cropped and reproduced (with permission) from Kaltenbach et al. 2015 (202) 
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1.4.4 The natural history of adenomatous polyps 
As discussed previously, the majority of CRCs arise as a result of the adenoma-carcinoma 
sequence via the chromosomal instability pathway (Section1.1.3.1). This is an essential 
aspect to consider regarding the natural history of adenomatous polyps. Since most 
adenomas are excised endoscopically when found, recent large trials examining their natural 
history is limited; however, historical studies which observed adenomas left in situ over time 
have previously reported on their natural history and provided evidence for the adenoma-
carcinoma sequence.  
A key historical study in 1987 by Stryker et al. reported some of the first and most important 
data on the natural history of colorectal polyps. This retrospective study was conducted in 
the pre-colonoscopy era in the Mayo Clinic, Minnesota, USA (203). The researchers 
identified 226 patients with radiographically diagnosed polyps ≥1cm in size. The single 
largest polyp per patient was labelled as the “index polyp” and where possible was left in 
situ for at least 12 months. The follow-up period included at least two surveillance barium 
enema studies. During follow-up, 83 (37%) polyps increased significantly in size, and 
ultimately 107 (47%) polyps were excised, either surgically or endoscopically, mainly due 
to concerns over continued growth. All excised polyps were adenomatous, and 21 invasive 
carcinomas were detected at the site of the index polyp on histological examination. In 
addition, invasive cancer was detected at a site separate from the index polyp in 11 patients 
during the same follow-up period. The researchers calculated the risk of cancer at the index 
polyp site, if left in situ, was 2.5% at 5 years, 8% at 10 years and rose to 24% at 20 years. 
This report by Stryker et al. was one of the first to suggest that a significant proportion of 
adenomas may progress to CRC if left in situ. These early studies that support the adenoma-
carcinoma sequence have since been corroborated by clinical, epidemiological, molecular, 
and post-mortem data. 
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As discussed previously in Section 1.3.1.2, larger adenoma size and villous histology are 
important determinants of malignant potential (204). Thus, given that larger polyps are more 
likely to progress to adenocarcinoma, these are almost never left in situ. More recent interest 
has surrounded the progression and growth rate over time of smaller polyps, which would 
aid decision making at colonoscopy and help to avoid potentially unnecessary and risky 
excision of small polyps. A historical study published in 1997 by Bersentes et al. monitored 
the growth rate of small polyps (3–9mm) left in situ for a 2-year observation period with bi-
annual colonoscopy  and reported that no polyps completely regressed, although hyperplastic 
polyps could reduce in size (205).  
A more recent study conducted in the USA in 2013 observed volumetric growth rates of 
small (6–9mm) colorectal polyps left in situ, using CTC. Median follow-up was 2 years, and 
the researchers reported that 50% of these small polyps remained static in size, while around 
25% regressed and 25% progressed (206). Histological evaluation of the polyps was 
undertaken, which demonstrated that adenomas with at least one advanced feature (size 
≥1cm, villous architecture or HGD) underwent more rapid growth, while no polyps 
progressed to adenocarcinoma in this study. 
In summary, it would appear that the majority of adenomas do not progress to invasive 
cancer, yet the risk increases the longer a polyp remains in situ, especially if that polyp is 
large. Most adenomas will remain the same size, and some will advance in size. Larger 
polyps, and those that progress in size, harbour the highest malignant potential while smaller 
polyps (<1cm) are unlikely to progress to malignancy in under 5 years (207). This timeline 
partly underpins the colonoscopy surveillance intervals outlined later in Section 1.4.7.  
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1.4.5 Management of colorectal polyps and colorectal adenomas 
1.4.5.1 Simple polypectomy 
Evidence exists that colorectal polypectomy reduces subsequent CRC incidence and 
mortality (208). For this reason, the principle management of these lesions is excision, where 
it is safe to do so, and if it is in the best interests of the patient. A number of manoeuvres can 
be employed for a polypectomy, including a cold biopsy or cold snare technique, which can 
be used on small polyps less than 4mm in size. For stalked lesions, a snare and diathermy 
technique can be used. The polyp should be snared and resected approximately halfway up 
the stalk to facilitate further endoscopic treatment should post-polypectomy bleeding occur. 
An effort should be made to retrieve the polyp for histological examination. 
1.4.5.2 Endoscopic mucosal resection 
Endoscopic mucosal resection (EMR) is a technique for resection of larger sessile or flat 
polyps. It requires the injection of fluid into the submucosa to elevate the polyp mucosa 
away from the muscularis layer of the bowel wall, which minimises thermal injury during 
the diathermy assisted snare (209). If a polyp does not lift easily, it should raise concern with 
the endoscopist that the lesion might have undergone malignant invasion of the submucosa. 
In these cases, the polyp should be marked with dye, biopsied, and referred to the local MDT 
meeting for discussion. 
1.4.5.3 Risk factor modification 
Although risk factor modification is not the mainstay of primary adenoma management, it 
should be emphasised to a patient. A teachable moment exists following polypectomy when 
patient education to minimise the risk of polyp recurrence should be undertaken. 
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1.4.5.4 Chemoprevention 
Several studies have examined the merit of agents for chemoprevention to reduce the 
incidence of colorectal adenomas and subsequent post-polypectomy recurrence. Aspirin is 
probably the best publicised of these agents. The use of aspirin as a chemopreventive agent 
for CRC was discussed in Section 1.1.2.2. In addition to aspirin, other agents such as vitamin 
D, calcium and fibre supplementation have been investigated. 
A recent well-designed, multi-centre, RCT, which was triple blinded and placebo-controlled 
was conducted in Europe, Russia and the USA. It aimed to compare the chemopreventive 
effects of aspirin, vitamin D and calcium vs. placebo on colorectal adenoma recurrence. The 
study concluded at three years and reported no effect on adenoma recurrence (210). These 
findings are in contrast to a recent meta-analysis which included nine studies with 8,521 
participants and examined the effect of NSAIDs on the risk of adenoma recurrence (211). 
The researchers concluded that, although NSAID use reduced adenoma recurrence, the effect 
was not maintained after three years. The narrative is similar when considering aspirin. A 
recent Cochrane controlled trial, the APACC (Association pour la Prévention par l’Aspirine 
du Cancer Colorectal Study Group) trial, published their 4-year follow-up results (212). The 
researchers found that although daily low dose aspirin reduced adenoma recurrence 
significantly at 1 year, the effect was diminished by 4 years (212). As a result of the above, 
and the potential side effect profile of aspirin and NSAIDs, there has not been a widespread 
recommendation for their use as chemo protective agents.
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1.4.6 Adenoma recurrence and post-polypectomy surveillance 
Follow-up studies have demonstrated a significant number of patients develop recurrent 
adenomas after polypectomy, and reports suggest that recurrence is detected in up to two-
thirds of patients. Since a significant proportion of patients are diagnosed with recurrent 
adenomas at follow-up, post-polypectomy surveillance guidelines have been developed, 
which differ slightly between the European Union (EU), USA and the UK. 
In the UK, the most recent guidelines, were published in 2010 by the BSG (15). The 
guidelines were developed using the best available evidence at the time that suggested the 
future risk of developing CRC, and any advanced adenomas were related to the size and 
multiplicity of the baseline adenomas. Based on this, post-polypectomy patients are classed 
as either low, intermediate or high-risk, and post-polypectomy surveillance varies for each 
group. The BSG guidelines recommend that for those with 1–2 small (<1cm) adenomas 
(low-risk), a repeat colonoscopy at 5 years can be offered, but it is optional. For patients with 
3–4 small adenomas or at least one adenoma ≥1cm (intermediate risk), a follow-up 
colonoscopy at 3 years is recommended, and for patients with ≥5 small adenomas or ≥3 
adenomas where at least one is ≥1cm (high risk), a colonoscopy is recommended at 1 year 
from the index examination [Figure 1.9]. Although the guidelines call for surveillance, it is 
meant only as a guide, and the clinician can use their discretion as to how closely it should 
be followed while considering the patient wishes, age and comorbid status. 
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Figure 1.9: BSG guidelines for post-polypectomy surveillance 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Cairns et al. (2010) (15), initially published by Atkin et al. (2002) (213) 
 
Reproduced with permission from BMJ Publishing Group LTD 
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1.4.7 Polyp cancer 
Polyp cancers, also known as malignant polyps, are those with a benign appearance on 
macroscopic examination, but on histological scrutiny, display a focus of invasive carcinoma 
that has breached the muscularis mucosae and invaded the submucosa (214). Up to 5% of 
all excised polyps may be polyp cancers (215).  
The management of a patient with a malignant polyp is troublesome because it can be 
challenging to determine whether malignant cells remain within the bowel wall or are present 
in regional lymph nodes after polypectomy. Currently, the evidence base underpinning the 
management of these lesions is poor. Clinicians can employ one of two strategies. The first 
is surgical resection of the affected bowel, with the risk of morbidity from surgical resection, 
but the advantage of full pathological staging. However, a significant proportion of patients 
undergoing resection as a result of polyp cancers turn out to be negative for residual disease 
and lymph node involvement. In essence, these patients have undergone an unnecessary 
operation, with the benefit of hindsight (216). 
The second option is surveillance only, with repeat biopsies and regular interval 
colonoscopy. In this approach, the challenge is to provide patients with a reasonable 
prognostic estimation, and some prognostic information can be yielded from the 
histopathological examination of the malignant polyp specimen. Two validated prognostic 
systems include the Haggitt criteria and the Kikuchi level. The Haggitt criteria are utilised 
mainly for pedunculated polyps and assess the degree of invasion based on the level of the 
stalk involved. Haggitt described four levels, with level 1, 2 or 3 less likely to be associated 
with lymphatic spread than level 4, which is classed as invasion below the stalk (217). 
When considering sessile malignant polyps, the absence of a stalk would automatically 
classify these lesions as a Haggitt level 4. In these instances, the Kikuchi level is more 
appropriate. The Kikuchi system divides the level of tumour invasion of the submucosa into 
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three (sm1, sm2, and sm3) (218). Sm1 and sm2 refer to the uppermost two-thirds of the 
submucosa and are associated with an approximate 10% risk of lymphatic involvement, 
whereas sm3 (lower third of the submucosa) equates to a 25% risk. The main drawback of 
this system relates to the requirement of muscularis propria in the biopsy, without which the 
level of submucosal involvement cannot be assessed. However, this depth of excision is not 
routinely conducted endoscopically, and similarly, piecemeal excision renders the sample 
challenging to orientate and process correctly. 
The ACPGBI in their position statement in 2013 followed a risk stratification model using a 
scoring system to predict the risk of residual disease after malignant polyp excision (214). 
They indicated that an endoscopic resection margin <1mm, Haggitt level 4, or Kikuchi level 
3 are associated with a >20% risk of residual disease. If any of these criteria are met, the 
ACPGBI recommends full surgical resection assuming patient fitness allows. Other risk 
factors such as poor cell differentiation, mucinous tumours, tumour budding and 
lymphovascular invasion were included in the model but were allocated less weighting 
(214). In any case all polyp cancers should be discussed at the MDT to decide on appropriate 
management.    
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1.5 Summary and aims 
1.5.1 Summary 
Important topic  
CRC is the fourth most common cancer in the UK. For males and females combined, it is 
the second most common cause of cancer death in the UK (1). A number of risk factors have 
been studied in relation to CRC development, with advancing age, male sex, lifestyle factors, 
IBD, obesity and genetic predisposition the most influential. Cancer prevention strategies 
could involve both risk factor modification and active intervention such as polypectomy as 
part of a bowel screening programme. A significant number of variables can be considered 
when staging colorectal cancer and deciding upon further treatment. Outside traditional 
methods such as tumour factors and lymph node status; systemic inflammation based scoring 
systems and body composition indices are increasingly linked with long term outcomes and 
prognosis. 
Polypectomy is effective 
The majority of CRCs arise as a result of malignant transformation of colorectal adenomas 
via the adenoma-carcinoma sequence. Data from medium and long-term follow-up trials, 
notably the long-running UK flexible sigmoidoscopy trial have consistently shown that 
lower gastrointestinal endoscopy reduces both the incidence (26% reduction) and mortality 
(30% reduction ) from CRC (219). This is most likely as a result of endoscopic polypectomy 
and post-polypectomy surveillance. The SboSP has been successfully rolled out across 
Scotland and has resulted in earlier stage presentation (in those without metastasis) (140). 
Furthermore, the SboSP is detecting and removing a sizable number of colorectal adenomas, 
and over the long term, it is likely this will reduce CRC incidence. 
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Risk factor identification to enhance post-polypectomy surveillance guidelines and 
streamline services  
With the above in mind, ensuring a colon clear of adenomatous polyps is highly desirable. 
Currently, UK guidelines for post-polypectomy surveillance are based solely on the number 
and size of excised adenomas. Nevertheless, increasingly, across all disciplines of medicine, 
a move towards patient-centred, personalised and host focussed treatment is underway. It is 
now accepted that a tumour cannot be considered separately from its host as complex 
interplay exists between the two. As such, the influence of host factors such as age, sex, and 
BMI require further examination, particularly within the context of a bowel screening 
programme to determine if they warrant inclusion into screening or post-polypectomy 
surveillance guidelines. In addition, a better understanding of adenoma-specific risk factors 
may lead to the identification of additional adenoma features that can predict future risk and 
influence modification of surveillance guidelines. This may help to streamline services and 
enhance cost effectiveness for the health service while minimising the frequency of 
investigation for patients. 
Inflammation as a link between the host and neoplastic formation and proliferation 
A significant body of evidence now exists linking inflammation with cancer and 
inflammation has been described as the 7th hallmark of cancer. While systemic inflammation 
is associated with poorer outcomes in CRC, the local inflammatory response is associated 
with improved outcomes. Ultimately this demonstrates there exists a complex interplay 
between local and systemic inflammation and its varying effect on early cancer development, 
proliferation and ultimately prognosis. What is not clear is the role systemic inflammation 
plays in the pre-malignant stage of CRC, and what influence it may have on initial adenoma 
formation and the progression to invasive carcinoma. There are a small number of population 
studies mainly retrospective that have investigated this, but there remains a paucity of 
evidence in the literature. Since there is some evidence that aspirin, likely due to its anti-
inflammatory properties, is a chemoprotective agent for CRC, it is likely that inflammatory 
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pathways may be involved in neoplastic initiation and proliferation. Exploring whether 
inflammation and in particular systemic inflammation is linked with early or pre-malignant 
stages of CRC might allow this to be targeted for intervention. It perhaps would allow 
modification of traditionally non-modifiable, but strong, CRC risk factors such as age and 
male sex if inflammation could be exposed as a link between the two.  
The role of obesity and body composition in pre-malignant and early disease 
Elevated BMI and obesity are modifiable lifestyle factors and implicated in several 
neoplastic and non-neoplastic diseases. Although moderate links between obesity and CRC 
specifically have been described, there remains a body of conflicting evidence. This is 
particularly evident with regards to adenomas and warrants further study, particularly within 
a West of Scotland population which has differing socioeconomic and demographic 
variables in comparison to populations in some previous reports. 
In terms of CRC, recent interest has centred on body composition, particularly with regards 
to visceral obesity and sarcopenia and its association with prognosis and outcomes. 
Certainly, growing evidence exists that body composition, in particular sarcopenia, is 
associated with poorer outcomes in established cancer. Nevertheless, the role of body 
composition with regards early and pre-malignant disease is not fully understood, and there 
is a paucity of studies examining this. A greater understanding of the interplay between body 
composition and its role in pre-malignant disease, the better to target timely intervention, is 
warranted.  
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Screening risk and benefits  
As previously mentioned, good evidence exists indicating that bowel screening leads to an 
earlier presentation of CRC, while colonoscopy and polypectomy reduce the incidence of 
CRC. However, there are risks and drawbacks of screening. Namely the cost, the >50% 
negative colonoscopy rate, the possible discomfort, and any complications associated with 
this intervention. Furthermore, boundaries are being pushed ever more for bowel screening 
resulting in a significant number of CTC scans conducted as a direct result of the SBoSP. 
Consequently, a significant number of incidental ECFs are identified. In some instances, 
these findings can have a positive impact on patient health by identifying serious pathology 
such as aneurysmal disease or occult malignancy. However, in a proportion of cases these 
findings can result in potentially distressing, expensive and sometimes invasive further 
investigation for what subsequently is benign disease. To date; in the UK, there are no 
previous reports examining the cost, risks, benefits and implications of CTC with regards 
ECFs as part of bowel screening, and this warrants scrutiny. This is particularly important 
given that screening is costly to both patients and the health service. Any additional burden 
on resources requires careful analysis. The goal being to streamline services in primary 
screening and post polypectomy follow up. 
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1.5.2 Aims 
1. To investigate the impact of advancing age, sex, and BMI on the incidence of post-
polypectomy adenoma recurrence by means of a systematic review and meta-analysis of 
the current literature. 
2. To investigate the association between adenoma-specific and host-specific risk factors 
for colorectal adenoma recurrence in intermediate and high-risk patients from the SBoSP. 
3. To examine the association between primary colorectal neoplasia incidence and host 
characteristics, including obesity and the systemic inflammatory response using 
prospectively collected data from patients attending for colonoscopy as part of the SBoSP. 
4. To examine the association between body composition, particularly visceral obesity and 
sarcopenia, and primary colorectal neoplasia incidence in patients attending for CTC as 
part of the SBoSP. 
5. To examine the cost, risks, benefits and implications of CTC with regards ECFs and its 
resulting impact on resources and streamlining of care in the SBoSP.
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2 THE INFLUENCE OF AGE, SEX AND BMI ON 
ADENOMA RECURRENCE, A SYSTEMATIC 
REVIEW OF THE LITERATURE AND META-
ANALYSIS 
2.1 Introduction 
An adenoma is a benign tumorous growth that arises from tissue of glandular origin. It is 
generally accepted that most CRCs arise in or from pre-existing adenomas (213). Evidence 
for the adenoma-carcinoma sequence stemmed from an early study carried out in 1987 by 
Stryker et al. that monitored colonic polyps ≥1cm left in situ for a minimum of 1 year (203). 
Invasive cancer was subsequently diagnosed at many of the polyp sites during follow-up. A 
similar but larger study by Nusko et al. (1997), supported the adenoma-carcinoma sequence 
in CRC (220). The researchers looked at 11,380 colorectal adenomas excised during surgery 
or colonoscopy and found 11.6% of them had invasive carcinoma. Cho and Vogelstein 
(1992) described a biological model of tumorigenesis via the adenoma-carcinoma sequence 
(221). Their model proposed that tumours arise as a result of mutational activation of 
oncogenes coupled with the inactivation of tumour-suppressor genes. They described 
evidence showing that a proportion of intermediate and end-stage adenomas display 
activation of the RAS oncogene in a similar manner to carcinomas. As such, there is 
significant interest in the detection and timely removal of colorectal adenomas prior to 
malignant transformation. 
In the UK, bowel screening programmes have been rolled out in a stepwise manner over the 
last decade. Their aim is to increase the frequency of “early-stage” CRC diagnoses and 
reduce long-term cancer incidence as a result of polypectomy (222). Since the introduction 
of the SBoSP in 2006, there has been a reduction in the rate of emergency cancer 
presentations and in those with no distal metastases; a notable shift towards the diagnosis of 
earlier stage colorectal tumours in this population (140). Atkin et al. (2010) published data 
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from the UK flexible sigmoidoscopy trial (223). This RCT reported that a once-off flexible 
sigmoidoscopy, as a screening tool for CRC, reduced both incidence and mortality from 
CRC. This reduction in incidence of CRC is most likely as a result of polypectomy at the 
time of sigmoidoscopy. This gave rise to a vested interest in removing adenomas whenever 
they are identified.  
Crucially, patients found to have newly diagnosed adenomatous polyps on initial 
colonoscopy are likely to have additional polyps diagnosed at follow-up examination (224). 
Older studies have reported an adenoma recurrence rate in post-polypectomy patients of 
30%–60% (225) (224). Some of these studies are ageing; however, even in the endoscopic 
era, the reported recurrence rates are similar (226-229). 
This recurrence rate is disputed by some observers on the basis that it may be unclear which 
adenomas are truly recurrent as opposed to synchronous adenomas that were missed at the 
time of the initial colonoscopy. Various studies have sought to quantify the adenoma miss 
rate at colonoscopy by conducting a second examination shortly after the initial 
polypectomy, and documented miss rates vary from 5–28%, with smaller polyps (<5mm) 
the most commonly missed (230-233). 
Adenoma size and number are the two factors that are used to produce the BSG guidelines 
for post-polypectomy surveillance (15). The guidelines recommend carrying out a follow-
up colonoscopy at three years in patients with 3–4 small adenomas or at least 1 adenoma 
≥1cm in size. For patients with ≥5 small adenomas or ≥3 adenomas where at least one is 
≥1cm, a colonoscopy is carried out at one year from the index procedure.  
However, in addition to adenoma-specific factors, it is increasingly recognised that host 
characteristics may play a role in adenoma recurrence. In particular, the current guidelines 
do not account for host factors such as age, sex, or BMI. 
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With this in mind, the aim of the present study was to carry out a systematic review and 
meta-analysis of the available raw data from the literature to investigate the influence of age, 
sex, and BMI on colorectal adenoma recurrence. This could potentially help refine the 
current surveillance guidelines by introducing patient-specific risk factors.  
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2.2 Materials and methods  
Search strategy 
The present study was conducted with three main areas of interest. The influence of age ≥60 
years, male sex, and BMI on the rate of recurrence of colorectal adenomas post-
polypectomy. 
A comprehensive keyword literature search was carried out using the following databases: 
The USA National Library of Medicine (MEDLINE), Excerpta Medica Database 
(EMBASE) and PubMed. Furthermore, the Cochrane Database of Systematic Reviews was 
searched. A pre-planned comprehensive search strategy was employed and carried out 
between October 2015 and January 2016. Appropriate Ovid truncation [($) (?)] was used to 
ensure variations in spelling and word endings did not result in potentially useful papers 
being missed. Non-English language (unless fully translated), animal, duplicate and abstract-
only studies were excluded. Systematic reviews were included in the meta-analysis only if 
the raw data required for the present study were able to be extracted, and the original papers 
were unavailable or not already included in the present review. The search strategy is 
outlined below. 
• For the influence of age ≥60 years on the incidence of colorectal adenoma recurrence: 
o (Age) AND (Colorectal OR Colon$ OR Rectal OR Rectum) AND (Polyp? 
OR Adenoma$) AND (Recur$ OR Metachronous) 
• For the influence of male sex on the incidence of colorectal adenoma recurrence: 
o (Sex OR Male OR Female OR Gender) AND (Colorectal OR Colon$ OR 
Rectal OR Rectum) AND (Polyp? OR Adenoma$) AND (Recur$ OR 
Metachronous) 
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• For the influence of BMI on the incidence of colorectal adenoma recurrence: 
o (BMI OR Body Mass Index OR obesity OR weight Or Obese) AND 
(Colorectal OR Colon$ OR Rectal OR Rectum) AND (Polyp? OR 
Adenoma$) AND (Recur$ OR Metachronous) 
Analysis of manuscripts 
The full text of each potentially relevant study was obtained and analysed. Inclusion criteria 
were decided on by the primary investigator (DD) and senior investigator DM). To be 
considered for inclusion, studies had to report on endpoint data with respect to age, sex, BMI 
and the number of patients in each group with a recurrence of adenomas. Adenoma 
recurrence of any subtype (such as non-advanced or advanced) was included. The most 
widely accepted definition of advanced adenomas is as follows: the presence of at least one 
adenoma with at least one of the following features: ≥1cm in size, any villous histology or 
HGD. Data from intervention trials were included if the tested intervention was shown to 
make no significant or only a borderline difference compared to the control group. Studies 
with <250 patients were excluded. Studies were required to include patients that had 
undergone at least one initial full colonoscopy and polypectomy, with a follow-up 
colonoscopy a minimum of six months later. Patients diagnosed with HNPCC, FAP, CRC, 
IBD or those who had undergone previous polypectomy were excluded. Similarly, studies 
that examined the colon by any method other than colonoscopy (barium enema, CTC, 
flexible sigmoidoscopy) were excluded. A hand search of bibliographies was initiated to 
identify additional papers of interest. Paper selection, examination and data extraction were 
completed by the author (DD) with any uncertainties discussed with a senior author (DM). 
Flow charts of the study selection process for each variable of interest are shown in Figure 
2.1, Figure 2.2 and Figure 2.3. 
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Studies used widely varying data reporting methods such as OR’s, RR, HRs, and simple 
percentages. In order to combine as many studies as possible, raw numerical data pertaining 
to the total number of participants and the number of these participants who went on to have 
recurrent adenomas were extracted from the studies for the meta-analysis. These data were 
analysed using Review Manager 5.3 (The Nordic Cochrane Centre, The Cochrane 
Collaboration, Copenhagen, Denmark) software. OR’s were calculated for the influence of 
age >60 years, male sex and BMI on adenomatous polyp recurrence. A random-effects 
model was used to account for the degree of variability in study methodology and adenoma 
detection. Heterogeneity of data was estimated using the I2 statistic, and two-tailed p-values 
<0.05 were considered to be statistically significant. The Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) statement was used as a basis for the 
methodology of this review.  
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Figure 2.1:Flow chart of the study selection process. Age ≥ 60yr as a risk factor for 
adenoma recurrence 
 
Primary search 
(n=2881) 
Excluded (n=2868) 
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language, non-relevant 
outcomes  
• Abstract review  
Bibliography hand search 
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Full text obtained 
(n=13) 
Full text assessed 
(n=26) 
Excluded (n=19) 
• Absent raw data 
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Studies included for analysis 
(n=7) 
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Figure 2.2: Flow chart of the study selection process. Male sex as a risk factor for 
adenoma recurrence 
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Figure 2.3: Flow chart of the study selection process. BMI ≥ 25 as a risk factor for 
adenoma recurrence 
Primary search 
(n=301) 
Excluded (n=291) 
• Duplicates, non-English 
language, non-human 
studies  
• Excluded at title/abstract 
review  
Bibliography hand search 
(n=3) 
Full text obtained 
(n=10) 
Full text assessed 
(n=13) 
Excluded (n=9) 
• <250 participants 
• Absent raw data 
Studies included for analysis 
(n=4) 
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2.3 Results 
The influence of age ≥60 years on colorectal adenoma recurrence 
A total of seven studies met the inclusion criteria to investigate age ≥60 years as a risk factor 
for colorectal adenoma recurrence including one RCT (224), 5 retrospective cohort studies, 
and 1 study which pooled data from non-effect RCTs [Table 2.1] (234-239). Two studies 
carried out a second colonoscopy within the first year of the baseline colonoscopy, to remove 
any missed polyps before re-assessing for recurrent adenomas >1 year after the clearing 
colonoscopy (236, 237). Six studies reported an OR pertaining to an increased risk of 
recurrence in those aged ≥60 years (224, 235-239); however, it did not reach statistical 
significance (239). A meta-analysis of the seven selected studies comparing the incidence of 
colorectal polyp recurrence included 22,547 patients, of which 7,087 (31%) had at least one 
recurrent adenoma at follow-up. 9,413 (42%) patients were aged ≥60 years. Among these 
patients, 3,319 (35%) had recurrent adenomas at surveillance compared to 3,768 (29%) in 
those aged <60 years. The summary OR for adenoma recurrence if aged ≥60 years compared 
to <60 years was 1.56 [95% CI; 1.13–2.14, p<0.01] [Figure 2.4].  
Assessment of heterogeneity and publication bias  
The I2 statistic was 95%, indicating a considerable degree of heterogeneity. The funnel plot 
[Figure 2.5] suggests minimal publication bias with smaller studies showing a greater spread 
of results.
  
 
 
1
0
4
 
Figure 2.4: Forrest plot. The impact of age ≥ 60 years on the incidence of colorectal adenoma recurrence 
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Figure 2.5: Funnel plot. Studies reporting the impact of age ≥ 60 years and the incidence of colorectal adenoma recurrence 
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The influence of male sex on colorectal adenoma recurrence 
Twelve studies met the present study meta-analysis inclusion criteria [Table 2.2] (234-236, 
239-247). Eight were retrospective cohort studies (234-236, 239, 242, 245-247), two were 
retrospective analyses of pooled data (240, 241) and two studies were conducted using data 
from non-effect RCTs (243, 244). A meta-analysis of the twelve studies included 31,277 
patients. 12,353 (39%) had a recurrent adenoma at follow-up. 20,215 (65%) were male. 
8,787 (43%) of males and 3,566 (32%) of females developed a recurrent adenoma during 
post-polypectomy surveillance. ORs calculated from all twelve studies individually 
indicated a positive association between male sex and adenoma recurrence. However, three 
studies only achieved borderline significance. The summary OR for the influence of male 
sex on adenoma recurrence at post-polypectomy surveillance was 1.58 [95% CI; 1.42–1.76, 
p<0.001] [Figure 2.6]. 
Assessment of heterogeneity and publication bias  
The I2 statistic was 71%, indicating a moderate degree of heterogeneity as indicated on the 
funnel plot [Figure 2.7].
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Figure 2.6: Forrest plot. The impact of male sex on colorectal adenoma recurrence 
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Figure 2.7: Funnel plot. Studies reporting the impact of male sex on colorectal adenoma recurrence 
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The influence of BMI on colorectal adenoma recurrence  
Four studies met the inclusion criteria, there was one retrospective cohort study, one pooled 
analysis, and two studies used data from non-effect RCTs [Table 2.3] (240, 241, 243, 246) 
and reported on both BMI and colorectal adenoma recurrence while citing raw data that 
could be used in the present meta-analysis. Three studies split participants into three groups 
as follows: BMI <25 (normal weight), 25 ≤ BMI <30 (overweight), and BMI ≥30 (obese) 
(240, 241, 243). One study split participants into two groups (BMI <25 and BMI ≥25) (246). 
The meta-analysis included 13,606 patients of which 6,275 (46%) developed at least one 
adenoma during follow-up. 9,224 (68%) patients had a BMI ≥25. 4,431 (48%) of those with 
a BMI ≥25 were found to have a recurrent adenoma, compared to 1,844 (42%) of those with 
BMI <25. The summary OR for developing recurrent adenomas in those with a BMI ≥25 
was 1.35 [95% CI; 1.14–1.58, p<0.001] [Figure 2.8]. 
Assessment of heterogeneity and publication bias  
The I2 statistic was 69%, indicating a moderate degree of heterogeneity. The funnel plot is 
limited by the low number of studies included, but a trend towards publication bias is evident 
with a small positive skew of the lowest precision study [Figure 2.9].
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Figure 2.8: Forrest plot. The impact of BMI ≥ 25 on colorectal adenoma recurrence 
 
 
 
 
 
 
 
 
 
 
  
  
 
1
1
1
 
Figure 2.9: Funnel Plot. Studies reporting on the impact of BMI ≥ 25 on colorectal adenoma recurrence 
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2.4 Discussion 
The results of the present meta-analysis suggest that advancing age and male sex are risk 
factors for the development of recurrent colorectal adenomas after polypectomy. 
Furthermore, the analysis supports the hypothesis that higher BMI was associated with an 
increased rate of colorectal adenoma recurrence compared to a lower BMI. Therefore, it is 
clear that host factors are likely to play a role in the development of recurrent colorectal 
adenomas, highlighting a potential benefit of including them in follow-up surveillance 
programmes. 
Regarding advancing age, the results of the present meta-analysis showed that age ≥60 years 
was associated with colorectal adenoma recurrence when compared to those <60 years. 
These results highlight older age as a risk factor for recurrence, but the magnitude of its 
effect varied between studies which likely accounted for the heterogeneity observed. The 
results of the present meta-analysis are consistent with two previously published meta-
analyses. Martinez and co-workers conducted a pooled analysis (n=9,167) of post-
polypectomy outcomes from eight North American interventional studies aimed at the 
prevention of colorectal adenoma recurrence (248). The researchers reported an association 
between advanced age and non-advanced adenoma recurrence, adjusted OR 1.10 [95% CI; 
0.98–1.24], OR 1.21 [95% CI; 1.05–1.38] and OR 1.24 [95% CI; 0.69–2.25] for ages 60–
69, 70–79 and 80+ years, respectively. However, only the trend was significant (p<0.001), 
making it difficult to accurately quantify the risk for each age group. In the same meta-
analysis, a significant association was reported between advancing age and the development 
of advanced adenomas (≥1cm size, villous features, or HGD). The researchers reported 
adjusted OR 1.39 [95% CI; 1.16–1.68], OR 1.72 [95% CI; 1.40–2.11] and OR 2.70 [95% 
CI; 1.31–5.57] in those aged 60–69, 70–79 and 80+ years respectively. In 2011, a further 
meta-analysis of 27 studies was conducted by De Jonge and colleagues, which included all 
  
113 
 
relevant studies where participants underwent a baseline colonoscopy and surveillance 
(249). They examined the association between adenoma and host factors and the recurrence 
of any adenoma, but they did not distinguish between non-advanced and advanced 
adenomas. Intervention trials aiming to reduce the rate of polyp recurrence were eligible for 
inclusion if no statistically significant difference had been found between the groups in the 
trial. In contrast to the present study, no minimum participant numbers were set, and follow-
up was not required to be endoscopic. Post-polypectomy surveillance carried out by barium 
enema, or CTC was included by the researchers. The researchers reported a summary RR of 
1.65 [95% CI; 1.38–1.93] for age ≥60 years vs. age <60 years.  
These results indicate that advancing age, particularly ≥60 years, is likely to be a risk factor 
for recurrent colorectal adenomas. The rate of recurrence may increase in a linear fashion 
with advancing age, and older patients may be more likely to develop advanced adenomas 
after polypectomy compared with their younger counterparts. 
Concerning sex, the results of the present meta-analysis suggest that male sex is a significant 
risk factor for the development of recurrent adenomas, consistent with the findings of the 
previous two meta-analyses described above. In the meta-analysis by Martinez and 
colleagues, the summary-adjusted OR of a male developing either a non-advanced or 
advanced, recurrent adenoma irrespective of age was 1.45 [95% CI; 1.30–1.62] and 1.40 
[95% CI; 1.19–1.62], respectively. In the meta-analysis by De Jonge and colleagues, male 
sex was associated with a RR of 1.22 [95% CI; 1.12–1.32] for recurrent adenomas of any 
type.  
Regarding BMI, the results of the present meta-analysis imply there is a significant 
association between higher BMI and recurrent colorectal adenomas when compared to those 
with a lower BMI. Taniguchi and colleagues in 2014 reported an OR of 1.97 [95% CI; 1.49–
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2.61, p<0.001] for any adenoma recurrence in subjects with higher BMI (≥25) compared to 
lower BMI (<25) (246). In the meta-analysis by Martinez and colleagues discussed 
previously, an OR of 1.23 [95% CI; 1.08–1.41, p<0.05] is reported for non-advanced 
adenoma recurrence, in those with a BMI ≥30, compared to those with a BMI <25.  
Considering advanced adenoma recurrence specifically, the same researchers report an OR 
of 1.00 [95% CI; 0.84–1.19] for those with a BMI of 25–29.9 and an OR of 1.13 [95% CI; 
0.93–1.38] for those with BMI ≥30, (p-trend=0.23) (248). Therefore, higher BMI would 
appear to be a risk factor for recurrence of non-advanced adenomas; however, it is unclear 
if the same can be said for advanced adenoma recurrence. 
Moreover, it remains unclear if risk increases with ever-increasing BMI in a linear fashion. 
None of the studies included in the present meta-analysis examined morbid obesity (BMI 
≥35). It is also unclear whether a higher BMI is associated with the development of advanced 
adenomas. Furthermore, the health risks associated with increasing BMI have been shown 
to occur at a lower BMI in Asian populations when compared to western populations (250). 
Although the WHO classification remains unchanged at present, it is likely the classification 
of obesity should be lower in Asian populations. This makes comparisons of the effect of 
BMI and the label of “obesity” on adenoma recurrence between studies in Asian and western 
populations difficult.  
The underlying mechanism for the observed association between advancing age, male sex, 
and increasing BMI on colorectal adenoma recurrence is not fully understood. A greater 
understanding of these mechanisms would help clinicians refine post-polypectomy 
surveillance guidelines. Finding and removing a colorectal adenoma may act as a “teachable 
moment” for a patient, where there can be a clinical intervention, such as dietary changes, 
weight loss or administration of a chemoprotective agent in order to reduce the chance of 
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adenoma recurrence. Unlike higher BMI, age and sex are non-modifiable risk factors; 
however, the mechanism by which age and sex mediate polyp recurrence may be modifiable.  
A plausible mechanism by which age and BMI play a role in adenoma formation is through 
a chronic inflammatory response. Clinical studies have previously suggested an association 
between colorectal adenoma prevalence and higher concentrations of circulating pro-
inflammatory cytokines IL-6 and tumour necrosis factor-α (TNF-α) (251). It has been 
suggested that advancing age is associated with chronic systemic inflammation (252), 
sometimes termed “inflammaging” and that this is associated with the morbidity and 
mortality seen in elderly people. In 2013, Delongui et al. reported that increasing age was 
associated with higher circulating CRP in otherwise apparently healthy individuals (253). 
Therefore, the presence of an age-associated chronic systemic inflammatory response may 
be a contributory factor for the higher polyp recurrence in older subjects. 
A higher BMI has been linked with CRC. A meta-analysis by Renehan et al. (2008) 
demonstrated the relationship between increasing BMI and the incidence of colonic as well 
as a number of additional adult cancers (254). Studies by Visser and colleagues in 1999 and 
Aronson in 2004  indicate that elevated levels of CRP were found in overweight and obese 
patients when compared to a population of non-obese patients (255) (256). In addition, 
Renehan and colleagues in 2006 commented that obesity is thought to induce a low-level 
systemic inflammatory response (257). Taken together, these studies suggest a correlation 
between obesity and colonic cancer which may be mediated through obesity-induced 
inflammation. It follows that these same inflammatory pathways may be driving the higher 
rate of colorectal adenoma formation, as the precursors of CRC in obese individuals. The 
link between colorectal polyp recurrence and inflammation may be further evidenced by the 
fact that aspirin has been shown to be more effective in preventing colorectal adenomas in 
those with a higher BMI, who may be systemically inflamed (258).  
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With the implication of systemic inflammation as a potential contributing factor in recurrent 
adenomas, interventions to prevent recurrence could be aimed at lowering obesity and age-
related systemic inflammation.  
Weight loss, following bariatric surgery, has been associated with a reduced CRP when 
compared to the preoperative levels in a study by Tedesco and colleagues in 2016 (259). 
Despite these results, Laiyemo and colleagues in 2012, did not find a significant reduction 
in the rate of adenoma recurrence with either weight loss or gain (243). It may be that the 
damage from long-term obesity and chronic inflammation has limited reversibility once 
already developed. Chronic obesity-related systemic inflammation could lead to adenoma 
formation through DNA damage or altered signalling pathways, but the true mechanism 
remains unclear.  
A large volume of work has been carried out examining the link between CRC, 
inflammation, and the use of aspirin as a chemoprotective agent (Section 1.1.2.2) and 
similarly with colorectal adenomas (Section 1.4.5.4). A Cochrane systematic review in 2014 
concluded that aspirin significantly reduces the recurrence of adenomatous polyps after 1–3 
years and that the drug may support regression of these polyps in patients with FAP (260). 
The mechanism by which aspirin achieves this effect may be as a result of its anti-
inflammatory properties, which supports the systemic inflammation theory of adenoma 
formation and recurrence.  
As discussed previously, NSAIDs have not been widely used for CRC (Section 1.1.2.2) or 
adenoma prophylaxis (Section 1.4.5.4). This is partly due to their toxicity in terms of GI 
bleeding risk and, in the case of COX-2 Inhibitors, their risk of serious cardiovascular events. 
Nonetheless, if a selected cohort of patients at increased risk can be identified, such as those 
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discussed in the present study (males, aged ≥60 years old, with an elevated BMI), then it 
may be that the protective benefits to these higher-risk patients will outweigh the risks (261). 
Strengths and limitations 
A significant strength of the present study is the large numbers of participants that were 
included in the meta-analysis (n=22,547, 31,277 and 13,606 for the influence of age ≥60 
years, male sex and elevated BMI, respectively). Studies were only included if there was full 
endoscopic surveillance of participants which ensured the contemporary relevance of the 
data analysed. In addition, the present study is unique in that it utilised the raw data provided 
by studies allowing it to be directly entered into the Review Manager software for summary 
and OR. 
A limitation of the present meta-analysis was the number of studies excluded. Only studies 
that provided raw data for the number of participants and the number of adenoma recurrences 
could be used. Several studies did not publish these data, or published OR, RR, HR or 
percentages, which precluded the inclusion of these studies. This resulted in the loss of some 
studies that would otherwise have been eligible for inclusion. Heterogeneity within the 
present meta-analysis may be explained by the varied designs of the included studies, patient 
demographics, endoscopic techniques and the retrospective collection of data used. 
Statistical tests of heterogeneity should be considered with caution, especially since the 
present meta-analysis included a relatively small number of studies in some outcomes such 
as the influence of BMI. Another limitation with regards to male sex as a risk factor was that 
approximately two-thirds of our data were from male patients (n=20,215) (65%) compared 
to females. This was a similar picture in the meta-analysis by De Jong et al. in 2011, where 
70% of the participants were male (249). This may have skewed the data, and it would be 
important for future analyses to be carried out with a more balanced ratio of males to females, 
such as a bowel screening population. An inherent weakness with any study examining 
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adenoma recurrence is the possibility that adenomas found at follow-up are actually those 
that were missed at the first examination. The impact of this was minimised in a number of 
the studies that were included in the present meta-analysis. In these cases, the researchers 
carried out a second colonoscopy within a year to clear any missed polyps before the final 
colonoscopy at the end of the study period (236, 237, 243). The generalisability of the results 
of the present meta-analysis may be somewhat limited, especially to the UK and in particular 
the West of Scotland population. The majority of studies included in the literature review 
are carried out in the USA and Southeast Asia where BMI thresholds, lifestyle, and diets can 
be quite different and where the indication for colonoscopy was wide and varied. 
Final conclusions and further work required 
Results from the present review indicate that host factors such as age ≥60 years, male sex 
and BMI ≥25 are associated with a higher risk of developing recurrent adenomas. The 
strength of the association was moderate (56% increased risk if ≥60 years, 58% for male sex, 
35% for BMI ≥25), yet adenoma number and size are the sole risk factors used in the BSG 
guidelines for colorectal polyp surveillance (15). The magnitude of effect for these adenoma-
specific factors appears larger than for host factors which likely validates the guidelines. In 
the National Polyp Study in the USA, the OR for adenoma recurrence at first follow-up 
colonoscopy after polypectomy was 2.4 [95% CI; 1.7–3.5, p<0.01] for those with three or 
more polyps at baseline. Similarly, for those with medium and large adenomas, the OR for 
recurrence at first follow-up was 1.6 [95% CI; 1.1–2.5; p<0.05] (224). 
Although the influence of host factors appears to be less than that of adenoma-specific 
factors, the present study supports the inclusion of host factors into current guidelines. This 
could be used to identify an increasingly patient-centred “high-risk” and “low-risk” 
population. The present meta-analysis cannot determine whether age >60 years, male sex 
and BMI ≥25 elicit a cumulative effect. It is also unable to determine whether these host 
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factors, in combination with the above adenoma factors, produce an ever-greater additive 
effect on predicting colorectal polyp recurrence. If this was the case, it could prove to be an 
important and powerful prognostic tool. Nevertheless, further studies are required to 
examine such a proposal. A closer investigation of the effect of both host and adenoma-
specific factors on adenoma recurrence within a bowel screening population would be useful. 
Finally, studies scrutinising the interaction between patient factors, the systemic 
inflammatory response and colorectal adenoma formation are warranted. 
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Table 2.1: Studies included in the meta-analysis: The impact of age ≥ 60 years on the incidence of colorectal adenoma recurrence 
Author Year Design Country Purpose of the study n Inclusion / exclusion criteria Corrected 
for missed 
adenomas? 
        
Winawer 
et al. (224) 
1993 RCT USA To determine the ideal follow-up period 
post-polypectomy. 1-year vs. 3-year 
colonoscopy. 
 
938 All patients referred for colonoscopy for any reason. IBD, 
FAP, CRC patients excluded. 
No 
Bertario et 
al. (234) 
2003 Retrospective 
cohort 
Italy To determine the risk of colonic 
neoplasia recurrence based on host and 
polyp characteristics. 
 
1086 Exclusion of patients with hyperplastic/inflammatory 
polyps, FAP, HNPCC. 
No 
Yood et al. 
(239) 
2003 Retrospective 
cohort 
USA To determine the natural history (risk of 
recurrence and timing of recurrence) of 
colorectal adenomas. 
8865 Data from a large integrated health management 
organisation in the USA. Excluded patients with a history 
of CRC, Crohn’s, or < 1year in the health scheme. 
 
No 
Yamaji et 
al. (238) 
2004 Retrospective 
cohort 
Japan 
 
 
 
To determine both the incidence and 
recurrence rate of colorectal neoplasm in 
asymptomatic Japanese patients. 
6225 Exclusion based on a personal history of CRC or IBD. No 
Cafferty et 
al. (235) 
2007 Retrospective 
cohort 
Taiwan 
 
 
 
To help determine post-polypectomy 
follow-up guidelines. 
2213 All patients undergoing colonoscopy for any reason. Even 
those with normal baseline scope were given a follow-up 
colonoscopy. A retrospective review of records. 
No 
Huang et 
al. (236) 
2010 Retrospective 
cohort 
China To determine the true recurrence rate of 
adenomas. 
 
 
1356 Prospectively collected database of adenomas excised at 
colonoscopy from 1976–2007 in a South China 
population. FAP, IBD, CRC patients excluded. 
Yes 
Laiyemo 
et al.(237) 
2013 Data from 
non-effect 
RCTs 
USA To analyse patient and demographic 
factors associated with colorectal 
adenoma recurrence. 
1864 Data from patients who were randomised and enrolled in 
the Polyp Prevention Trial (dietary intervention trial). 
Exclusion of patients with IBD, CRC or FAP. 
Yes 
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Table 2.2: Studies included in the meta-analysis: The impact of male sex on the incidence of colorectal adenoma recurrence 
 
Author Year Design Country Purpose of the study n Inclusion / exclusion criteria Corrected 
for 
missed 
adenomas 
        
Yood et al. 
(239)  
2003 Retrospective 
cohort 
USA To determine the natural history (risk 
of recurrence and timing of 
recurrence) of colorectal adenomas. 
8,865 Data from a large integrated health management 
organisation in the USA. Excluded patients with a history 
of CRC, Crohn’s, or <1year in the health scheme. 
 
No 
Bertario et al. 
(234) 
2003 Retrospective 
cohort 
Italy To determine the risk of colonic 
neoplasia recurrence based on host 
and polyp characteristics. 
 
1,086 Exclusion of patients with hyperplastic/inflammatory 
polyps, FAP, HNPCC. 
No 
Cafferty et al. 
(235) 
2007 Retrospective 
cohort 
Taiwan 
 
 
 
To help determine post-polypectomy 
follow-up guidelines. 
2,213 All patients undergoing colonoscopy for any reason. Even 
those with normal baseline scope were given a follow-up 
colonoscopy. Retrospective review of records. 
No 
Jacobs et al. 
(240) 
2007 Retrospective 
pooled analysis 
USA Investigate the effect of obesity on 
adenoma recurrence. 
2,465 All patients who completed the UDCA (ursodeoxycholic 
acid) and WBF (Wheat Bran Fibre) trial in the USA. 
 
 
Jacobs et al. 
(241)  
2009 Retrospective 
pooled analysis 
USA To determine the relationship between 
BMI, sex and the incidence of 
recurrent colorectal adenomas. 
8,213 All studies ≥800 participants, at least one follow-up 
colonoscopy. Endpoint data had to be available for all 
adenomas detected. Exclusion of those who had CRC 
detected at baseline or if <6 months follow-up. 
 
No 
Gao et al. 
(242)  
2010 Retrospective 
cohort 
China To determine the ideal follow-
up/surveillance programme after 
polypectomy and to analyse the risk 
factors for colorectal adenoma 
recurrence. 
 
 
1,208 
Included patients had lower GI symptoms present. (not a 
screening population). Patient excluded if a clean colon 
was found on the index scope, IBD, FAP, HNPCC or 
CRC. Must have had a polypectomy at index scope and at 
least one follow-up colonoscopy. 
No 
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Huang et al. 
(236)  
2010 Retrospective 
cohort 
China To determine the true recurrence rate 
of adenomas 
 
1,356 Prospectively collected database of adenomas excised at 
colonoscopy from 1976–2007 in a South China 
population. FAP, IBD, CRC patients excluded. 
 
Yes 
Laiyemo et al. 
(243) 
2012 Retrospective 
analysis of data 
from non-effect 
RCTs 
USA To analyse patient and demographic 
factors associated with colorectal 
adenoma recurrence. 
1,826 Data extracted from patients who were randomised and 
enrolled on the Polyp Prevention Trial (dietary 
intervention trial). Exclusion of IBD, CRC, previous 
polyp resection or FAP. 
 
Yes 
Kitahara et al. 
(244) 
2013 Retrospective 
analysis of 
subgroup data 
from RCT 
USA A RCT to evaluate the efficacy of 
screening methods for cancer. An 
ancillary study nested within the main 
trial examined the recurrent colorectal 
adenoma. 
1,676 Baseline colonoscopy and polypectomy required for 
inclusion. Must have undergone surveillance colonoscopy 
>6 months to 10 years later. Excluded IBD, polyposis, 
Gardner’s syndrome, previous colorectal polyps, missing 
results or extremes of BMI . 
 
No 
Lin et al. 
(245) 
2014 Retrospective 
cohort 
Taiwan To evaluate the predictors of recurrent 
colorectal adenomas after screening 
colonoscopy. 
356 Asymptomatic patients who underwent two consecutive 
“health check” colonoscopies with polypectomy at first 
colonoscopy between 2003–2010. Exclusion of CRC, 
IBD, non-adenomatous polyps, NSAID use. 
 
No 
Taniguchi et 
al. (246) 
2014 Retrospective 
cohort 
Japan To investigate the role of metabolic 
factors on the recurrence of colorectal 
adenomas. 
1,111 Must have undergone complete colonoscopy with 
polypectomy for screening purposes. Required 3 follow-
up colonoscopies. Exclusion if age <50yr, or >85yr, IBD, 
HNPCC, FAP, CRC, NSAID use, previous colonic or 
appendicular resection, or life expectancy <2 years. 
 
No 
Xu et al. (247)  2015 Retrospective 
cohort 
China To determine the incidence of 
advanced, recurrent adenoma over a 5-
year period. 
828 Colonoscopy database accessed. Clear colon, non or 
advanced adenomas included. Excluded IBD, Intestinal 
TB, coagulopathy, any polyposis syndromes, prior 
colorectal resection or prior adenomas. 
No 
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Table 2.3: Studies included in the meta-analysis: The impact of BMI ≥ 25 on the incidence of colorectal adenoma recurrence 
 
 
 
Author Year Design Country Purpose of the study n Inclusion / exclusion criteria Corrected 
for missed 
adenomas 
        
Jacobs et al. 
(240) 
2007 Data extracted from two RCTs 
that showed no difference 
between the outcomes in each 
group.  
 
USA To assess whether obesity 
and/or waist circumference 
were associated with 
colorectal adenoma 
recurrence. 
 
2465 All patients who had taken part and completed the 
studies from which the data were pooled: The UDCA 
(ursodeoxycholic acid) and WBF (Wheat Bran Fibre) 
trial in the USA. 
No 
Jacobs et al. 
(241) 
2009 Retrospective pooled analysis. USA To determine the 
relationship between BMI, 
sex and the incidence of 
recurrent colorectal 
adenomas. 
 
8213 All studies ≥800 participants, at least one follow-up 
colonoscopy. Endpoint data had to be available for all 
adenomas detected. Exclusion of those who had CRC 
detected at baseline or if <6 months follow-up. 
 
No 
Laiyemo et 
al. (243) 
2012 Retrospective analysis of data 
from non-effect RCT. 
USA To analyse patient and 
demographic factors 
associated with colorectal 
adenoma recurrence. 
 
1826 Data extracted from the polyp prevention trial (dietary 
intervention trial). Exclusion of IBD, CRC, previous 
polyp resection or FAP. 
Yes 
Taniguchi et 
al. (246)   
2014 Retrospective cohort. Japan To investigate the role of 
metabolic factors on the 
recurrence of colorectal 
adenomas. 
1111 Must have undergone complete colonoscopy with 
polypectomy for screening purposes. Required 3 
follow-up colonoscopies. Excluded if age <50years, or 
>85years, IBD, HNPCC, FAP, CRC, NSAID use, 
previous colonic or appendicular resection, or life 
expectancy <2 years. 
No 
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3 THE DETERMINANTS OF ADENOMA 
RECURRENCE WITHIN A BOWEL SCREENING 
POPULATION 
3.1 Introduction 
CRC is the fourth most common cancer by incidence, and the second most common cause 
of cancer death in the UK (1). The majority of cancers originate from colorectal adenomas 
through the adenoma-carcinoma sequence (203, 204, 262, 263). Identification and excision 
of adenomas prior to malignant transformation is recommended to reduce CRC incidence. 
The UK flexible sigmoidoscopy trial showed that a once-only flexible sigmoidoscopy 
reduced the incidence of CRC, most likely as a result of prophylactic polypectomy (223). 
Other large well-designed studies such as the Minnesota Colon Cancer Control Study, the 
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial  and the National 
Polyp Study  drew similar conclusions (264) (265) (208). 
In the UK, EU and the USA, recommendations for post-polypectomy surveillance follow a 
risk stratification model. Certain adenoma characteristics are thought to confer a higher risk 
of malignant transformation and lead to a predisposition towards advanced neoplasia (CRC 
or advanced adenomas). Adenomas with at least one of the following characteristics are 
classed as advanced adenomas: large size (≥1cm), villous architecture or the presence of 
HGD (266). Currently, in the UK, patients with one or more adenomas at colonoscopy are 
classified into low, intermediate or high-risk groups with patients then offered post-
polypectomy surveillance at varying intervals based on the perceived level of risk. The BSG 
published guidelines in 2002 (updated in 2010) to direct clinicians on optimal post-
polypectomy surveillance (15). For those classed as low-risk (1–2 small adenomas <1cm), 
they recommend a 5-year re-examination by colonoscopy or no further examination at all. 
Patients classed as intermediate (3–4 small adenomas or at least one ≥1cm), or high-risk (≥5 
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small adenomas or ≥3 adenomas with at least one ≥1cm) should be offered a three or 1-year 
endoscopic re-examination, respectively.  
Surveillance is a costly component of bowel screening  meaning it is vital to weigh the 
perceived benefits against the burden on resources, patient discomfort and the risk of 
complications (267). As such, surveillance colonoscopy is best utilised in selected groups of 
individuals most at risk of developing recurrent adenomas, advanced adenomas or cancer.  
As mentioned in Chapter 2, current UK surveillance guidelines are based on baseline 
adenoma-specific characteristics of size and number. They do not account for adenoma 
histology or host characteristics despite evidence that host characteristics may play a role in 
adenoma recurrence (Chapter 2). Questions remain as to the applicability of the above 
evidence (of which a significant volume is from Southeast Asia), to a bowel screening 
population, particularly in Scotland. Further examination is warranted. In particular, scrutiny 
of the case for host factors to be included in future post-polypectomy surveillance guidelines 
would be useful. 
The present study utilises a UK bowel cancer screening population, with an extended median 
follow-up of more than six years to examine the association between adenoma-specific and 
host characteristics on the incidence of adenoma recurrence.  
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3.2 Materials and methods 
Study protocol, inclusion and exclusion criteria 
Primary data were obtained from the GGC bowel screening database. In Scotland, patients 
aged between 50–74 years who tested positive in the SBoSP were invited for colonoscopy. 
In the present study, all screening patients between March 2009–April 2011 who underwent 
polypectomy and were classed as intermediate or high-risk according to the BSG guidelines 
were included in the study (15). The risk classification of these patients meant they were 
recommended for surveillance colonoscopy at least once within the follow-up period. 
Patients required to have undergone a full baseline colonoscopy complete to the caecum. 
Only those with colorectal polyps identified, who underwent excision of all visible lesions 
and at least one follow-up colonoscopy ≥1 year from the baseline examination were 
included. Cold or hot biopsy of polyps using forceps for polyps <5mm was classed as full 
excision. For polyps ≥5mm, a formal polypectomy or Endoscopic Mucosal Resection (EMR) 
was required for acceptable excision.  
Patients in whom there was uncertainty regarding the removal of all polyps were excluded 
from the study. In addition, follow-up by any means other than colonoscopy, the presence 
of cancer at baseline, or during follow-up (in the absence of synchronous adenomas), or 
segmental colonic resection during the follow-up period, resulted in exclusion. A number of 
patients required more than one colonoscopy to remove all baseline polyps. Colonoscopy 
results for this or any other reason <1 year from the initial colonoscopy were combined and 
considered as a single baseline colonoscopy. Initial examination findings were recorded 
from medical notes, pathology reports and the endoscopy reporting system (UNISOFT®). 
Medical notes covering the period between March 2009 and October 2016 were examined 
for post-polypectomy surveillance colonoscopy results. Any finding of at least one 
histologically proven adenoma at any follow-up colonoscopy during the study period was 
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classed as adenoma recurrence. Those who were found to have CRC at follow-up were 
included if they had synchronous adenomas.  
Data collection and analysis: Adenoma characteristics 
Identical polyp and adenoma-specific findings at both baseline and follow-up colonoscopy 
were sought from the endoscopy report. The total number of polyps visualised, excised, and 
received in the lab were recorded. From the histological analysis, the number of confirmed 
hyperplastic polyps, non-advanced and advanced adenomas were recorded. Hyperplastic 
polyps were excluded. Only patients with a histologically proven adenoma at baseline were 
included. In those with adenoma recurrence, the presence of advanced adenomas was 
recorded along with the size of the adenomas and the presence of any advanced histological 
features. Patients were classed as having advanced adenomas if at least one of the adenomas 
removed had one or more of the following features: size (from pathology specimen) ≥1cm 
or villous features and / or HGD.  
Data collection: Host factors 
Age, sex, BMI, socioeconomic deprivation, smoking status and medication use, were 
recorded. Age was recorded at the date of baseline colonoscopy. BMI was calculated from 
the General Practitioner (GP) records of height and weight. Deprivation was assessed using 
the Scottish Index of Multiple Deprivation (SIMD) 2009. This is an index of relative 
deprivation combining multiple detailed indicators based on postcodes across seven domains 
(268). Scores for SIMD were ordered with patients grouped into quintiles. Those in the first 
quintile (most deprived), are likely to have higher levels of poverty, unemployment, and 
poorer health than those in the fifth quintile (least deprived). Data on the use of ACE 
inhibitors, aspirin or statins for enrolled patients were recorded from GP records. Those who 
had a repeat prescription for these medications valid at the date of baseline colonoscopy were 
assumed to be actively using the medication.  
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Study endpoints 
The two main endpoints of the study were: 
1. Any adenoma recurrence: the presence of at least one adenoma, of any type 
(advanced or non-advanced) at post-polypectomy follow-up ≥1 year from baseline 
examination 
2. Advanced adenoma recurrence: the presence of at least one advanced adenoma at 
follow-up ≥1 year from baseline examination 
Statistical analyses 
Statistical analyses were conducted to assess the relationship between adenoma-specific and 
host characteristics and adenoma recurrence. Patients were grouped appropriately to prepare 
categorical variables for analysis. Standard WHO thresholds for BMI were used to categorise 
patients as underweight, normal weight, overweight or obese (269). Age groups were 
selected based on established and validated age ranges used to stratify risk in CRC patients. 
A χ2 test was used to test for statistical significance. ORs were expressed to estimate risk. 
Binary logistic regression was used to assess categorical variables with two or more groups 
against a reference group. Any odds ratios associated with a p-value <0.1 at univariable 
analysis were included in the multivariable model. In all analyses, a two-tailed p-value of 
<0.05 was considered statistically significant. All statistical analysis was carried out using 
IBM® SPSS® Statistics version 22 (SPSS Inc., Chicago, IL, USA).
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3.3 Results 
Figure 3.1 illustrates the outcome and follow-up from the 4,188 patients undergoing 
screening-based colonoscopy. 2,876 (69%) patients were classed as low-risk (no adenomas 
or 1–2 small adenomas <1cm). 1,312 (31%) were classed as intermediate or high-risk (>2 
adenomas or at least one ≥1cm) and recommended for repeat colonoscopy in 1–3 years. 605 
(46%) patients were excluded or lost to follow-up [Table 3.1]. Complete follow-up data 
were available for 707 (54%) patients. 
Figure 3.1: Flow diagram for those attending colonoscopy and post-polypectomy 
surveillance 
Colonoscopy 
 (n=4188) 
No adenoma or low-
risk 
(n=2876) (69%) 
CRC at follow-up 
(n=12)  
(2%) 
Adenoma recurrence 
(n=354)  
(50%) 
No adenoma recurrence 
 (n=353)  
(50%) 
Follow-up data 
available (n=707) 
(54%) 
Excluded 
(n=605) 
(46%) 
Intermediate or high-
risk  
(n=1312) 
Advanced adenoma 
recurrence 
(n=130) 
(37%) 
Non-advanced 
adenoma recurrence 
(n=224) 
(63%) 
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Baseline patient characteristics 
Baseline characteristics are displayed in Table 3.2. There were 515 (73%) males, and the 
median age was 65 years [interquartile (IQ) range 59–69]. BMI data were available for 430 
(61%) patients. The cohort was predominantly overweight, with a median BMI of 29 kg/m2 
[IQ range 26–32]. The majority of the cohort lived in areas of high socioeconomic 
deprivation, with 374 (53%) classed in the most deprived SIMD quintiles (1st and 2nd). 446 
(63%) were ex or current smokers. Median follow-up was 75 months [IQ range 69–81].  
Any adenoma recurrence 
354 (50%) patients had adenoma recurrence at the follow-up colonoscopy [Table 3.2]. In 
terms of adenoma-specific characteristics, a greater number of adenomas at baseline were 
significantly associated with an increased risk of recurrence. Compared to 1–2 adenomas at 
baseline, the presence of 3–4 or ≥5 adenomas at baseline resulted in an OR of 2.47 [95% CI; 
1.72–3.52, p<0.001] and 4.60 [95% CI; 2.81–7.54, p<0.001] for adenoma recurrence 
respectively. The presence of any adenoma ≥1cm was associated with a reduced risk of 
adenoma recurrence, OR 0.52 [95% CI; 0.33–0.84, p<0.01]. HGD and the presence of 
villous features individually were not associated with adenoma recurrence. The presence of 
any advanced adenoma, which was predominantly driven by the presence of larger adenomas 
was associated with a lower risk of recurrence, OR 0.45 [95% CI; 0.29–0.70, p<0.001]. 
However, this did not retain significance on multivariable analysis when adjusting for 
adenoma number. 
Multivariable analysis was carried out to adjust for sex, adenoma number, advanced 
adenomas and the presence of any adenoma ≥1cm at baseline. Baseline adenoma number 
remained a statistically significant risk factor for any adenoma recurrence on the 
multivariable model. Compared to 1–2 adenomas at baseline, the presence of 3–4 or ≥5 
adenomas resulted in an OR of 2.23 [95% CI; 1.53–3.25, p<0.001] and 4.19 [95% CI; 2.53–
6.97, p<0.001] respectively. 
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Concerning host characteristics, only male sex, OR 1.46 [95% CI; 1.05–2.04, p<0.05] was 
associated with adenoma recurrence at follow-up, but statistical significance was not 
retained on multivariable analysis. Advancing age, elevated BMI, socioeconomic 
deprivation, the use of aspirin, ACE inhibitors or statins were not associated with adenoma 
recurrence in this cohort.  
Adenoma number at baseline was compared with other baseline characteristics that were 
significantly associated with adenoma recurrence [Table 3.3]. At baseline, higher adenoma 
numbers were associated with male sex (p<0.001) and those with higher numbers of 
adenomas were less likely to have large (p<0.001) or advanced adenomas (p<0.001).  
Advanced adenoma recurrence 
Of the 354 patients with adenoma recurrence, 130 (37%) had advanced adenoma recurrence 
at follow-up. This equates to 18% of the entire study cohort of 707 [Table 3.4]. 
With respect to adenoma-specific factors, overall adenoma number at baseline did not 
influence the risk of advanced adenoma at follow-up. However, the presence of advanced 
adenomas at baseline was associated with advanced adenomas at follow-up, OR 2.34 [95% 
CI; 1.18–4.61, p<0.05]. There was no similar association found when the features of 
advanced adenoma (size ≥1cm, villous histology or HGD) were considered separately. 
With respect to baseline host characteristics, none were significantly associated with 
advanced adenomas at follow-up.
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3.4 Discussion 
This longitudinal cohort study reports on the association between adenoma and host 
characteristics at baseline colonoscopy and the subsequent risk of recurrent adenomas and 
advanced adenomas in a bowel screening population. The results suggest that in this 
population, increasing adenoma number significantly increases the risk of adenoma 
recurrence. In addition, the presence of an advanced adenoma at baseline colonoscopy is 
associated with an increased risk of an advanced adenoma at follow-up. These findings were 
independent of age, sex and BMI. 
Approximately 50% of patients were found to have a recurrent adenoma at follow-up. This 
is in keeping with the literature where recurrence rates range from 22–53% (235, 246, 248, 
270-273). Of those who had any adenoma recurrence, 130 (37%) had features of advanced 
adenomas, equating to 18% of the entire screening cohort. Thus, the present study largely 
supports the BSG guidelines recommending patients with multiple adenomas and advanced 
adenomas (larger size) undergo surveillance colonoscopy within 1–3 years (15). 
Adenoma-specific factors and adenoma recurrence 
This study reports on the relationship between baseline adenoma characteristics and the risk 
of any and advanced adenoma recurrence. A number of previous studies with similar 
methodologies have been published over the last 15 years with varying results. These are 
shown in Table 3.5. 
Current UK guidelines are based on adenoma-specific factors of size and multiplicity to 
recommend post-polypectomy surveillance. This is based upon the perceived increased risk 
of advanced neoplasia in patients at follow-up. Histological subtypes and colonic location 
are not used. In the USA, recommendations for follow-up are largely similar but, in addition, 
they consider histological subtypes of adenomas at baseline (274). Increased adenoma 
number at baseline has been consistently shown to increase the risk of any adenoma 
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recurrence during surveillance (234, 246-248, 267, 270-272, 275-278). The results of the 
present study are consistent with these observations. It is possible that patients with higher 
numbers of adenomas are predisposed, by genetic or environmental factors, to be “polyp 
formers”. In addition, the miss rate at colonoscopy has been reported as between 5 and 28% 
(230-232); therefore, it may be that those with higher adenoma numbers result in some 
adenomas being missed during colonoscopy.  
Evidence of the relationship between adenoma number at baseline and the risk of advanced 
adenoma recurrence is less well established. A number of studies report a higher incidence 
of advanced adenoma recurrence in those with multiple adenomas at baseline (272), yet other 
studies found no effect of multiplicity (234, 247). The present study did not find an 
association between baseline adenoma multiplicity and advanced adenoma recurrence. 
Villous features or HGD were not associated with any adenoma recurrence when considered 
individually, although patients with larger adenomas (≥1cm) at baseline were significantly 
less likely to have any adenoma at follow-up. However, this was not retained on 
multivariable analysis when correcting for baseline adenoma number. This is likely due to 
the finding that larger adenomas were associated with fewer adenoma numbers overall.  
With respect to advanced adenoma recurrence, villous features, larger size and the presence 
of HGD at baseline have been associated with advanced neoplasia at follow-up (274). This 
forms the basis of the USA post-polypectomy guidelines. These class patients with larger 
adenomas (≥1cm), multiple adenomas (3+), or any adenomas with HGD or villous features 
as high-risk for advanced, recurrent neoplasia. As such, they recommend a repeat 
colonoscopy at three years for this patient subgroup (274). The European Society of 
Gastrointestinal Endoscopy surveillance guidelines are largely similar to those of the USA 
(279). 
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Currently, in the UK, the histological subtype is not considered as a predictor of future risk; 
a decision based on the opinion that histological subtyping is inconsistent, with poor 
reproducibility. Furthermore, it could be argued that for patients with larger or multiple 
adenomas, the presence of HGD or villous architecture may be academic only, as these 
patient cases are already classed as high-risk due to their size and multiplicity. In addition, 
size is often strongly correlated to histology, and as such, most villous adenomas are 
encompassed into the high-risk surveillance group based on size criteria (280).  
In the present study, villous features, larger adenomas (≥1cm) and HGD did not appear to 
influence advanced adenoma recurrence in isolation, however, when combined into one 
variable (the presence of an adenoma with any advanced feature), they were associated with 
a significantly higher risk of subsequent advanced adenomas at follow-up. This may 
strengthen the case for the inclusion of advanced histological factors as a combined package 
into future UK guidelines similar to those from the USA. 
Host characteristics and any adenoma recurrence 
Older age is strongly associated with CRC (139). In the present study, advancing age was 
not associated with adenoma recurrence. Contrary to these findings, the majority of 
published studies, including meta-analyses, have reported that advancing age is associated 
with adenoma recurrence (223, 224, 235-239, 249). Multiple studies enrol a substantial 
number of patients aged <50 years (235-238, 272, 273, 277, 281, 282), which is younger 
than the 50-year minimum age of bowel screening patients. As such, it may account for the 
conflicting results reported in this study. Moreover, it is plausible that by 50 years, the “age 
effect” has already induced its influence. In addition, the present study used a cohort of 
patients who were defined as having higher risk adenomas at baseline and were specifically 
selected for follow-up based on the BSG criteria; therefore, this population may differ 
slightly from previous studies. 
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The role of male sex as a risk factor for adenoma recurrence is plausible, given its association 
with CRC (139). Previous studies have reported similar results for male sex with respect to 
adenoma recurrence (195, 234-236, 239-246), including a meta-analysis (272) and a pooled 
analysis (248). However, in the present study, the effect of male sex was not significant in 
the multivariable analysis. Since higher adenoma number is a strong predictor of recurrence 
and also associated with male sex in the present study, it may be that the adenoma 
multiplicity is acting as a confounder.  
Nonetheless, it is biologically plausible for there to be a male preponderance to adenoma 
formation, especially given the suggestion that oestrogen may provide a chemoprotective 
action for women (283). In 2008, Kennelly and co-workers suggested that in particular, 
oestrogen receptor β has a crucial role in colonic cell homeostasis, including modulation of 
cell proliferation and apoptosis, although the exact mechanisms are yet to be determined 
(284). In addition, differing patterns of potential confounding factors such as BMI, comorbid 
disease, smoking and lifestyle may contribute to sex-specific differences in prevalence. More 
recently, the differences in body composition between males and females and their effect on 
cancer incidence have been examined. Intersex comparison has shown that in general men 
have a higher volume of visceral adipose tissue while women tend towards higher volumes 
of subcutaneous adipose tissue for a given BMI (285). Considering that recent work has 
linked higher visceral adipose tissue to colorectal adenoma incidence (286, 287), body 
composition differences between the sexes may play a role in any disparity. 
The present study did not find an association between socioeconomic deprivation and any 
or advanced adenoma recurrence. Previous large population studies have reported on the 
associations between socioeconomic deprivation and CRC. In particular, a recent large study 
of 17,000 patients in the UK reports that those from a Black Afro-Caribbean or socially 
deprived background were more likely to present with late, stage IV disease, than white 
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British or patients from a more affluent background, OR 1.37 [95% CI; 1.18–1.59, p<0.001] 
and OR 1.26 [95% CI; 1.13–1.14, P<0.001], respectively (288). In addition, a recent study 
examining a bowel screening cohort in the same geographical region as the present study 
was conducted by Mansouri et al. (139). It was reported that patients with a high level of 
socioeconomic deprivation were less likely to attend for screening. However, there are a 
limited number of studies examining the influence of social deprivation with regards to 
adenoma incidence and recurrence. Although no significant association was found in the 
present study, any effect may benefit from further investigation, given that social deprivation 
is associated with many other health inequalities, particularly in Scotland. 
The present study did not find a difference in any or advanced adenoma recurrence rates in 
those who currently or previously smoked compared to lifelong non-smokers. Smoking has 
been linked with CRC incidence  as well as mortality (289) (290). Two studies reported an 
association between smoking and adenomatous polyp incidence (291, 292) and in particular, 
the incidence of advanced neoplasia (292). This agrees with an earlier study in 2005 (293).  
The present study did not find an appreciable link between the use of daily aspirin, statins or 
ACE inhibitors and adenoma recurrence, including advanced adenomas. Many studies have 
investigated the role of NSAIDs, notably aspirin, in reducing the incidence and recurrence 
of colorectal adenomas. These include a Cochrane review  and two systematic reviews (260) 
(211, 294). The Cochrane review was published in 2004. It cautiously reported that there 
was some evidence to support daily aspirin or regular NSAID use as a risk reduction strategy 
for recurrent colorectal adenoma. However, the reviewers noted that universal agreement 
regarding timing, dose and duration of use was yet to be gained. Overall the review did not 
recommend general use of NSAIDs and aspirin for chemoprevention, mainly due to the risk 
of adverse effects (260). More recently, the first of two systematic reviews was conducted 
in 2015 and included nine studies with 8,521 subjects (211). The researchers reported that 
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NSAID use was associated with a reduction in the recurrence of any type of adenoma and 
specifically advanced adenomas; however, the effect was not retained at three years. The 
second systematic review and meta-analysis concluded that approximately 10 years of 
aspirin use was required to achieve a reduction in CRC incidence and mortality (294). The 
researchers found some evidence that aspirin use reduced adenoma recurrence, but results 
were inconsistent, especially with regards to dosing, which ranged from 81–325 mg/day. 
The contrasting results in the present study may be explained by the relatively small numbers 
of patients taking these medications and an absence of data regarding the duration of 
treatment. 
In the present study, BMI was not associated with overall adenoma recurrence. This is in 
contrast to some previous reports. Firstly, when considering primary adenoma incidence 
rather than recurrence, studies have reported that higher BMI is associated with higher 
adenoma incidence, including advanced adenomas (295). Although as mentioned previously 
(Chapter 1, Chapter 2), the results are not consistent and a linear relationship with BMI is 
not certain (240, 241, 243, 244, 246, 296, 297). This can make it difficult to draw clear 
conclusions. A large and recent trial in Korea examined 2,176 patients with respect to any 
and advanced adenoma recurrence. No significant relationship between baseline BMI and 
any adenoma recurrence was found in a similar manner to the present study (298). The 
researchers did, however, find a significant risk of advanced adenoma recurrence in patients 
with a baseline BMI ≥30, HR 4.66 [95% CI; 1.70–12.7]. A direct comparison between the 
above and the present study must be considered with caution however since the Korean study 
used a much younger patient cohort (mean age 41 years) where participants underwent a 
colonoscopy as part of a routine health check-up. In contrast, the present study had an older 
population and used patients with intermediate and high-risk baseline risk from a bowel 
screening population.  
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An additional three studies reported an increased risk of recurrence of any adenoma type in 
those with higher BMI (241, 243, 246). One study split participants into two groups (BMI 
<25 and BMI ≥25) (246), while the others used three groups (<25, 25–29.9, ≥30) (241, 243) 
rendering comparison more difficult.  
Two additional studies found no effect of increasing BMI on any adenoma recurrence when 
genders were combined (240, 244), but one study found a slight association between any 
adenoma recurrence and increasing BMI in males alone (240).  
It appears however that studies showing the closest relationship between BMI and adenoma 
recurrence were those from Japan (246) and South Korea (296), suggesting that Southeast 
Asian populations are potentially more BMI sensitive, an effect that has been shown 
previously in relation to cardiovascular disease (299). In the present study, the population 
was predominantly male and overweight (median BMI 29) and had intermediate or high-risk 
adenomas at baseline. It may be that a younger population encompassing those with low-
risk baseline adenomas and a more even gender split would show a greater influence of BMI. 
In summary, in terms of baseline host characteristics, the present study suggests host factors 
do not play a crucial role in predicting adenoma recurrence in a high-risk bowel screening 
group. Increasing BMI may be associated with adenoma recurrence and potentially in 
advanced adenoma recurrence at follow-up, but clear conclusions cannot be drawn from the 
present study. 
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Strengths and limitations 
The present study aimed to investigate adenoma recurrence rates in a bowel screening 
population in the West of Scotland. Many of the studies used to collate current evidence in 
this field are based on the USA and Southeast Asian populations. This limits generalisation 
to our patient population. The West of Scotland has a unique population in that there are 
significantly high levels of socioeconomic deprivation and comorbidity. As such, findings 
from the present study may be more valid in this population. In addition, the present study 
used a relatively long follow-up time, with a median of 72 months. 
A number of limitations were identified. Firstly, the large attrition rate. Of the original 1,312 
patients that were expected to undergo colonoscopy surveillance, 605 were excluded from 
the analysis; the majority were due to a lack of follow-up data available in medical records 
(n=416). The reasons for loss of follow-up data are varied with a combination of patients not 
attending appointments, changing their geographical base, clinicians not adhering to 
surveillance guidelines and patients being lost to follow-up as a result of administration 
pathways. It is not uncommon to see this, with previous studies showing that up to 40% of 
patients with advanced neoplasia had not undergone surveillance within five years (300). In 
addition, the 1,312 patients initially eligible for analysis were selected as they had been 
identified as intermediate or high-risk at baseline, making them potentially more likely to 
develop subsequent adenoma. A useful control group may have been those with no adenoma 
or small and non-advanced adenomas only at baseline. These low-risk patients are not 
routinely re-examined in the UK; hence their inclusion in a real-world analysis such as this 
was not possible. 
In any study examining adenoma recurrence, there are inherent methodological weaknesses. 
The present study assumed a colon free of polyps at baseline such that any adenoma at 
follow-up was assumed to be new. It is likely that some adenomas, likely small, could be 
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missed at the initial colonoscopy and it is those that are found at follow-up. However, index 
colonoscopy was performed as part of the SBoSP. This is noted as high-quality endoscopy, 
with all endoscopists being registered with, and meeting the criteria set out by the Joint 
Advisory Group (JAG) on gastrointestinal endoscopy. 
Final conclusions and further work required 
The present study concludes that in a bowel screening population higher adenoma number 
at baseline is associated with adenoma recurrence. The presence of advanced adenomas at 
baseline is strongly associated with advanced adenomas at follow-up; therefore, those with 
advanced and multiple adenomas require robust surveillance. The present study supports the 
current BSG post-polypectomy surveillance guidelines thus cannot recommend 
incorporation of host factors at present. However, including patients with any features of 
advanced adenomas at baseline in the high-risk group should be considered in future updates. 
The relationship between BMI and adenoma recurrence may warrant further investigation, 
given the contrasting results in the present study with other reports. It is feasible that BMI 
may be a less useful measure in this cohort which represents a predominantly overweight 
population. As such, measures of body composition in place of BMI may provide a more 
sensitive analysis. This should be explored further. Since both obesity and body composition 
are modifiable characteristics, further work on the precise relationship between body 
composition and adenoma incidence and recurrence is warranted. 
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Table 3.1 Reason for exclusion or attrition in the present study 
 
 
Reason for exclusion  
 
Explanation n 
   
All patients  605 
   
Follow-up colonoscopy 
report could not be 
sourced 
 
-Did not attend follow-up colonoscopy (DNA) 
-Extensive comorbid disease, further colonoscopy clinically 
inappropriate 
-Unclear reason for absence of follow-up 
416 
Death -Patient death prior to follow-up colonoscopy 
 
63 
Cancer -Cancer diagnosed at follow-up (including polyp cancer) in the 
absence of synchronous polyps/adenomas 
-Cancer diagnosed from baseline colonoscopy findings at a later date 
(delayed result) 
 
9 
Missing or unsatisfactory 
data 
-Missing colonoscopy report 
-Missing pathology report 
-Unclear report 
-Colonoscopy completion failure 
-No colonoscopy follow-up (barium enema, CT pneumocolon, 
flexible sigmoidoscopy) 
 
77 
Unable to confirm a clear 
colon 
-Colonoscopy and pathological reports did not indicate if all visible 
polyps were excised. 
 
13 
Insufficient follow-up 
time 
-Follow-up colonoscopy <1 year from baseline 
 
5 
Cancer at baseline -Cancer diagnosed at baseline, resulting in non-standard follow-up 
and / or resection 
 
2 
Colonic resection during 
follow-up 
-Patients who underwent any form of colonic resection, for either 
benign or malignant disease during follow-up, were 
excluded on the basis that they would have an incomplete colon 
 
15 
Incomplete colon at 
baseline 
-Those with an incomplete colon due to previous resection, would 
likely have less change of developing adenomas due to the smaller 
length of colon and were therefore excluded 
 
4 
Active inflammation -Severe inflammation limiting the identification of polyps 
 
1 
  
 
 
1
4
2
 
Table 3.2: The influence of adenoma-specific and host characteristics on any adenoma recurrence at follow-up 
Baseline characteristics 
 
All patients with 
follow-up colonoscopy 
(%) 
No adenoma at 
follow-up (%) 
Adenoma at 
follow-up (%) 
OR (univariable) 
[95% CI] 
p-value OR (multivariable)1 
[95% CI] 
p-value 
        
All patients 707 (100) 353 (50) 354 (50)     
        
Age (years)        
      <55 90 (13) 53 (15) 37 (11) 1.0 - - - 
      55–64 252 (36) 124 (35) 128 (36) 1.48 [0.91–2.41] - - - 
      65–74 322 (45) 151 (43) 171 (48) 1.62 [1.01–2.61] - - - 
      75+ 
 
43 (6) 25 (7) 18 (5) 1.03 [0.49–2.16] 0.31 - - 
Sex        
     Female 192 (27) 109 (31) 82 (23) - - -  
     Male 
 
515 (73) 244 (69) 272 (77) 1.46 [1.05–2.04] 0.03 1.21 [0.85–1.71] 0.29 
BMI2 (kg/m2)        
     20–24.9    (normal weight) 82 (19) 40 (20) 42 (18) 1.0 - - - 
    <20            (underweight) 12 (3) 3 (2) 9 (4) 2.86 [0.72–11.32] - - - 
     25–29.9    (overweight) 161 (37) 77 (38) 84 (36) 1.04 [0.61–1.77] - - - 
     30+           (obese) 
 
175 (41) 80 (40) 95 (42) 1.13 [0.67–0.91] 0.82 - - 
Social deprivation quintile        
      5 (least deprived) 142 (20) 78 (22) 64 (18) 1.0 - - - 
      4  85 (12) 44 (12) 41 (11) 0.93 [0.61–1.46] - - - 
      3 106 (15) 53 (15) 53 (15) 1.00 [0.68–1.46] - - - 
      2 139 (20) 73 (21) 66 (19) 0.90 [0.65–1.26] - - - 
      1 (most deprived) 
 
235 (33) 105 (30) 130 (37) 1.24 [0.96–1.60] 0.34 - - 
Smoking status        
     Never 253 (37) 128 (37) 125 (36) - - - - 
     Ex / current 
 
 
446 (63) 221 (63) 225 (64) 1.04 [0.77–1.42] 0.79 - - 
  
 
 
1
4
3
 
Aspirin        
      No 614 (87) 312 (88) 302 (85) - - - - 
      Yes 93 (13) 41 (12) 52 (15) 1.31 [0.85–2.03] 0.23 - - 
Statin        
      No 582 (82) 297 (84) 285 (81) - - - - 
      Yes 
 
125 (18) 56 (16) 69 (19) 1.28 [0.87–1.89] 0.21 - - 
ACE-inhibitor        
      No 635 (90) 322 (91) 313 (88) - - - - 
      Yes 
 
72 (10) 31 (9) 41 (12) 1.36 [0.83–2.23] 0.22 - - 
Adenoma number        
      1-2 424 (60) 258 (73) 166 (47) - - - - 
      3-4 181 (26) 70 (20) 111 (32) 2.47 [1.72–3.52] - 2.23 [1.53–3.25] - 
      ≥5 
 
99 (14) 25 (7) 74 (21) 4.60 [2.81–7.54] <0.001 4.19 [2.53–6.97] <0.001 
Advanced adenomas3        
      Absent 86 (12) 31 (9) 55 (15) - - 1.0  
      Present 
 
621 (88) 322 (91) 299 (85) 0.52 [0.33–0.84] 0.006 1.82 [0.63–5.31] 0.27 
Villous features        
      Absent 339 (48) 162 (46) 177 (50) - - - - 
      Present 
 
368 (52) 191 (54) 177 (50) 0.85 [0.64–1.14] 0.27 - - 
Adenoma size ≥1cm        
      No 104 (15) 35 (10) 69 (20) - - -  
      Yes 
 
603 (85) 318 (90) 285 (80) 0.45 [0.29–0.70] <0.001 0.42 [0.15–1.15] 0.09 
HGD        
      Absent 605 (86) 301 (85) 304 (86) 1.0 - - - 
      Present 102 (14) 52 (15) 50 (14) 0.95 [0.63–1.45] 0.82 - - 
 
 
          1After adjustment for sex, adenoma number, advanced adenomas and the presence of large adenomas ≥1cm 
          2430 patients with BMI data available 
          3The presence of at least 1 adenoma with advanced features (≥1cm, villous features, HGD) at baseline colonoscopy 
  
  
 
 
1
4
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Table 3.3: The relationship between baseline adenoma number, sex, adenoma size and advanced adenomas 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
                    1704 included in this analysis. 3 patients excluded as overall baseline adenoma number not clear from endoscopy report 
  
Baseline characteristics 
 
All patients with 
follow-up colonoscopy 
(%) 
1–2 adenomas at 
baseline (%) 
3–4 adenomas at baseline 
(%) 
5+ adenomas at 
baseline (%) 
p-value 
(linear by linear) 
      
All patients 7071 424 (60) 181 (26) 99 (14)  
      
Sex      
     Female 192 (27) 139 (33) 43 (24) 10 (10) - 
     Male 
 
512 (73) 285 (67) 138 (76) 89 (90) <0.001 
Adenoma size ≥1cm      
      No 103 (15) 22 (5) 57 (31) 24 (24) - 
      Yes 
 
601 (85) 402 (95) 124 (69) 75 (76) <0.001 
Advanced adenomas      
      Absent 86 (12) 17 (4) 48 (27) 21 (21) - 
      Present 618 (88) 407 (96) 133 (73) 78 (79) <0.001 
      
  
 
 
1
4
5
 
Table 3.4: The influence of adenoma-specific and host characteristics on advanced adenoma recurrence in those with any adenomas at follow-up 
Baseline characteristics 
 
All patients 
with adenoma 
recurrence (%) 
Non-advanced 
adenomas at follow-up 
(%) 
Advanced adenomas at 
follow-up (%) 
 
OR (univariate) 
[95% CI] 
p-value 
      
All patients 354 (100) 224 (63) 130 (37)   
      
Age (years)      
      <55 37 (11) 27 (12) 10 (8) 1.0 - 
      55–64 128 (36) 83 (37) 45 (35) 1.46 [0.65–3.29] - 
      65–74 171 (48) 103 (46) 68 (52) 1.78 [0.81–3.92] - 
      75+ 
 
18 (5) 11 (5) 7 (5) 1.72 [0.52–5.67] 0.16 
Sex      
     Female 82 (23) 50 (22) 33 (25) - - 
     Male 
 
272 (7) 174 (78) 97 (75) 0.88 [0.51–1.39] 0.51 
BMI1 (kg/m2)      
     20–24.9  (normal weight) 42 (18) 27 (19) 15 (17) 1.0 - 
     < 20        (underweight) 9 (4) 7 (5) 2 (2) 0.51 [0.09–2.79] - 
     25–29.9  (overweight) 84 (37) 54 (39) 30 (33) 1.00 [0.46–2.17] - 
     30+         (obese) 
 
95 (41) 52 (37) 43 (48) 1.49 [0.70–3.15] 0.21 
Smoking status      
     Never 125 (36) 85 (38) 40 (32) - - 
     Ex/current 
 
225 (64) 138 (62) 87 (68) 1.34 [0.84–2.13] 0.21 
Social deprivation quintile      
     5 (least deprived) 64 (18) 43 (19) 21 (16) 1.0 - 
     4 41 (11) 24 (10) 17 (13) 1.45 [0.64–3.26] - 
     3 53 (15) 35 (16) 18 (14) 1.05 [0.49–2.28] - 
     2 
     1 (most deprived) 
 
 
66 (19) 
130 (37) 
37 (17) 
85 (38) 
29 (22) 
45 (35) 
1.60 [0.79–3.27] 
1.08 [0.57–2.06] 
- 
0.87 
  
 
 
1
4
6
 
Aspirin      
     No 302(85) 192 (86) 110 (85) - - 
     Yes 
 
52 (15) 32 (14) 20 (15) 1.09 [0.59–1.99] 0.78 
Statin      
     No 285 (80) 182 (81) 103 (79) - - 
     Yes 69 (20) 
 
42 (19) 27 (21) 1.14 [0.66–1.95] 0.64 
ACE-inhibitor      
     No 313 (88) 197 (88) 116 (89) - - 
     Yes 
 
41 (12) 27 (12) 14 (11) 0.88 [0.44–1.75] 0.72 
Adenoma number      
     1–2 166 (47) 101 (45) 65 (51) 1.0 - 
     3–4 111 (32) 73 (33) 38 (30) 0.81 [0.49–1.33] - 
     ≥5 
 
74 (21) 49 (22) 25 (19) 0.79 [0.45–1.41] 0.36 
Advanced adenomas      
     Absent 55 (16) 43 (19) 12 (9) - - 
     Present 
 
298 (84) 181 (81) 117 (91) 2.34 [1.18–4.61] 0.02 
Villous features      
     Absent 177 (50) 118 (53) 59 (45) - - 
     Present 
 
177 (50) 106 (47) 71 (55) 1.36 [0.87–2.07] 0.19 
Adenoma size ≥1cm      
     No 69 (20) 49 (22) 20 (16)  - 
     Yes 
 
285 (80) 175 (78) 110 (84) 1.54 [0.87–2.73] 0.14 
HGD      
    Absent 304 (86) 197 (88) 107 (82)  - 
    Present 
 
50 (14) 27 (12) 23 (18) 1.57 [0.86–2.87] 0.14 
                   1230 patients with BMI data available 
             2250 patients with smoking status available 
                  3351 patients with adenoma number at baseline data available 
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Table 3.5: Studies reporting on the relationship between baseline adenoma characteristics 
and adenoma recurrence 
Author Year Design 
 
Variable Any 
adenoma 
recurrence1 
Advanced 
adenoma 
recurrence2 
      
Kulling et 
al.(276) 
2002 Retrospective 
cohort 
↑Adenoma number 
Size ≥1cm 
HGD 
Villous features 
 
↑ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
Avidan et 
al.(278) 
2002 Retrospective 
Cohort 
↑Adenoma number 
Size ≥1cm 
Villous features 
 
↑ 
↑ 
↔ 
n/a 
n/a 
n/a 
 
Bertario et 
al.(234) 
2003 Prospective cohort ↑Adenoma number 
Size ≥1cm 
HGD 
Villous features 
 
↑ 
Inconclusive4 
↔ 
↑ 
↔ 
↔ 
↔ 
↔ 
Bonithon-
Kopp et 
al.(272) 
2004 From a non-effect 
intervention trial 
↑Adenoma number 
Size ≥1cm 
HGD 
Villous features 
 
↑ 
↔ 
↔ 
↔ 
 
↑ 
↔ 
↔ 
↔ 
 
Lieberman et 
al.(301) 
2007 Prospective cohort ↑Adenoma number 
Size ≥1cm 
HGD 
Villous features 
 
n/a 
n/a 
n/a 
n/a 
↑ 
↑ 
↑ 
↑ 
Nusko et 
al.(270) 
2009 Prospective cohort ↑Adenoma number 
Size ≥1cm 
HGD 
Villous features 
 
↑ 
↑ 
↔ 
↔ 
 
↑ 
↑ 
n/a 
↑ 
 
Martinez et 
al.(248) 
2009 Pooled data from 
prospective trial 
↑Adenoma number 
Size ≥1cm 
HGD 
Villous features 
 
↑ 
↔ 
↔ 
↔ 
 
↑ 
↑ 
↑3 
↑ 
Chung et 
al.(277) 
2011 Prospective cohort ↑Adenoma umber 
Size ≥1cm 
Villous features 
 
↑ 
↔ 
↔ 
↑ 
↑ 
↔ 
Viel et 
al.(275) 
2012 
 
 
Prospective cohort ↑Adenoma umber 
 
↑ 
 
n/a 
Van 
Heijningen et 
al.(267) 
2013 Retrospective 
cohort 
↑Adenoma umber 
Size ≥1cm 
HGD 
Villous features 
 
↑ 
↔ 
↔ 
↔ 
↑ 
↑ 
↑3 
↑ 
Taniguchi et 
al.(246) 
2014 Retrospective 
cohort 
↑Adenoma number 
Size ≥1cm 
HGD 
Villous features 
 
↑ 
↑ 
↑ 
↑c 
 
n/a 
n/a 
n/a 
n/a 
 
Van 
Enckevort et 
al.(271) 
2014 Retrospective 
cohort 
↑Adenoma number 
Size ≥1cm 
HGD 
Villous features 
↑ 
↔ 
↑ 
↔ 
n/a 
n/a 
n/a 
n/a 
 148 
 
Xu et al. 
(247) 
2015 Retrospective 
review 
 
 
↑Adenoma number 
Size ≥1cm 
HGD 
Villous features 
↑ 
↔ 
n/a 
n/a 
↔ 
↔ 
n/a 
n/a 
 
 
↑    Increased risk of recurrence 
↔   No significant difference found 
 n/a Study did no analyse data for these endpoints 
1Any adenoma recurrence of any type or non-advanced adenoma recurrence 
2Advanced adenoma recurrence; the presence of any features of (≥1cm size, villous features, HGD) 
3significance lost on multivariable analysis 
4Study reports hazard ratios for adenomas ≥1cm, 1–2cm and >2cm rather than a simple <1cm ≥ category
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4 THE RELATIONSHIP BETWEEN COLORECTAL 
NEOPLASIA, SYSTEMIC INFLAMMATION AND 
HOST CHARACTERISTICS IN A BOWEL 
SCREENING POPULATION 
4.1 Introduction 
In many cancers, there exists a pre-malignant stage. Screening reduces the incidence of CRC 
largely due to endoscopic polypectomy (223). Nonetheless, there remains a high adenoma 
recurrence rate post-polypectomy of 30–60% (224, 225, 302). It follows that a reduction in 
the incidence of both primary and recurrent adenomas could lead to a reduction in CRC 
incidence. In terms of healthcare economics this would minimise screening and treatment 
costs. Identifying modifiable risk factors for adenoma development would also be a logical 
next step. 
Hanahan and Weinberg (2000) proposed six hallmarks of cancer in their paper discussing 
the multistep process of tumorogenesis (47). Inflammation has since been described as the 
7th hallmark of cancer (48). Large studies have shown that blood biomarkers of the systemic 
inflammatory response (SIR), such as elevated CRP, are associated with the presence of 
cancer (303, 304). They have also been associated specifically with CRC risk in long-term 
follow-up and epidemiological studies (305) (306). However, this association is not 
unanimous (307). In addition, the SIR has demonstrated a predictive value on disease 
progression and poorer outcomes in both operable  and non-operable disease  across a range 
of cancer types (142) (308). In CRC, the SIR is noted as a predictor of poorer outcomes 
independent of tumour stage (142). Furthermore, a link between systemic inflammation and 
cancer is biologically plausible. As part of the SIR, pro-inflammatory cytokines and growth 
factors are released and may contribute to tumour maintenance and proliferation (309).  
To date, despite the links between systemic inflammation and established cancer, the role of 
the SIR at the pre-cancerous and early neoplastic stage of CRC is less well studied. It is 
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feasible that the SIR may play a stimulatory role in the formation of colorectal adenomas 
from otherwise normal colorectal mucosa. Although largely experimental, studies 
investigating the mechanisms of colitis-associated cancer development have shown that IL-
6 is a critical tumour promoter (310). Furthermore, one study used a colitis-inducing mouse 
model to demonstrate that up-regulation of TNF-α was associated with the development of 
multiple colonic tumours (311). Moreover, when these mice were treated with a TNF-α 
blocker, the number and size of tumours in the colon were reduced (311). It is likely that the 
same inflammatory mechanism could be acting on otherwise normal colonic mucosa 
inducing a dysplastic change. In addition, case-control studies have shown that patients with 
adenomas are more likely to have high circulating endotoxin concentrations (312). It is 
postulated that this is due to dysbiosis between colonic flora, resulting in a higher 
concentration of Gram-negative bacteria. The result is an increased release of pro-
inflammatory cytokines and subsequent bloodstream absorption of endotoxin, which may 
demonstrate a link between inflammatory cytokines and adenoma formation mediated by 
gut bacteria (312).  
Clinically, CRP can be used as a surrogate marker of the pro-inflammatory cytokines, IL-6 
and TNF-α. CRP is released into the circulation by hepatocytes in response to elevations in 
the above two cytokines. This suggests CRP, which is routinely measured by laboratories, 
could be used in epidemiologic studies, as a clinically relevant biomarker of inflammation 
(313). Clinically, establishing a link between systemic inflammation, as measured by CRP, 
and the pre-malignant stage of CRC, could help in developing early intervention pathways. 
Given the aforementioned relationship between the inflammatory process and cancer 
development, it would be clinically advantageous to determine which, if any, host 
characteristics are associated with systemic inflammation to allow clinical interventions 
within an “at-risk” population. Previous studies have suggested links between obesity, as 
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part of the metabolic syndrome (314) and ageing, often termed “inflammageing” with low-
grade systemic inflammation (315). 
The present prospective study aimed to examine the relationship between the incidence of 
colorectal neoplasia, host characteristics and systemic inflammation within a UK bowel 
screening population. 
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4.2 Methods 
Study design 
The present study was a multi-centre prospective cohort study carried out within NHS GGC, 
Scotland, UK. Research ethics approval was obtained as outlined in the thesis declaration 
(page 14). Patients were recruited from those attending for a colonoscopy at any of five 
major Glasgow hospitals as part of the SBoSP from February 2016 to July 2017. All patients 
who had tested positive as part of the previously described bowel screening programme 
(140) (Section 1.2.2), were eligible for inclusion. The recruitment and data gathering process 
are summarised in Figure 4.1. 
Colonoscopy lists were sourced two weeks in advance. This enabled study invitation packs 
to be posted to patients prior to their colonoscopy. There were no pre-selection exclusion 
criteria. On attendance for the colonoscopy, each consenting patient underwent height and 
weight measurement from which BMI (kg/m2) was calculated. For patients whose height 
and weight were not measured on the day, data were obtained from recent primary care 
medical records. Blood sampling was undertaken on the day of colonoscopy and used to 
obtain a full blood count (FBC), along with urea and electrolyte (U+E), liver function test 
(LFT), CRP and bone profile (calcium, phosphate and alkaline phosphatase) measurements. 
Demographic data including age, sex, medication use, smoking status and socioeconomic 
deprivation were obtained from medical records. Deprivation was assessed using the SIMD 
ranking system (Chapter 3). Scores for SIMD were then ordered, and patients grouped into 
quintiles. The screening colonoscopy reports were reviewed, and pathology results from 
excised polyps were recorded. Non-neoplastic polyps were excluded. Non-advanced 
neoplasia was defined as; the presence of an adenoma without advanced features and the 
absence of cancer. Advanced neoplasia was the presence of an advanced adenoma (≥1cm 
size, villous histology, HGD) or adenocarcinoma. Active colonic inflammation was noted 
either macroscopically during colonoscopy or microscopically based on pathology results.  
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Post-participation exclusion criteria were: any previous colonic resection, or an incomplete 
colonoscopy, when these findings became apparent during the data collection process. 
Criteria for markers of the SIR  
CRP thresholds of ≥5mg/l and ≥10mg/l have been validated as markers of the SIR in patients 
with established cancer (308). Several previous studies have grouped CRP into quartiles and 
used the 1st quartile as a reference group when examining the risk of colorectal neoplasia. 
The present study set the threshold for systemic inflammation as CRP ≥3 mg/l. It is accepted 
that this threshold for the SIR allows stratification of patients into a high risk group future 
cardiac events (316). Furthermore using this threshold provides a clinically relevant cut-off 
point. 
Study endpoints 
The study had a number of endpoints. Firstly, the association between host factors and the 
SIR as measured by elevated CRP (≥3mg/l) was examined. The study further sought to 
determine the association between host factors, including the SIR and the incidence of 
abnormal findings at colonoscopy. Abnormal findings at colonoscopy were defined as any 
colorectal pathology, both neoplastic or non-neoplastic (haemorrhoids, diverticulosis, anal 
fissure, proctitis, angiodysplasia, colitis). Considering only patients with an abnormal 
colonoscopy, the relationship between host factors and advancing severity of pathology 
(non-neoplastic colorectal pathology, [NNCP], adenoma only, or adenocarcinoma) was 
examined. The relationship between host factors and the presence of any neoplasia or 
advanced neoplasia was examined. 
Statistical analyses 
Statistical analyses were carried out using IBM® SPSS® Statistics version 22 (SPSS Inc., 
Chicago, IL, USA). Associations between categorical variables with two groups were 
examined using a χ2 test. For categorical variables with more than two groups, a binary 
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logistic regression was carried out comparing each variable to the reference group. Any 
known or likely associated variables or those with a p<0.1 were included in the multivariable 
analysis. Ors were calculated for risk, and a value of p<0.05 was considered statistically 
significant.   
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Figure 4.1: Recruitment and data gathering process for consenting patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients aged 50–74 years with positive screening 
test attending for colonoscopy were invited to 
participate by post 
 
Signed study participation consent forms were 
returned, and any questions answered by 
colonoscopy nursing staff or researchers at the 
colonoscopy appointment 
Height and weight were measured in the endoscopy 
department by nursing staff prior to colonoscopy 
Blood sampling was completed during intravenous 
cannulation prior to colonoscopy. Blood was sent 
for FBC, U+E, bone profile and LFTs 
Complete colonoscopy was conducted and biopsies 
/ polypectomy tissue sent for histopathological 
analysis 
Medical records were viewed along with 
colonoscopy and histopathology results to collect 
data for analysis 
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4.3 Results 
1,867 invitation packs were sent to patients between February 2016 and June 2017. 456 
(24%) patients consented and were eligible for inclusion with 12 patients subsequently 
excluded due to previous colorectal resections (n=5), or incomplete investigations (n=7). 
This left 444 patients for the final analysis [Figure 4.2]. Baseline characteristics are shown 
in Table 4.1. 209 (47%) participants were male. The median age was 63 years (IQ range 56–
67). The cohort were predominantly overweight: 303 (75%) had a BMI of ≥25. There was a 
high level of socioeconomic deprivation among the included participants: 206 (47%) were 
classed in the two most deprived quintiles (1st and 2nd) using the SIMD scoring system.  
The relationship between host factors and any abnormal findings at colonoscopy 
Figure 4.3 shows the outcomes of colonoscopy. Of the 444 participants, 308 (69%) had an 
abnormal finding at colonoscopy. Of these patients, 107 (35%) had NNCP, 182 (59%) had 
an adenoma. 19 (6%) had an adenocarcinoma. Among those with an adenoma, 87 (48%) had 
a non-advanced adenoma, and 95 (52%) had at least one advanced adenoma. When 
examining this entire bowel screening cohort, the incidence of adenoma and 
adenocarcinomas were 41 % and 4%, respectively. In considering the group as a whole, 201 
(45%) patients had neoplastic findings at colonoscopy. 
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Figure 4.2: Flow chart of recruitment and exclusion process  
  
Research invitation packs 
posted to patients 
(n=1867) 
Consenting patients 
(n=456) 
(24%) 
Non-responders 
(n=1411) 
(76%) 
Excluded 
(n=12)  
(3%) 
Incomplete 
investigations (n=7) 
(58%) 
Previous colorectal 
resection (n=5 ) 
(42%) 
Patients included in final 
analysis (n=444) 
(97%) 
 158 
 
Table 4.2 shows the relationship between host factors and abnormal findings at 
colonoscopy. Advancing age was associated with abnormal colonoscopy (p<0.001). Patients 
aged 65–74 years had an OR of 3.81 [95% CI; 2.19–6.61] when compared to those <55 
years. This observation remained consistent on multivariable analysis when adjusting for sex 
and smoking, OR 3.65 [95% CI; 2.05–6.48] (p<0.001). When compared to females, males 
were less likely to have abnormal colonoscopy findings overall, OR 0.63 [95% CI; 0.42–
0.94, p<0.05]. This observation remained significant on the multivariable analysis when 
adjusting for age and smoking status, OR 0.63 [95% CI; 0.41–0.97, p<0.05]. Patients with a 
history of smoking were significantly more likely to have abnormalities detected at 
colonoscopy on univariable analysis, OR 1.86 [95% CI; 1.22–2.83, p<0.01]. This 
observation remained significant on multivariable analysis when adjusting for age and sex, 
OR 1.59 [95% CI; 1.03–2.47, p<0.05]. Social deprivation, BMI, CRP and medication use 
were not associated with abnormal colonoscopy findings in this cohort. 
The relationship between host factors and severity of abnormality at colonoscopy 
Of the 308 patients with an abnormality at colonoscopy, 107 (35%) had the least severe 
abnormal finding (NNCP), 182 (59%) had moderate pathology (adenoma), and 19 (6%) had 
the most severe abnormality (CRC) [Figure 4.3]. The relationship between host factors and 
the increasing severity of abnormalities found at colonoscopy is displayed in [Table 4.3]. 
There was no significant association between host factors, including the SIR and the severity 
of abnormalities detected at colonoscopy.  
.
  
 
1
5
9
 
Figure 4.3: Prospectively recorded outcomes from screening colonoscopy 
Normal colonoscopy 
(n=136) 
(31%) 
 
Abnormal colonoscopy 
(n=308) 
(69%) 
Overall findings 
  Adenocarcinoma 
(n=19) 
(6%) 
 Adenoma 
(n=182) 
 (59%) 
 
 NNCP 
(n=107) 
(35%) 
Advanced adenoma 
(n=95) 
(52%) 
Non-advanced adenoma 
(n=87) 
(48%) 
Neoplasia 
(n=201) 
(45%) 
Neoplastic findings  
No neoplasia  
(n=243) 
(55%) 
All participants 
(n= 444) 
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The relationship between host factors and the incidence of any colorectal neoplasia 
Table 4.4 shows the relationship between host factors and the incidence of neoplasia. Only 
advancing age was associated with the presence of neoplasia, OR 2.49 [95% CI; 1.48–4.22] 
for those aged 65–74 years when compared to those aged <55 years, (p<0.01). This 
observation remained significant on multivariable analysis when adjusting for age, sex, 
smoking status and aspirin use, OR 2.84 [95% CI; 1.62–4.99] (p<0.01). There was no 
association between any other host characteristics, including the SIR, as measured by CRP 
≥3mg/l, and neoplasia in the present study. 
Table 4.5 shows the relationship between host characteristics and the incidence of advanced 
and non-advanced neoplasia in those with any neoplastic findings. Statin users were less 
likely to have advanced adenomas at colonoscopy OR, 0.49 [95% CI; 0.28–0.87, p<0.05]. 
There was no significant relationship between host characteristics, including the SIR as 
measured by CRP ≥3mg/l, and the incidence of advanced neoplasia. In the absence of any 
significant findings upon univariable analysis, a multivariable analysis was not carried out. 
The relationship between host factors and markers of the SIR 
Table 4.6 shows the relationship between host factors and the SIR, as measured by CRP ≥ 
3 mg/l. Social deprivation was associated with the SIR on univariable analysis, OR 2.69 
[95% CI; 1.28–5.65, p<0.01] and OR 2.36 [95% CI; 1.27–4.39, p<0.01] for those in the two 
most deprived quintiles (1st and 2nd) compared with the least deprived quintile (5th) 
respectively. This observation did not retain statistical significance on the multivariable 
model when correcting for BMI, smoking and aspirin use. Obesity (BMI ≥30), was 
associated with the SIR, OR 2.54 [95% CI; 1.33–4.87, p<0.01] and this relationship 
remained on multivariable analysis when adjusting for socioeconomic deprivation, smoking 
and aspirin use, OR 2.72 [95% CI; 1.35–5.49, p<0.01]. The SIR was associated with smoking 
history, OR 2.37 [95% CI; 1.49–3.76, p<0.0001] and aspirin use, OR 3.43 [95% CI; 1.63–
7.22, p<0.01] and both of these variables remained statistically significant on multivariable 
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analysis, OR 2.26 [95% CI; 1.33–3.84, p<0.01] and OR 2.59 [95% CI; 1.15–5.86, p<0.05] 
respectively.
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4.4 Discussion 
The present prospective study reports on the relationship between the incidence of colorectal 
neoplasia, the SIR, as measured by elevated CRP, and host characteristics in a UK bowel 
screening population. 
In the present study, age, female sex and smoking increased the likelihood of abnormal 
colonoscopy findings. None of the host characteristics were associated with more advanced 
pathology at colonoscopy. Advancing age was associated with an increased risk of incident 
neoplasia at colonoscopy, while those using aspirin were less likely to have incident 
neoplasia. No host factors were associated with an increased risk of advanced neoplasia. The 
SIR, as measured by elevated CRP, was not associated with the presence of colorectal 
neoplasia but was strongly associated with obesity, smoking, aspirin use and moderately 
associated with socioeconomic deprivation. 
Increasingly, a “host targeted” approach to bowel screening is desirable to reduce costs and 
the burden on healthcare services. Identification of a higher risk group, which is then targeted 
for colonoscopy, may be beneficial towards delivering this. As such, the present study aimed 
to determine whether clinically relevant and modifiable risk factors for colorectal neoplasia 
could be identified in a bowel screening population. It also aimed to investigate the 
relationship between the SIR, host characteristics and colorectal neoplasia incidence. This 
was on the basis that systemic inflammation might be a linking mechanism between host 
factors such as age, male sex, and elevated BMI  previously associated with colorectal 
neoplasia incidence and recurrence (317, 318) (319) (193). This may allow targeting of the 
SIR for intervention, which could be particularly useful with respect to the above host 
characteristics that are either, non-modifiable (e.g. age and sex), or difficult to modify in the 
short term (e.g. socioeconomic deprivation and obesity)  
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Host characteristics and systemic inflammation 
In the present study, elevated CRP was strongly associated with obesity as measured by BMI 
≥30. This supports the theory that obesity induces a pro-inflammatory state within the body. 
Obesity, as a reflection of high body adiposity, has previously been linked to inflammation 
(251, 320, 321). This association is plausible given that adipose tissue is recognised as an 
endocrine organ rather than simply a fat storage site. Furthermore, obesity has been 
specifically associated with increased circulating levels of CRP and the pro-inflammatory 
cytokines: TNF-α and IL-6 (251). A recent systematic review and meta-analysis reported on 
the relationship between BMI, body fat percentage, exercise and systemic inflammation, as 
measured by CRP (322). The researchers noted that exercise is associated with a reduction 
in CRP and that this effect is largely driven by a decrease in BMI and body fat percentage. 
These findings support the results of the present study. 
In the present study, aspirin use was associated with the SIR, as measured by elevated CRP. 
This would seem counterintuitive given the anti-inflammatory properties of aspirin. In this 
study, it is likely that patients using aspirin for clinical reasons (mainly cardiovascular risk 
modification) are subject to an increased burden of comorbid disease compared to the 
general population. This could induce a low-level SIR in aspirin users, such that the elevated 
CRP in these patients is reflective of their comorbid state rather than their aspirin use. Similar 
conclusions were drawn in a study in 2008 (251), which investigated the relationship 
between pro-inflammatory cytokines and colorectal adenoma incidence and reported higher 
levels of pro-inflammatory cytokines in who regularly used NSAIDs. Overall, the 
relationship between inflammatory markers and aspirin use has been inconsistent, with some 
studies finding aspirin was associated with a reduction in CRP (323) and other studies 
finding no change in CRP concentration with aspirin use (324). 
Smoking was also associated with an elevated SIR in the present study. Smoking is linked 
to a number of medical conditions; thus, it is plausible that the elevated SIR is likely to 
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reflect this link. In addition, smoking itself may well induce a low-level inflammatory 
response.  
The present study did not detect a strong link between advancing age and systemic 
inflammation. Previous researchers have suggested that ageing results in a global reduction 
in the body’s ability to deal with a variety of physical stressors. This results in a pro-
inflammatory state (325). It is likely that a low-level inflammatory response associated with 
ageing remains largely subclinical and difficult to detect with more routine blood sampling 
such as CRP.  
Host characteristics and abnormal colonoscopy findings 
With respect to host characteristics and the likelihood of an abnormal finding at 
colonoscopy, older patients and those who smoked were more likely to have abnormalities 
at colonoscopy, either neoplastic or NNCP. Advancing age and smoking are both associated 
with worsening general health, so this result is unsurprising. However, female sex was 
significantly associated with an abnormal colonoscopy. When isolating only those with 
NNCP and then considering neoplastic pathology, 54% and 58%, respectively, were female. 
This suggests that the increased rate of abnormal findings at colonoscopy in females is driven 
by both neoplastic and non-neoplastic pathology. The mechanism for this effect is not clear, 
especially given that CRC incidence in the UK is higher in males (1). However, the 
difference between sexes is marginal, and the use of large studies may allow clarification or 
attenuation of this observation. Besides this, the present study sought to determine whether 
specific host characteristics were associated with more advanced pathology at colonoscopy, 
such as adenocarcinoma vs. adenoma vs. non-neoplastic pathology [Table 4.3]. The present 
study found no association in this regard but was not designed for the analysis of CRC 
incidence. 
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The relationship between host factors and incident colorectal neoplasia 
This study found that increasing age was associated with an increased incidence of colorectal 
neoplasia at the screening. This observation was maintained when adjusting for sex, smoking 
and aspirin use. This is perhaps unsurprising, given that age is an accepted risk factor for 
colorectal adenomas (326). Neither sex nor smoking were associated with neoplasia 
incidence in the present study. This is in contrast to a population-based study in the USA 
using data from phase I and II of the national colonoscopy study. The study suggested that 
male sex and smoking were risk factors for adenoma incidence (p<0.001) (326). Most 
notably, the researchers used data obtained from a younger cohort with a large number of 
patients under 55 years collected from the general population. This is in contrast to the 
present study that reports on an older, bowel-screened population. Furthermore, the present 
study population had previously tested positive at bowel screening and therefore, were more 
likely to harbour pathology at the outset. These differences in study populations may explain 
the contrasting results. 
The present study found no appreciable association between BMI, in particular, obesity, and 
colorectal neoplasia incidence. This is in contrast to a meta-analysis carried out in 2012. It 
concluded that higher BMI (per 5-unit increase) was associated with higher colorectal 
adenoma incidence (192). However, there was significant heterogeneity between the 
included studies in this meta-analysis as reflected by the forest plot and I2 statistic of 76.8%. 
The overall effect was small, with a pooled RR of 1.19 [95% CI; 1.13–1.26]. Another recent 
meta-analysis reached similar conclusions to the above study (297). Similarly, the 
conclusions were based on a pooled OR, and many of the included studies reported non-
significant results. Neither of these studies reported a linear relationship between BMI and 
colorectal adenoma incidence. Inherently when assessing increasing BMI and neoplasia 
incidence, there are a considerable number of confounding variables, particularly in 
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retrospective observational studies. In reality, it seems the relationship between BMI and 
early colorectal neoplasia (e.g. adenomas) remains inconclusive and small. 
The present study noted that when adjusting for age, sex and smoking, aspirin use was 
associated with a 50% reduction in colorectal neoplasia incidence. This is perhaps 
unsurprising as aspirin has been associated with a reduction in CRC and colorectal adenoma 
incidence. This association was discussed at length in Chapter 1 (Section 1.1.2.2 and 
Section 1.4.4.4) and Chapter 2. 
Systemic inflammation and colorectal neoplasia 
It was hypothesised that systemic inflammation might play a role in the formation and pre-
malignant stage of CRC and thus may provide a target for intervention at an early stage of 
the disease. In the present study, the SIR, as measured by elevated CRP, was not associated 
with the presence of either non-advanced or advanced colorectal neoplasia. Additional 
analysis produced the same result when considering adenoma and adenocarcinoma 
individually. A recent meta-analysis of observational studies investigating the effect of 
systemic inflammation on colorectal adenoma incidence was published in 2017, and similar 
to the present study, the authors were unable to determine a definite relationship between 
circulating IL-6, TNF-α and CRP, and adenoma incidence (327). However, in contrast to the 
present study, the researchers found a weak association between elevated CRP and advanced 
adenoma incidence with a pooled OR of 1.59 [95% CI; 1.09-2.32]. 
The results of the present study are in contrast to a study carried out in 2008, investigating 
the relationship between colorectal adenoma incidence and the circulating inflammatory 
cytokines, TNF-α, IL-6 and CRP (251). The study concluded that only patients in the highest 
tertile groups of circulating TNF-α and IL-6 were associated with the presence of colorectal 
adenomas (OR 1.85 and 1.66, respectively). The researchers also concluded that those in the 
highest tertile group for CRP were more likely to have colorectal adenomas, OR 1.47 [95% 
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CI; 0.96–2.25], compared to the lowest tertile. However, the confidence interval crosses 1.0, 
and therefore, statistical significance is questionable. There were 873 participants in the 
above study; however, there were significantly more males (p<0.04), and patients as young 
as 30 years were included. In addition, eligible patients included those with abdominal pain 
and PR bleeding, as well as asymptomatic screened patients. These significant differences 
between the cohort used in the above study and the present study could explain our 
contrasting findings.  
Systemic inflammation and established colorectal cancer 
The present study was not powered to investigate the relationship between the SIR and 
incident CRC. Nonetheless, previous work investigating this is worth mentioning. Based on 
the results of the present study, it would seem reasonable to conclude that the association 
between circulating CRP, colorectal adenomas and early neoplasia remains unproven. In 
terms of established CRC, there appears to be a stronger association with systemic 
inflammation. A recent study by Park et al. published in 2016 examined data from 1,000 
consecutive patients undergoing potentially curative CRC resection from the same 
geographical region as the present study. They found that 37% of patients had elevated CRP 
(>10mg/l). These results conflict with those from the present study, which showed that only 
13% of individuals with pre-cancerous colorectal adenomas had CRP > 10mg/l. Thus, it 
would seem plausible that the progression from pre-malignant disease to malignant disease 
explains the higher inflammatory response in cancer patients. 
A meta-analysis published in 2014 concluded that increasing pre-diagnosis CRP was weakly 
associated with CRC risk, OR 1.12 [95% CI; 1.05–1.21] (53). However, when looking at 
colon and rectal cancer separately, the association was lost for rectal cancer. In addition, the 
researchers found that when analysing the sexes separately, the relationship was only present 
in men, making it difficult to draw any firm conclusions. Furthermore, a recent study 
published in the British Journal of Cancer, investigating 4,764 patients diagnosed with CRC 
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did not find any association between baseline CRP many years prior and subsequent to the 
development of CRC. However, the researchers did find a weak association between CRC 
risk and circulating leukocytes and haptoglobins (307). A number of weaknesses were 
inherent in the above study; for example, the blood markers were collected between 1986 
and 1999 (a time when high sensitivity CRP testing was not available) meaning 
measurements <10mg/l could not be detected. The one-off blood measurements were carried 
out many years prior to the eventual diagnosis of CRC, with a mean follow-up of 18 years. 
This is in contrast to the present study which evaluated the SIR at diagnosis. These 
differences in methodology are understandable given that the present study aimed to 
determine if CRP, as a marker of current, active, systemic inflammation, could be used as a 
potential marker of early neoplasia. 
In summary, the relationship between CRP and early CRC development or diagnosis is as 
yet, inconclusive. 
Strengths and limitations 
To our knowledge, this is the first study within a UK bowel screening cohort to investigate 
the relationship between systemic inflammation, host factors and colorectal neoplasia at the 
time of diagnosis. Data were collected prospectively in order to minimise bias. Bowel 
screening patients have a high incidence of colorectal neoplasia (45% in the present study), 
and neoplastic findings are overwhelmingly pre-malignant adenomas. As such, this group 
are an optimal cohort with which to study the impact of potentially modifiable risk factors 
on early and pre-malignant disease. This makes the present study clinically relevant. 
There are, however, a number of weaknesses in the present study. It was not possible to draw 
firm conclusions with respect to CRC given that there were only 19 cases from the 444 
patients. Furthermore, cross-sectional measurement of host factors such as CRP or BMI at 
the time of colonoscopy is useful to determine whether these host factors can be used to form 
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a “high-risk” patient profile for colonoscopy. The disadvantage of this method is that it only 
reflects the status at the time of diagnosis, meaning that without knowledge of the long-term 
trend of a patient’s BMI, CRP, and other host factors over time, it is more difficult to draw 
firm conclusions as to whether certain host factors could have contributed to the diagnosis. 
Final conclusions and further work required 
The present study has found that elevated BMI, smoking and aspirin use is associated with 
a systemic inflammatory response. Advancing age is associated with an increased risk of 
colorectal neoplasia. Active aspirin use may reduce this risk. Systemic inflammation was 
neither associated with non-advanced nor advanced neoplasia. As such, the present study 
was unable to link the SIR associated with the host factors above, to colorectal neoplasia 
incidence. Thus, the present study is unable to determine the clinical usefulness of CRP or 
other host factors in predicting those at risk of colorectal neoplasia in bowel screened 
patients. 
With specific reference to BMI, although it was not associated with colorectal neoplasia in 
the present study, it is a modifiable risk factor, and other studies have found a link between 
the two. Thus, future work in bowel screening patients could focus on different measures of 
adiposity and “body fatness” other than BMI, which has several limitations as a specific 
marker of adiposity. Recent focus has been on body fat distribution rather than overall weight 
or fat load. In addition, future studies might wish to follow-up cohorts of screening patients 
over time, perhaps with serial measurements of CRP and BMI to study the role of longer-
term chronic systemic inflammation and obesity on CRC development. Screening patients 
who undergo polypectomy in the UK are routinely followed-up by means of subsequent 
colonoscopy and as such, are an ideal population to be used in investigating the long-term 
effect of systemic inflammation and host factors.  
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Table 4.1: Baseline characteristics of the study cohort  
 
Baseline characteristics Number (%) 
  
All 444 (100) 
  
  
Age (years)  
      <55 92 (21) 
      55–64 156 (35) 
      65–74 187 (42) 
      75+ 9 (2) 
  
Sex  
     Female 235 (53) 
     Male 209 (47) 
  
Social deprivation quintile  
      5 (least deprived) 95 (21) 
      4  72 (16) 
      3 71 (16) 
      2 74 (17) 
      1 (most deprived) 132 (30) 
  
BMI1 (kg/m2) groups  
      20–24.9    (normal weight) 92 (23) 
      <20           (underweight) 8 (2) 
      25–29.9    (overweight) 150 (37) 
      30+           (obese) 153 (38) 
  
Smoking status2  
     Never smoked 204 (48) 
     Ever smoked 219 (52) 
  
CRP (mg/l)3  
      <3 120 (33) 
      ≥3 248 (67) 
  
Aspirin   
      No 369 (83) 
      Yes 74 (17) 
  
Statin  
      No 268 (60) 
      Yes 175 (40) 
  
ACE-inhibitor  
      No 354 (80) 
      Yes 89 (20) 
 
1Data available for 403 patients 
2Data available for 423 patients 
3Data available for 368 patients 
 
 
  
1
7
1
 
Table 4.2: The relationship between host factors and abnormal findings at colonoscopy 
Baseline characteristics All patients 
(%) 
 
Normal 
colonoscopy (%) 
Abnormal 
colonoscopy (%) 
OR (univariable) p-value OR (multivariable)1 p-value 
 
        
All patients 444 (100) 136 (31) 308 (69)     
        
Age (years)        
      <55 92 (21) 43 (32) 49 (16) 1.0 - 1.0 - 
      55–64 156 (35) 56 (41) 100 (33) 1.57 [0.93–2.65] - 1.59 [0.92–2.75] - 
      65–74 187 (42) 35 (26) 152 (49) 3.81 [2.19–6.61] - 3.65 [2.05–6.48] - 
      75+ 9 (2) 2 (1) 7 (2) 3.07 [0.61–15.58] <0.001 6.15 [0.70–52.2] <0.001 
        
Sex        
     Female 235 (53) 61 (45) 174 (56) - - 1.0 - 
     Male 209 (47) 75 (55) 134 (44) 0.63 [0.42–0.94] 0.02 0.63 [0.41–0.97] 0.04 
        
Social deprivation quintile        
      5 (least deprived) 95 (21) 25 (18) 70 (23) 1.0 - - - 
      4  72 (16) 21 (15) 51 (17) 0.87 [0.44–1.72] - - - 
      3 71 (16) 21 (15) 50 (16) 0.85 [0.43–1.69] - - - 
      2 74 (17) 22 (16) 52 (16) 0.84 [0.43–1.66] - - - 
      1 (most deprived) 132 (30) 47 (36) 85 (28) 0.65 [0.36–1.15] 0.15 - - 
        
BMI (kg/m2) groups         
      20–24.9     (normal weight) 92 (23) 31 (25) 61 (22) 1.0 - - - 
      <20            (underweight) 8 (2) 1 (1) 7 (2) 0.36 [0.42–30.2] - - - 
      25–29.9     (overweight) 150 (37) 41 (34) 109 (39) 1.35 [0.77–2.37] - - - 
      30+            (obese) 153 (38) 49 (40) 104 (37) 1.08 [0.62–1.87] 0.84 - - 
        
Smoking status        
     Never smoked 204 (48) 76 (59) 128 (44) - - 1.0 - 
     Ever smoked 219 (52) 53 (41) 166 (56) 1.86 [1.22–2.83] 0.004 1.59 [1.03–2.47] 0.04 
 
 
       
  
1
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CRP (mg/l)        
      <3 120 (33) 34 (32) 86 (33) - - - - 
      ≥3 248 (67) 72 (68) 176 (67) 1.035 [0.645–1.68] 0.89 - - 
Aspirin        
      No 370 (83) 111 (82) 259 (84) - - - - 
      Yes 74 (17) 25 (18) 49(16) 0.84 [0.49–1.43] 0.52 - - 
        
Statin        
      No 268 (60) 86 (63) 182 (59) - - - - 
      Yes 176 (40) 50 (37) 126 (41) 1.19 [0.79–1.81] 0.41 - - 
        
ACE-inhibitor        
      No 355 (80) 110 (81) 245 (80) - - - - 
      Yes 89 (20) 26 (19) 63 (20) 1.09 [0.65–1.81] 0.75 - - 
 
 
       1Adjusted for age, sex and smoking status 
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Table 4.3: The relationship between host factors and severity of abnormality found at colonoscopy in those with an abnormal colonoscopy 
Baseline characteristics Patients with any 
abnormality at 
colonoscopy1 (%) 
 
NNCP 
(%) 
Adenoma 
(%) 
Adenocarcinoma 
(%) 
p-value 
(linear by 
linear) 
      
All patients 308 (100) 107 (35) 182 (59) 19 (6)  
      
Age (years)      
      <55 49 (16) 20 (19) 28 (15) 1 (5) - 
      55–64 100 (33) 32 (30) 63 (35) 5 (27) - 
      65–74 152 (49) 52 (48) 88 (48) 12 (63) - 
      75+ 7 (2) 3 (3) 3 (2) 1 (5) 0.28 
      
Sex      
        Female 174 (56) 58 (54) 107(59) 9 (47) - 
         Male 134 (44) 49 (46) 75 (41) 10 (53) 0.89 
      
Social deprivation quintile      
       5 (least deprived) 70 (23) 20 (19) 46 (25) 4 (21) - 
       4 51 (16) 20 (19) 26 (14) 5 (26) - 
       3 50 (16) 20 (19) 26 (14) 4 (21) - 
       2 52 (17) 15 (14) 34 (19) 3 (16) - 
       1 (most deprived) 85 (28) 32 (29) 50 (28) 3 (16) 0.36 
      
BMI2 Groups(kg/m2)      
      20–24.9    (normal weight) 61 (22) 24 (24) 35 (21) 2 (12) - 
      <20           (underweight) 7 (2) 4 (4) 3 (2) 0 (0) - 
      25–29.9    (overweight) 109 (39) 32 (32) 69 (42) 8 (50) - 
      30+           (obese) 
 
104 (37) 40 (40) 58 (35) 6 (38) 0.54 
Smoking Status      
       Never smoked 128 (44) 44 (43) 75 (43) 9 (50) - 
       Ever smoked 
 
166 (56) 58 (57) 99 (57) 9 (50) 0.85 
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                1Number of those with any abnormality (excluding haemorrhoids) at colonoscopy were 308 of the entire cohort of 444 (not all patients had blood results available) 
                2Data available for 281 patients 
                3Data available for 262 patients 
 
  
CRP (mg/l)3      
      <3 86 (33) 30 (34) 50 (32) 6 (35) - 
      ≥3 
 
176 (67) 59 (66) 106 (68) 11 (65) 0.93 
Aspirin      
       No 259 (84) 85 (79) 157 (86) 17 (90) - 
       Yes 49 (16) 22 (21) 25 (14) 2 (10) 0.10 
      
Statin      
       No 182 (59) 63 (59) 105 (58) 14 (74) - 
       Yes 126 (41) 44 (41) 77 (42) 5 (26) 0.52 
      
ACE-inhibitor      
       No 245 (80) 81 (76) 147 (81) 17 (90) - 
       Yes 63 (20) 26 (24) 35 (19) 2 (10) 0.14 
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Table 4.4: The relationship between host factors and incident neoplasia at bowel screening colonoscopy 
Baseline characteristics All patients 
(%) 
No neoplasia 
(%) 
Any neoplasia 
(% ) 
 
OR (univariable) p-value OR (multivariable)1 p-value 
        
All patients  444 243 (55) 201 (45)     
        
Age (years)        
      <55 92 (21) 63 (26) 29 (14) 1.0 - 1.0 - 
      55–64 156 (35) 88 (36) 68 (34) 1.68 [0.98–2.89] - 1.82 [1.04–3.23] - 
      65–74 187 (42) 87 (36) 100 (50) 2.49 [1.48–4.22] - 2.84 [1.62–4.99] - 
      75+ 9 (2) 5 (2) 4 (2) 1.73 [0.43–6.95] 0.001 2.69 [0.59–12.05] <0.001 
        
Sex        
        Female 235 (53) 119 (49) 116 (58) - - - - 
        Male 209 (47) 124 (51) 85 (42) 0.70 [0.48–1.02] 0.07 0.73 [0.49–1.09] 0.12 
        
Social deprivation quintiles        
        5 (least deprived) 95 (21) 45 (19) 50 (25) 1.0 - - - 
        4 72 (16) 41 (17) 31 (15) 0.68 [0.37–1.26] - - - 
        3 71 (16) 41 (17) 30 (15) 0.66 [0.35–1.22] - - - 
        2 74 (17) 37 (15) 37 (19) 0.90 [0.49–1.65] - - - 
        1 (most deprived) 132 (30) 79 (32) 53 (26) 0.60 [0.36–1.03] 0.16 - - 
        
BMI (kg/m2) groups        
      20–24.9     (normal weight) 92 (23) 55 (25) 37 (20) 1.0 - - - 
      <20            (underweight) 8 (2) 5 (2) 3 (2) 0.89 [0.20–3.96] - - - 
      25–29.9     (overweight) 150 (37) 73 (33) 77 (43) 1.57 [0.93–2.65] - - - 
      30+            (obese) 153 (38) 89 (40) 64 (35) 1.07 [0.63–1.81] 0.69 - - 
        
Smoking status        
        Never smoked 204 (48) 120 (52) 84 (44) - - - - 
        Ever smoked 219 (52) 111 (48) 108 (56) 1.39 [0.95–2.04] 0.09 1.34 [0.89–2.01] 0.15 
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CRP (mg/l)        
      <3 120 (33) 64 (33) 56 (32) - - - - 
      ≥3 248 (67) 131 (67) 117 (68) 1.02 [0.66–1.58] 0.93 - - 
        
Aspirin        
        No 370 (83) 196 (81) 174 (87) - - - - 
        Yes 74 (17) 47 (19) 27 (13) 0.65 [0.39–1.08] 0.09 0.51 [0.29–0.89] 0.02 
        
Statin        
        No 268 (60) 149 (61) 119 (60) - - - - 
        Yes 176 (40) 94 (39) 82 (40) 1.09 [0.75–1.60] 0.65 - - 
        
ACE-inhibitor        
        No 355 (80) 191 (79) 164 (82) - - - - 
        Yes 89 (20) 52 (21) 37 (18) 0.83 [0.52–1.33] 0.43 - - 
 
 
   1Adjusted for age, sex, smoking and aspirin use 
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Table 4.5: The relationship between host factors and the incidence of non-advanced vs. advanced neoplasia 
Baseline characteristics Patients with 
neoplasia 
(%) 
Non-advanced 
neoplasia1 
(%) 
Advanced 
neoplasia2 
(%) 
OR (univariable) p-value 
      
All patients 201 87 (43) 114 (57)   
      
Age (years)      
      <55 29 (14) 13 (15) 16 (14) 1.0 - 
      55–64 68 (34) 31 (36) 37 (32) 0.97 [0.41–2.32] - 
      65–74 100 (50) 42 (48) 58 (51) 1.12 [0.49–2.58] - 
      75+ 4 (2) 1 (1) 3 (3) 2.44 [0.23–26.3] 0.23 
      
Sex      
        Female 116 (58) 54 (62) 62 (54) 1.0 - 
        Male 85 (42) 33 (38) 52 (46) 1.37 [0.78–2.42] 0.28 
      
Social deprivation quintile      
        5 (least deprived) 50 (25) 26 (30) 24 (21) 1.0 - 
        4 31 (15) 12 (14) 19 (17) 1.72 [0.69–4.27] - 
        3 30 (15) 11 (13) 19 (17) 1.87 [0.74–4.73] - 
        2 37 (18) 17 (19) 20 (17) 1.28 [0.54–2.99] - 
        1 (most deprived) 53 (26) 21 (24) 32 (28) 1.65 [0.76–3.61] 0.23 
      
BMI (kg/m2) groups      
      20–24.9    (normal weight) 37 (20) 17 (21) 20 (20) 1.0 - 
      <20           (underweight) 3 (2) 2 (3) 1 (1) 0.43 [0.04–5.11] - 
      25–29.9    (overweight) 77 (43) 38 (47) 39 (38) 0.87 [0.39–1.91] - 
      30+           (obese) 64 (35) 23 (29) 41 (40) 1.52 [0.67–3.45] 0.42 
Smoking status      
        Never smoked 84 (44) 32 (39) 52 (48) - - 
        Ever smoked 108 (56) 51 (61) 57 (52) 0.69 [0.39–1.23] 0.21 
      
CRP (mg/l)      
      <3 56 (32) 22 (30) 34 (34) - - 
      ≥3 117 (68) 52 (70) 65 (66) 0.81 [0.42–1.55] 0.52 
  
1
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Aspirin      
        No 174 (87) 73 (84) 101 (89) - - 
        Yes 27  (13) 14 (16) 13  (11) 0.67 [0.30–1.51] 0.33 
      
Statin      
        No 119 (59) 43 (49) 76 (67) - - 
        Yes 82  (41) 44 (51) 38 (33) 0.49 [0.28–0.87] 0.01 
      
ACE-inhibitor      
        No 164 (82) 68 (78) 96 (84) - - 
        Yes  37  (18) 19 (22) 18 (26) 0.67 [0.33–1.37] 0.27 
 
 
 
        1Refers to the finding of any small (<1cm) adenoma with no advanced features 
        2Refers to either an advanced adenoma (at least one of the following features: ≥1cm, HGD, villous histology) or an adenocarcinoma 
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Table 4.6: The relationship between host factors and markers of the SIR 
Baseline characteristics All patients (%) CRP <3 mg/l (%) CRP ≥3 mg/l (%) OR (univariable) p-value OR (multivariable)2 p-value 
        
All patients1 368 (100) 120 (33) 248 (67)     
        
Age (years)        
      <55 78 (20) 31 (26) 47 (19) 1.0 - - - 
      55–64 130 (36) 37 (31) 93 (37) 1.66 [0.92–2.99] - - - 
      65–74 153 (42) 49 (41) 104 (42) 1.40 [0.79–2.47] - - - 
      75+ 7 (2) 3 (2) 4 (2) 0.88 [0.18–4.20] 0.49 - - 
        
Sex        
     female 196 (53) 58 (57) 128 (52)  - - - 
     Male 172 (47) 53 (43) 120 (48) 1.23 [0.79–1.90] 0.36 - - 
        
Social deprivation quintile        
      5 (least deprived) 80 (22) 36 (30) 44 (18) 1.0 - 1.0 - 
      4  61 (16) 23 (19) 38 (15) 1.35 [0.69–2.67] 0.39 1.09 [0.50–2.41] 0.81 
      3 62 (17) 20 (17) 42 (17) 1.72 [0.86–3.43] 0.13 1.41 [0.62–3.22] 0.42 
      2 60 (16) 14 (12) 46 (19) 2.69 [1.28–5.65] 0.009 2.33 [0.98–5.58] 0.06 
      1 (most deprived) 
 
105 (29) 27 (22) 78 (31) 2.36 [1.27–4.39] 0.007 1.79 [0.88–3.64] 0.11 
BMI (kg/m2)         
      20–24.9     (normal weight) 73(22) 27 (24) 46 (21) 1.0 - 1.0 - 
      <20            (underweight) 7 (2) 4 (4) 3 (1) 0.44 [0.09–2.12] 0.31 0.59 [0.09–3.77] 0.58 
      25–29.9     (overweight) 125 (37) 56 (51) 69 (31) 0.72 [0.40–1.31] 0.28 0.69 [0.36–1.34] 0.28 
      30+            (obese) 128 (38) 24 (21) 104 (47) 2.54 [1.33–4.87] 0.005 2.72 [1.35–5.49] 0.005 
         
Smoking Status        
     Never smoked 171 (49) 72 (63) 99 (42) - - - - 
     Ever smoked 179 (51) 42 (37) 137 (58) 2.37 [1.49–3.76] <0.0001 2.26 [1.33–3.84] 0.003 
        
Aspirin         
      No 305 (83) 111 (93) 194 (78) - - - - 
      Yes 63 (17) 9 (7) 54 (22) 3.43 [1.63–7.22] 0.001 2.59 [1.15–5.86] 0.02 
  
1
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Statin        
      No 221 (60) 73 (61) 148 (60) - - - - 
      Yes 147 (40) 47 (39) 100 (40) 1.07 [0.69–1.68] 0.83 - - 
        
ACE-inhibitor        
      No 296 (80) 101 (84) 195 (79) - - - - 
      Yes 72 (20) 19 (16) 53 (21) 1.45 [0.81–2.57] 0.21 - - 
 
 
1368 patients with CRP results 
2Adjusted for social deprivation, BMI, smoking and aspirin use.  
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5 THE RELATIONSHIP BETWEEN COLORECTAL 
NEOPLASIA AND BODY COMPOSITION IN A 
BOWEL SCREENING POPULATION 
5.1 Introduction 
Elevated BMI, as a crude measure of obesity and adiposity, has been associated with an 
increased risk of CRC in large population-based studies (328-330). In general, the 
association appears to be stronger in males  and in colon rather than rectal cancer (329, 331, 
332) (279, 333). Additional measures of adiposity, such as elevated waist circumference 
(WC) and waist: hip ratio (WHR) have also been reported as risk factors for CRC (279, 333).  
However, BMI, WHR and WC are crude surrogate markers of adiposity (329). Historically, 
adipose tissue was regarded as an energy storage site while contributing to body insulation 
and padding for physical protection. It is now accepted that adipose tissue is metabolically 
active and has an endocrine role, producing adipose-derived cytokines, commonly referred 
to as adipokines. The most well-known of these are leptin which regulates appetite, and 
adiponectin, which is an anti-inflammatory and insulin-sensitising hormone (285).  
In descriptive terms, body fat can be divided into subcutaneous adipose tissue (SAT), which 
is located below the skin in the hypodermis, and visceral adipose tissue (VAT), the intra-
peritoneal fat surrounding the abdominal organs. Surrogate markers of body fat mentioned 
previously, most notably BMI, do not account for the different distribution of adipose tissue. 
It has been suggested that adipose tissue distribution, rather than volume alone, may be an 
important determinant of CRC risk and previous reports have associated elevated VAT 
volume with the development of ischaemic heart disease, hypertension, insulin resistance 
and solid organ tumours (329) (334). Intersex comparisons have demonstrated that men 
generally have a higher volume of VAT than women, who often have a higher volume of 
SAT. For a given BMI, women typically carry 10% more body fat overall than men (285). 
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It is therefore plausible that higher levels of VAT in men may underpin the relationship 
between higher BMI, WC, WHR, male sex and an increased risk of CRC. 
In addition, when considering pre-malignant disease, it is accepted that the majority of CRCs 
arise within colorectal adenomas as a result of the adenoma-carcinoma sequence (223, 280). 
In addition to CRC, obesity (according to BMI), has been associated with colorectal 
adenoma incidence with several meta-analyses demonstrating a positive but inconsistent 
correlation between the two (193, 297, 335) (Chapter 3 and Chapter 4). 
Moreover, there has been recent interest in the relationship between sarcopenia and CRC. 
Sarcopenia is characterised by progressive and generalised loss of skeletal muscle mass. It 
is associated with frailty, poor quality of life and comorbid disease (158). The condition has 
been associated with several chronic illnesses such as diabetes, renal failure and 
cardiovascular disease (336). There is evidence for the disproportionate loss of skeletal 
muscle tissue as an independent prognostic factor for both cancer-specific and overall 
survival in patients with CRC (337). However, there is little evidence pertaining to the role 
of sarcopenia in the early or pre-malignant stage of CRC.  
The present study proposed that body composition, in particular, adipose tissue distribution, 
rather than overall adiposity (according to BMI) is an enhanced method with which to study 
the relationship between adiposity and colorectal neoplasia. Accordingly, the aim of this 
study was to examine the relationship between host characteristics, BMI, VAT, SAT, 
sarcopenia, and the incidence of colorectal neoplasia in a bowel screening population. 
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5.2 Methods 
Study design and population 
All population members aged between 50–74 years in Scotland are invited to take part in the 
SBoSP. The SBoSP has been described in detail previously (140) (Section 1.2.2). Patients 
with comorbid disease who are unable to undergo colonoscopy as part of bowel screening, 
and those in whom colonoscopy is incomplete, are offered a CTC as an alternative. Patients 
undergoing CTC as part of the SBoSP in NHS GGC between July 2009 and February 2016 
were eligible for inclusion. 
Data collection 
Patients must have undergone thorough colonic investigation by CTC as a minimum, and in 
most cases, an additional colonoscopy or flexible sigmoidoscopy was carried out either 
before or after the CTC. Following CTC, patients with suspected colorectal polyps or 
carcinoma underwent a colonoscopy to remove, biopsy, or clarify the CTC findings. Medical 
records and CTC images were accessed for all eligible patients. Age, sex, height, weight and 
BMI were recorded from medical records. Smoking status, aspirin or NSAID use, and 
socioeconomic deprivation were also recorded. Socioeconomic deprivation was assessed 
using the SIMD system, as outlined previously (Chapter 3). 
Colonoscopy and pathology reports for each patient were reviewed to collect data on the 
number, size, and histopathological subtypes of colorectal neoplasia. Colorectal neoplasia 
was defined as either an adenomatous polyp of any subtype or invasive colorectal carcinoma. 
Advanced colorectal neoplasia was defined as either an advanced adenoma (at least one of; 
adenoma size ≥1cm, villous histology or HGD) or adenocarcinoma. In patients who had 
undergone colonoscopy before and after CTC, the results from all three tests were combined 
to give an overall outcome. 
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Body composition measurement using CT  
Hounsfield Units and radiodensity 
A CT scan builds images by sending a rotating beam of X-rays 360 degrees around a patient 
for multiple cycles. The pictures are based on the principle that X-ray absorption is variable 
depending on the tissue type it is passed through. Attenuation and absorption of the X-ray 
beam depend upon the thickness and composition of the tissues in the path of the beam, 
which reflects the radiodensity of the tissue (338). The Hounsfield scale is a quantitative 
scale for describing radiodensity and the corresponding units in this scale are Hounsfield 
Units (HU). The scale has two fixed points, where zero HU represents the radiodensity of 
distilled water, and -1000 HU represents the radiodensity of air when both are at standard 
temperature and pressure.  
After scanning is complete, the image is reconstructed, HU are assigned to each pixel, and 
based on the Hounsfield scale, the radiodensity of the tissue represented in the pixel can be 
determined. The present study used previously validated HU attenuation thresholds of [-190 
to -30 HU] and [-29 to +150 HU] as thresholds for adipose and skeletal muscle tissue, 
respectively (339). 
Measuring VAT, SAT and skeletal muscle area  
CT images were viewed at the level of the 3rd and 4th lumbar vertebral interspace with the 
patient in the supine position (339). Scans with significant movement artefact or missing 
regions of interest were excluded. Medical imaging software was used for image analysis 
and the freely available software: NIH (National Institutes of Health), ImageJ version 1.46 
was used to calculate body composition areas. This programme is available for download 
from https://imagej.nih.gov/ij/. The ImageJ programme and methods used in the present 
study have previously been validated against commercially available software (339). The 
primary investigator (DD) carried out all analysis using Image J. DD was trained in the use 
of this programme by two members of staff at the University of Glasgow (SM and RD) who 
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were highly experienced in its use. These two staff members had previously completed inter-
rater reliability studies after training others on the use of the software and found good 
reliability. This indicated that the training methods were accurate and acceptable. The 
present study made use of published protocols to calculate the cross-sectional areas of VAT, 
SAT, and skeletal muscle (339, 340). VAT was defined as an area of intra-abdominal fat, 
bound by the parietal peritoneum with the paraspinal muscles and vertebral column 
excluded. SAT was defined as adipose tissue superficial to the peritoneal cavity, the bulk of 
which is also superficial to the abdominal and paraspinal muscles. Skeletal muscle area was 
defined as the total area of skeletal muscle comprising the abdominal wall, lumbar and 
paraspinal region.  
In NHS GGC, medical images, including CTC, are stored as Digital Imaging and 
Communications in Medicine files (DICOM). These images can then be viewed using the 
Picture Archiving and Communication System (PACS). In order to export to ImageJ, the 
cross-sectional CTC slice was downloaded as a maximal resolution “Joint Photographic 
Experts Group” (JPEG) image from the PACS system. It was then opened with the ImageJ 
software, and attenuation thresholds specific for adipose and skeletal muscle tissue 
mentioned above were set (339). This instructed ImageJ to highlight the specific tissue types 
in isolation. Figure 5.1 outlines the steps for measuring VAT (cm2) and SAT (cm2). Figure 
5.2 outlines the steps used to calculate the skeletal muscle area (cm2).  
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Figure 5.1: An example of CT image analysis using NIH ImageJ software to calculate 
VAT and SAT 
 
(A) The original CT image in JPEG format. A known distance of 10cm was set. This had been pre-marked in 
the PACS CT image viewer for accurate measurement.  
 
(B) Tissue attenuation thresholds were set to selectively display adipose tissue [-190 to -30 HU]. 
 
(C)The polygon manual outline drawing tool was used to encompass the CT slice, and ImageJ was used to 
measure the area in red which represented the total adipose tissue area (TAT).  
 
(D) Using the polygon manual drawing tool again, careful outlining of the peritoneal cavity was carried out, 
and ImageJ was used to calculate the area of adipose only within the outline. This represented the VAT area. 
A simple subtraction of the VAT area from the TAT area gave the SAT. (T–T - VAT = SAT). 
 
  
10cm 
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Figure 5.2: An example of CT image analysis using NIH ImageJ software to calculate 
skeletal muscle area 
 
 
 
(A) The CT image in JPEG had a known distance of 10 cm marked prior to capture from the primary image 
viewing software to enable accurate measurement. The image was then opened with ImageJ software. 
 
(B) Thresholds in ImageJ were set to represent skeletal muscle tissue [-29 to +150 HU]. Muscle tissue was 
now highlighted in red. 
 
(C) To exclude other tissue areas that are picked up at the same HU thresholds, the manual polygon tool was 
used to draw carefully round only the skeletal muscle area. This instructed ImageJ to only measure the 
skeletal muscle (red areas) within the selected boundaries and ensured an accurate measurement of the 
skeletal muscle area. 
 
 
 
 
 
 
  
10cm 
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Study endpoints 
Study endpoints for analysis were as follows: 
1. The presence of any histologically confirmed colorectal neoplasia as part of the 
bowel screening process 
2. The presence of any advanced colorectal neoplasia (advanced adenoma or 
adenocarcinoma) as part of the screening process 
Preparation of data for analysis 
Data were grouped, standardised, and categorised. Patients were allocated into one of four 
groups according to the WHO classification for BMI: normal weight (BMI 20–24.9) was 
used as the reference group. Further groupings were: underweight (BMI <20), overweight 
(BMI 25–29.9) and obese (BMI ≥30). Visceral obesity was defined as VAT area >160cm2 
for male patients and VAT area >80cm2 for female patients according to established 
thresholds (341). SAT was normalised for height to obtain the subcutaneous fat index (SFI) 
(cm2/m2). High SFI was defined as ≥50 in men and ≥42 in women using thresholds defined 
by Dolan et al. (154) and Ebadi et al. (342). Skeletal muscle area was normalised for height 
to obtain the skeletal muscle index (SMI) (cm2/m2). Sarcopenia was defined as per Dolan 
and colleagues, which represents an SMI for a given BMI (154). Male patients with SMI 
<45.6 (if BMI ≤30) and SMI <56.8 (if BMI >30) were defined as sarcopenic. Similarly, 
female patients with SMI <39.1 (if BMI ≤30) and SMI <44.6 (if BMI >30) were defined as 
sarcopenic. 
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Statistical analyses 
Comparisons of group characteristics at baseline in the present study were compared to those 
in the prospectively collected bowel screening cohort (Chapter 4). Statistical analysis was 
carried out using a non-parametric independent samples median test for age, social 
deprivation and BMI. The χ2 test was used for comparisons between these groups of the 
proportion of smokers, aspirin and NSAID users. In the principal analysis of outcomes, 
categorical variables were analysed using the χ2 test, and ORs were calculated for an estimate 
of risk. Categorical variables with more than two groups were analysed using binary logistic 
regression, and the lowest quartile of each independent variable was selected as the reference 
group. Multivariable analysis was carried out using binary logistic regression. Covariates 
with a significance value of p<0.1 in the univariable were included in the multivariable 
analysis. A two-tailed p-value <0.05 was considered statistically significant in this study. All 
statistical analyses were carried out using IBM SPSS statistics version 24.0, IBM Co, 
Armonk, NY, USA. 
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5.3 Results 
Study group characteristics 
Between July 2009 and February 2016, 400 patients underwent CTC following a positive 
screening test as part of the SBoSP and were eligible for inclusion [Figure 5.3]. 89 (22%) 
were allocated directly to CTC, while 311 (78%) underwent CTC due to failed colonoscopy. 
42 (10%) patients were excluded from the study [Table 5.1], leaving 358 for analysis.  
The median age was 65 years [IQ range 59–71]. There were 121 (34%) males, and the study 
population was predominantly overweight with a median BMI of 27.8 [IQ range 24–33]. 
The baseline characteristics for the group in the present study were compared to those from 
the prospectively studied bowel screening group presented in Chapter 4, and the results are 
shown in Table 5.2. There were no statistically significant differences in age or BMI 
between the groups. The group in the present study comprised a higher proportion of females 
(66% vs. 53%, p<0.001), were more likely to suffer from socioeconomic deprivation 
(p<0.001), and were more likely to have been active or ex-smokers (66% vs. 52%, p<0.001). 
In addition, the present study group were more likely to be regular users of aspirin (29% vs. 
17%, p<0.001) or NSAIDs (21% vs. 15%, p<0.05). 
Study outcomes 
Study outcomes are displayed in Figure 5.3. Of the 358 patients included, 126 (35%) were 
diagnosed with colorectal neoplasia. Among these, 84 (67%) had advanced neoplasia. Of 
those with advanced neoplasia, 26 (31%) had adenocarcinoma, and 58 (69%) had an 
advanced adenoma (in the absence of CRC). From the CTC group overall (n=400), 7% of 
patients (n=26) were found to have an adenocarcinoma.  
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Figure 5.3: Outcomes following colonoscopy and CTC 
 
 
  
Patients undergoing CTC 
and colonoscopy 
(n=400) 
Patients eligible for 
inclusion 
(n=358) 
Excluded  
(n=42) 
No neoplasia  
(n=232) 
(65%) 
Neoplasia 
(n=126) 
(35%) 
Adenocarcinoma 
(n=26) 
(31%) 
Advanced adenomas 
(n=58) 
(69%) 
Advanced neoplasia 
(n=84) 
(67%) 
Non-advanced neoplasia 
(n=42) 
(33%) 
 192 
 
Outcome: Any colorectal neoplasia 
The relationship between colorectal neoplasia incidence and non-body composition host 
characteristics  
Results are shown in Table 5.3. On univariable analysis, male sex was associated with the 
presence of colorectal neoplasia, OR 2.17 [95% CI; 1.38–3.41, p<0.01]. This remained 
significant on multivariable analysis, OR 2.35 [95% CI; 1.47–3.77, p<0.001] when adjusting 
for age and visceral obesity. Neither advancing age, social deprivation, elevated BMI, 
smoking, aspirin or NSAID use were significantly associated with colorectal neoplasia 
incidence.  
The relationship between colorectal neoplasia incidence and body composition 
Results are shown in Table 5.3. On univariable analysis, visceral obesity was associated 
with colorectal neoplasia, OR 2.69 [95% CI; 1.46–4.98, p<0.01]. This relationship persisted 
on multivariable analysis when adjusting for age and sex, OR 2.79 [95% CI; 1.48–5.25, 
p<0.01]. Neither high SFI nor sarcopenia were associated with colorectal neoplasia 
incidence. 
The relationship between visceral adiposity and adenoma number 
Results are shown in Table 5.4. There was no significant relationship between increasing 
visceral adiposity and adenoma number.  
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Outcome: Advanced colorectal neoplasia 
The relationship between advanced colorectal neoplasia incidence and non-body 
composition host characteristics  
Results are shown in Table 5.5. Older age was associated with a reduced risk of advanced 
neoplasia when adjusting for SFI with an OR of 0.93 [95% CI; 0.87–0.99, p<0.05]. None of 
the other host characteristics were associated with advanced colorectal neoplasia. 
The relationship between advanced colorectal neoplasia incidence and body composition 
Results are shown in Table 5.5. A high SFI was associated with an increased risk of 
advanced neoplasia, OR 5.1 [ 95% CI; 1.55–16.73, p<0.01]. This observation remained 
following adjustment for age in the multivariable model, OR 6.28 [95% CI; 1.79–21.98, 
p<0.01]. Neither visceral obesity nor sarcopenia were associated with advanced neoplasia. 
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5.4 Discussion 
The present study reports on the association between host factors, CT-derived measures of 
body composition, and the incidence of colorectal neoplasia within the SBoSP. The results 
indicate that male sex and visceral obesity are independently associated with an increased 
risk of colorectal neoplasia. There was no association between elevated BMI or sarcopenia 
and colorectal neoplasia incidence.  
It is generally accepted that central adiposity, measured by WC and WHR, is associated with 
poor health outcomes, particularly with regards to cardiovascular disease, although the 
association with BMI is inconsistent (343). Systematic reviews have shown an association 
between increased WC and increased risk of developing CRC (344). Furthermore, in a large 
population study, BMI was associated with only a modest increase in the risk of colon 
cancer, HR 1.10 [95% CI; 1.07–1.13] and a borderline association with rectal cancer, HR 
1.04 [95% CI; 1.00–1.08] (59). These results are mirrored by other researchers who agree 
that WC and WHR demonstrate stronger correlations with colorectal neoplasia than BMI 
(345). BMI and WC are used as surrogate markers of adiposity, although it is now more 
evident that adipose tissue distribution, rather than volume, may be an important determinant 
of CRC risk (329). It is plausible, therefore, that the association between WC, WHR and 
CRC may reflect visceral adiposity. The present study supports this suggestion by reporting 
that visceral obesity resulted in an almost 3-fold increase in the risk of colorectal neoplasia 
after adjustment for age and sex [Table 5.3].  
A number of studies have investigated the relationship between VAT and colorectal 
neoplasia. 12 of the largest are summarised in Table 5.6 (345-356). The majority of these 
studies report similar results to the present study. Five of the 12 studies reported a positive 
association with elevated VAT, but not elevated BMI, and colorectal neoplasia incidence 
(346, 349-351, 356). This finding supports the suggestion that visceral obesity could be a 
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superior method of measurement when examining the relationship between colorectal 
neoplasia and adiposity. Similar observations have been reported in recent meta-analyses 
(286, 287). 
To our knowledge, no previous studies investigating the relationship between body 
composition and colorectal neoplasia have been conducted within a bowel screening 
population similar to ours. In addition, the vast majority of studies mentioned above [Table 
5.6] were conducted in Southeast Asia with only two in the USA (352, 354). Thus, the 
applicability of previous work to a western population, particularly a screening cohort, is 
debatable and highlights the importance of our results. 
The mechanisms underpinning the association between visceral obesity and colorectal 
neoplasia in the present study are not clear. It is likely that the mechanisms are complex. 
Several are biologically plausible. It has been suggested that VAT is metabolically more 
active than SAT. Relative to SAT, it is thought that higher volumes of VAT results in 
elevated levels of circulating pro-inflammatory cytokines such as IL-6 and TNF-α. 
Furthermore, elevated VAT volume is thought to promote insulin resistance and the 
bioavailability of insulin-like growth factor-1 (IGF-1). Recent work has demonstrated a 
correlation between CT-derived measurements of VAT and both inflammatory and 
angiogenic biomarkers such as CRP and vascular endothelial growth factor (VEGF) in 
patients with CRC (357). It is believed that the pro-inflammatory, pro-proliferative, insulin-
resistant environment promoted by VAT may play a role in the formation and growth of 
colorectal neoplasia (287, 347). This theory is supported by previous work, demonstrating 
that insulin and insulin-like growth factors are associated with the development and 
progression of adenomatous polyps (352). 
Inflammatory cytokines released by adipose tissue such as leptin and adiponectin may play 
an additional role in the formation and promotion of colorectal neoplasia. In particular, 
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adiponectin is noted for its anti-diabetic and anti-inflammatory properties and is lower in 
obese patients, and those with CRC according to a previous meta-analysis (358) (192). 
However, the precise mechanisms of these interactions are likely to be complex and remain 
poorly understood. 
The present study reported that male sex was associated with colorectal neoplasia. It is 
plausible that the association is mediated through visceral obesity, especially given that 
median VAT area was higher in males than females (264.9 cm2 vs. 157.2cm2, p<0.0001), 
which has been reported previously (285). 
Adenoma number is a risk factor for adenoma recurrence (Chapter 3) and is regarded as a 
high-risk finding based on the BSG adenoma surveillance guidelines (Section 1.4.7) (15). 
The present study sought to determine if visceral adiposity influenced adenoma number in a 
similar manner to incident neoplasia [Table 5.4]. No statistically significant relationship was 
identified making it difficult to draw firm conclusions. 
The present study also sought to investigate the relationship between body composition and 
advanced neoplasia. In those with any neoplasia, high SFI was associated with the presence 
of advanced neoplasia. This remained significant when adjusting for both BMI and visceral 
obesity. The reason for this finding is not clear; however, previous studies have reported that 
VAT decreases in the later stages of CRC (347). This would be consistent with cancer 
cachexia. It may be that VAT is potentially adenoma-promoting in the early stages as per 
the results of the present study, but its volume and influence decrease as adenomas progress 
towards advanced neoplasia and cancer, such that VAT becomes less influential than SFI. 
Further work comparing body composition measures in a group of patients with pre-
malignant disease and those with established CRC may be of value in examining this theory 
further. 
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In a study by Im et al. (2018), the researchers reported that increased VAT area is associated 
with incident colorectal neoplasia but not with recurrent colorectal neoplasia after 
polypectomy (346). The researchers followed patients for a median of 43 months to 
determine if any patients developed a subsequent adenoma. The findings suggested the effect 
of VAT on adenoma formation may not have an influence on adenoma formation during the 
43-month follow up. The study did note that elevated VAT was associated with incident 
adenomas, which are likely to have developed over a prolonged period. As such, it is 
plausible that the effects of VAT are slow-acting and prolonged, possibly spanning decades. 
If this is the case, there may be a window of opportunity for clinical intervention. 
Reports on sarcopenia and its effect on chronic disease and cancer are gaining interest. With 
respect to CRC, sarcopenia has been associated with poor cancer-specific and overall 
survival (359). However, limited work has been conducted to examine the role of sarcopenia 
during the pre-malignant and early stages of CRC. The present study did not detect an 
association between sarcopenia and the incidence of any, or advanced colorectal neoplasia. 
Therefore, it would appear that visceral obesity is more likely to drive the early and pre-
malignant stage of CRC than sarcopenia, which remains relevant in established cancer. The 
findings of the present study suggest that sarcopenia plays a marginal role in early or pre-
malignant disease when visceral adiposity is more relevant. These results contrast with two 
recent studies from South Korea. They concluded that sarcopenia was associated with 
advanced adenomas when compared with those who were non-sarcopenic (336, 360). 
However, there are a number of methodological differences between the present study and 
those from South Korea where younger patients were recruited (40+ years and 50+ years), 
excluded patients with a positive FOB test, and used the Asian-Pacific region criteria to 
define obesity (BMI ≥25) (336). Moreover, the researchers used bioelectrical impendence to 
measure muscle mass and calculate sarcopenia, rather than the widely validated CT-derived 
measures. Neither of the studies examined patients in a bowel screened population. 
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Therefore, the varied methodology and selection criteria limit the extent to which these 
studies and the present study are comparable. 
The present study compared the baseline group characteristics with those from Chapter 4, 
which included consenting patients attending for bowel screening for whom data were 
collected prospectively. There were no differences in age or BMI between these two groups 
[Table 5.2]. The present study group consisted of a significantly higher proportion of 
females, ex or current smokers, as well as aspirin and NSAID users. In addition, they were 
likely to suffer higher levels of socioeconomic deprivation. It is appreciated that the 
colonoscopy procedure itself can be more difficult to perform in females with a lower 
completion rate compared to males (361). Thus, it is unsurprising that the current group, who 
are undergoing CTC mostly as a result of incomplete colonoscopy, has a higher proportion 
of females. In addition, many of the patients in the present study underwent CTC for a first-
line investigation as they were deemed unfit for colonoscopy due to comorbid disease. Thus, 
it is unsurprising that the comorbid group in the present study were likely to be regular 
aspirin or NSAID users, ex, or current smokers, and socially and economically deprived. 
These factors are often associated with poorer health outcomes, as compared to a voluntary 
study group such as those presented in Chapter 4. 
Moreover, although there are a number of features that potentially make the present study 
group unique, they are still drawn from the participants of the SBoSP. Given that the BMI 
of both groups is similar, it is likely that the findings of the present study in relation to body 
composition and incidence of neoplasia can still be generalised to a standard bowel screening 
group.  
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Strengths and limitations 
The present study has a number of strengths. To our knowledge, it is the first study carried 
out on a bowel screening cohort similar to the SBoSP. This enhances its validity in screening 
groups. Previous studies have predominantly been conducted in Southeast Asia where 
demographics are different compared to western populations, particularly in terms of BMI 
and adiposity. Furthermore, these studies tended to have younger patients and patients were 
often those who attended for a standard health check-up rather than screening. In contrast, 
the present study provides real-world data with respect to a bowel screening population. 
There were limitations, however, in that by using JPEG rather than DICOM files for body 
composition measurements, it was not possible to measure muscle quality, and in particular, 
myosteatosis which is an emerging area of interest in CRC research (154). In addition, a 
significant number of patients had CTC as their first-line investigation due to multiple 
comorbidities that rendered them unfit for colonoscopy. It could be construed that this group 
may be slightly less representative of standard SBoSP patients; however, the 7% cancer 
diagnosis rate in this group mirrors that in the SBoSP nationally (165). 
Final conclusions and further work required 
The results of the present study demonstrate that visceral obesity may be a significant risk 
factor for incident colorectal neoplasia. It is likely that body fat distribution is a superior 
measure to BMI for studying the relationship between adiposity and colorectal neoplasia. 
Sarcopenia, although relevant as a prognostic indicator in established CRC, is not associated 
with pre-malignant disease. However, further work comparing measures of body 
composition in a pre-malignant population and those with established cancer would be of 
interest. The present study supports lifestyle changes that aim to reduce overall adiposity 
and methods which could specifically target visceral adiposity as a primary prevention 
strategy for colorectal neoplasia. Further large studies in western populations would be 
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beneficial, particularly those designed to investigate the relationship between myosteatosis 
and colorectal neoplasia incidence.  
 201 
 
Table 5.1: Reasons for exclusion from the study 
 
 
  
Reason for exclusion 
 
n 
  
Total exclusions 42 
  
• Lost to follow-up: inadequate or unavailable information in the medical notes 
 
13 
• Poor CTC picture quality. Movement artefact, metal or otherwise implants and picture blurring 
rendering inaccurate tissue area measurements 
 
10 
• Technical difficulty rendering CTC unreliable. Failure to carry out faecal tagging, poor bowel 
prep, inadequate colonic distension if mentioned in report 
 
7 
• Patient unable to tolerate CTC. Unable to hold gaseous distension 
 
2 
 
• Died soon after CTC prior to follow-up colonoscopy 
 
2 
• Patient refusal for post-CTC colonoscopy to determine the histology of detected polyps 
 
2 
• Polyp excised but inadvertently lost at colonoscopy. No histopathological data available 
 
2 
• Known previous colonic resection (malignant or benign indication) 
 
2 
• Poor views and technical failure on both colonoscopy and CTC. Thus, non-diagnostic tests 
 
1 
• Missing pathology reports from excised and retrieved polyps 1 
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Table 5.2: A comparison of baseline characteristics between the present study group and 
volunteers from a prospectively studied bowel screening group in the same geographical 
region (Chapter 4) 
 
 
1See Chapter 4 
2As per SIMD ranking 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Prospectively studied 
bowel screening group1 
 
Present study group p-value 
    
All patients    
    
Age (median; years) 63  65  0.07 
    
Female sex (%) 53 66 <0.001 
    
Social Deprivation (median)2 3082 2223 <0.001 
    
BMI (median; kg/m2) 28.1 27.8 0.45 
    
Active or ex-smokers (%) 52 66 <0.001 
    
Aspirin users (%) 17 29 <0.001 
    
NSAID users (%) 15 21 <0.05 
  
 
2
0
3
 
Table 5.3: The relationship between colorectal neoplasia incidence and host characteristics including CT-derived body composition 
Baseline characteristics All patients (%) No neoplasia (%) Any neoplasia (%) OR (univariable) p-value OR (multivariable)1 p-value 
 
        
All patients 358 (100) 232 (65) 126 (35)     
        
Age (years)        
      <55 49 (14) 37 (16) 12 (9) 1.0 - - - 
      55–64 125 (35) 84 (36) 41 (33) 1.51 [0.71–3.19] - - - 
      65–74 154 (43) 93 (40) 61 (48) 2.02 [0.99–4.18] - - - 
      75+ 30 (8) 18 (8) 12 (10) 2.06 [0.77–5.47] 0.05 1.03 [0.99–1.06] 0.06 
        
Sex        
      Female 237 (66) 168 (72) 69 (55) - - - - 
      Male 121 (34) 64 (28) 57 (45) 2.17 [1.38–3.41] 0.001 2.35 [1.47–3.77] <0.001 
        
Social deprivation quintile        
     5 (least deprived) 61 (18) 33 (15) 28 (23) 1.0 - - - 
     4 39 (11) 29 (13) 10 (8) 0.41 [0.17–0.98] - - - 
     3 48 (14) 26 (11) 22 (18) 0.99 [0.47–2.13] - - - 
     2 73 (21) 53 (24) 20 (16) 0.45 [0.22–0.91] - - - 
     1 (most deprived) 125 (36) 82 (37) 43 (35) 0.62 [0.33–1.15] 0.19 - - 
        
BMI2 (kg/m2)        
      20–24.9     (normal weight) 71 (25) 48 (27) 23 (22) 1.0 - - - 
      <20            (underweight) 18 (6) 10 (5) 8 (7) 1.67 [0.58–4.79] - - - 
      25–29.9     (overweight) 81 (28) 50 (27) 31 (30) 1.29 [0.66–2.52] - - - 
      30+            (obese) 
 
116 (41) 73 (41) 43 (41) 1.23 [0.66–2.29] 0.59 - - 
Visceral obesity (all sexes)        
      No 77 (22) 62 (27) 15 (12) - - - - 
      Yes 281 (78) 170 (73) 111 (88) 2.69 [1.46–4.98] 0.001 2.79 [1.48–5.25] 0.001 
 
 
       
        
  
 
2
0
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    1Adjusted for age, sex and visceral obesity 
    2BMI data available for 286 patients 
    3Data available for 286 patients for SFI and sarcopenia since height data not available for all patients 
    4Regular low dose aspirin use 
    5Regular use of NSAIDs including diclofenac, naproxen, ibuprofen, celocoxib, rofecoxib, indomethacin 
  
High SFI3 (all sexes)        
      No 34 (12) 20 (11) 14 (13) - - - - 
      Yes 
 
252 (88) 160 (89) 92 (87) 0.82 [0.39–1.70] 0.59 - - 
Sarcopenia3 (all sexes)        
     No 137 (48) 89 (49) 48 (46) - - - - 
     Yes 
 
149 (52) 92 (51) 57 (54) 1.15 [0.71–1.86] 0.57 - - 
Smoking status        
     Never smoked 118 (34) 74 (33) 44 (36) - - - - 
     Ever smoked 
 
228 (66) 149 (67) 79 (64) 0.89 [0.56–1.42] 0.63 - - 
Aspirin4        
      No 247 (71) 157 (69) 90 (73) - - - - 
      Yes 
 
103 (29) 69 (31) 34 (27) 0.86 [0.53–1.39] 0.54 - - 
NSAIDs5        
      No 277 (79) 175 (77) 102 (82) - - - - 
      Yes 73 (21) 51 (23) 22 (18) 0.74 [0.42–1.29] 0.29 - - 
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Table 5.4: The relationship between visceral adiposity and adenoma number 
 
 
  
 
  
  
  
  
 
 
  
  
  
  
  
 
 
 
 
 
 
                      1Excluding patients with cancer 
        
 
  
VAT 
 
All adenoma patients1 
(%) 
1–2 adenomas 
(%) 
≥3 adenomas 
(%) 
OR (univariable) p-value 
      
All patients 100 (100) 86 (86) 14 (14)   
      
VAT quartiles      
      
Q1 (0–109.9 cm2) 
 
16 (16) 15 (17) 1 (7) 1.0 - 
Q2 (110–180 cm2) 
 
22 (22) 16 (19) 6 (43) 5.63 [0.60–52.4] 0.13 
Q3 (180.1–256.9 cm2) 
 
26 (26) 23 (27) 3 (21) 1.96 [0.19–20.6] 0.58 
Q4 (>256.9 cm2) 
 
36 (36) 32 (37) 4 (29) 1.88 [0.19–18.2] 0.59 
  
 
2
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Table 5.5: The relationship between advanced colorectal neoplasia and host characteristics including CT-derived body composition 
Baseline characteristics All patients with 
neoplasia (%) 
 
Non-advanced 
neoplasia (%) 
Advanced neoplasia 
(%) 
OR (univariable) p-value OR (multivariable)1 p-value 
        
All patients 126 (100) 42 (33) 84 (67)     
        
Age (years)        
      <55 12 (9) 2 (5) 10 (12) 1.0 - - - 
      55–64 41 (33) 13 (31) 28 (33) 0.43 [0.08–2.25] - - - 
      65–74 61 (48) 20 (47) 41 (49) 0.41 [0.08–2.05] - - - 
      75+ 12 (10) 7 (17) 5 (6) 0.14 [0.02–0.96] 0.07 0.93 [0.87–0.99] 0.04 
        
Sex        
      Female 69 (55) 21 (50) 48 (57) - - - - 
      Male 57 (45) 21 (50) 36 (43) 0.75 [0.36–1.58] 0.45 - - 
        
Social deprivation quintile        
     5 (least deprived) 28 (23) 9 (22) 19 (23) 1.0 - - - 
     4 10 (8) 3 (7) 7 (8) 1.11 [0.23–5.30] - - - 
     3 22 (18) 10 (25) 12 (15) 0.57 [0.18–1.80] - - - 
     2 20 (16) 7 (17) 13 (16) 0.89 [0.26–2.96] - - - 
     1 (most deprived) 43 (35) 12 (29) 31 (38) 1.22 [0.43–3.45] 0.69 - - 
        
BMI (kg/m2)        
      20–24.9  (normal weight) 23 (22) 10 (30) 13 (18) 1.0 - - - 
      <20         (underweight) 8 (8) 5 (15) 3 (4) 0.46 [0.19–2.41] - - - 
      25–29.9  (overweight) 31 (29) 6 (18) 25 (35) 3.21 [0.95–10.79] - - - 
      30+         (obese) 
 
43 (41) 12 (37) 31 (43) 1.99 [0.69–5.74] 0.24 - - 
Visceral obesity (all sexes)        
      No 15 (12) 6 (14) 9 (11) - - - - 
      Yes 111 (88) 36 (86) 75 (89) 1.39 [0.46–4.20] 0.56 - - 
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1Adjusted for age and SFI 
2Regular low dose aspirin use 
3Regular use of NSAIDs including diclofenac, naproxen, ibuprofen, celocoxib, rofecoxib, indomethacin 
  
High SFI (all sexes)        
      No 14 (13) 9 (27) 5 (7) - - - - 
      Yes 
 
92 (87) 24 (73) 68 (93) 5.1 [1.55–16.73] 0.004 6.28 [1.79–21.98] 0.004 
Sarcopenia (all sexes)        
     No 48 (46) 15 (46) 33 (46) - - - - 
     Yes 
 
57 (54) 18 (54) 39 (54) 0.99 [0.43–2.25] 0.97 - - 
Smoking status        
     Never smoked 44 (36) 15 (37) 29 (35) - - - - 
     Ever smoked 
 
79 (64) 26 (63) 53 (65) 1.05 [0.48–2.30] 0.89 - - 
Aspirin2        
      No 90 (73) 29 (69) 61 (74) - - - - 
      Yes 
 
34 (27) 13 (31) 21 (26) 0.77 [0.34–1.75] 0.53 - - 
NSAIDs3        
      No 102 (82) 33 (79) 69 (84) - - - - 
      Yes 22 (18) 9 (21) 13 (16) 0.69 [0.27–1.78] 0.44 - - 
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Table 5.6: Studies reporting on the association between colorectal neoplasia and visceral adiposity 
Author Year Country Design n VAT 
measurement 
Independent 
variable 
Dependent 
variable 
VAT associated 
with colorectal 
neoplasia 
BMI associated 
with colorectal 
neoplasia  
 
Statistical ratios  
(OR, HR) 
           
Schoen et al. 
(352)  
2005 USA Cohort study 
with data 
from RCT 
 
458 CT L4–L5 
interspace 
VAT volume Incident 
adenoma 
No No Adjusted OR 0.87 
[0.47–1.6, p=0.52] for 
4th quartile vs. 1st 
           
Oh et al. 
(351) 
2008 South 
Korea 
Observational 
case-control 
200 CT from L4–
L5 interspace 
VAT area 
quartiles. Lowest 
quartile as the 
reference group 
 
Incident 
colorectal 
neoplasia 
Yes 
(but no dose-
dependent 
relationship) 
No Adjusted OR 4.07 
[1.01–16.43, p<0.05] 
for 4th quartile vs. 1st 
           
Yamaji et al. 
(355) 
2009 Japan Case-control 1205 CT derived at 
the level of 
the umbilicus 
VAT area 
quartiles. Lowest 
quartile as the 
reference group 
 
Incident 
adenoma 
Borderline Yes Adjusted OR 1.46 
[1.03–2.06, p=0.06] for 
4th quartile vs. 1st 
           
Kang et al. 
(348) 
2010 South 
Korea 
Cross-
sectional 
case-control 
2244 CT derived at 
level of the 
umbilicus 
VAT area 
quintiles lowest 
quintile as the 
reference group 
 
Incident 
adenoma 
Yes Not measured Adjusted OR 3.09 
[2.19–4.36, p<0.001] 
for 5th quintile vs. 1st 
           
Nam et al. 
(350) 
2010 South 
Korea 
Observational 
cohort 
3933 CT derived 
from 50mm 
above and 
below the 
umbilicus 
 
VAT volume at 
four pre-set 
thresholds 
Incident 
adenoma 
Yes No Adjusted OR 1.43 
[10.6–1.94, p<0.05] for 
highest vs. lowest VAT 
volume group 
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Summers et 
al. (354) 
2012 USA Observational 
case-control 
1233 CT from top 
L2– bottom 
L3 
 
VAT area 
quintiles lowest 
quintile as the 
reference group 
Incident 
adenoma, or 
advanced 
adenoma 
Yes Not measured Unadjusted OR 2.06 
[1.36–3.13, p< 0.001] 
for 5th quintile VAT vs. 
1st quintile 
           
Chloe et al. 
(345) 
2013 South 
Korea 
Case-control 1264 CT derived at 
level of the 
umbilicus 
VAT area 
quartiles. Lowest 
quartile as the 
reference group 
Incident early 
CRC 
No Borderline 
(BMI only 
associated as p for 
trend) 
Adjusted OR 0.82 
[0.47–1.46, p = 0.51] 
for 4th quartile vs. 1st 
           
Nagata et al. 
(349) 
2014 Japan Observational 
case-control 
1328 CT derived at 
level of the 
umbilicus 
VAT area 
quartiles. Lowest 
quartile as the 
reference group 
Incident 
adenoma 
Yes No Adjusted OR 1.90 
[1.16–3.13, p<0.01] 
for 4th quartile VAT 
vs. 1st 
           
Yamaji et al. 
(356) 
2014 Japan Observational 
cohort of 
asymptomatic 
subjects 
907 CT derived at 
level of the 
umbilicus 
VAT area 
quartiles. Lowest 
quartile as the 
reference group 
Incident 
adenoma 
Yes No Adjusted OR 2.42 
[1.46–4.03, p<0.001] 
for 4th vs. 1st quartile 
           
Seo et al. 
(353) 
2017 South 
Korea 
Observational 
cohort 
309 L 3–4 
interspace 
VAT area 
quartiles. Lowest 
quartile as the 
reference group 
 
Incident 
adenoma 
Yes Not measured Adjusted OR 2.81 
[1.02–7.73, p<0.05] 
for 4th quartile vs. 1st 
           
Im et al. 
(346) 
2018 South 
Korea 
Observational 
case-control 
1163 CT derived at 
level of the 
umbilicus 
VAT area 
quintiles lowest 
quintile as the 
reference group 
 
Incident 
adenoma 
Yes No Adjusted HR 2.16 
[1.26–3.71, p<0.01] 
for 5th quintile VAT 
vs. 1st 
           
Jung et al. 
(347) 
2018 South 
Korea 
Observational 
case-control 
551 CT derived at 
level of the 
umbilicus 
VAT area 
quartiles. Lowest 
quartile as the 
reference group 
Incident 
adenoma, 
early or late-
stage CRC 
Y  
for adenoma, No 
for CRC 
Not measured Adjusted OR 3.90 
[2.11–7.20, p<0.001] 
for 4th quartile vs. 1st 
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6 THE INCIDENCE, IMPLICATIONS AND RISK 
FACTORS FOR INCIDENTAL EXTRACOLONIC 
FINDINGS AT CT COLONOSCOPY IN A BOWEL 
SCREENING POPULATION 
6.1 Introduction 
All members of the population aged from 50–74 years in Scotland are invited to take part in 
the SBoSP. The SBoSP has been described in detail previously (Section1.2.2). The 
screening programme accounts for 18% of all CRCs encountered in clinical practice in 
Scotland (140). Between November 2015 and October 2017, just over 1 million people in 
Scotland were screened for CRC with 20,000 (2%) returning a positive screening test (186). 
Approximately 16,000 (80%) of those with a positive screening test attended for 
colonoscopy (186). 
Not all colonoscopies in the screening programme are successfully completed and 
approximately 5-10% of cases end in failure to visualise the caecum (362). Public Health 
Scotland now release Key Performance Indicator (KPI) reports for bowel screening 
outcomes biannually, with the latest reporting an overall colonoscopy completion rate of 
96% (95% for females, 98% for males) (165).  
In addition, a proportion of patients are deemed unsuitable for colonoscopy due to either 
comorbid disease, the high burden of full bowel preparation or the inability to tolerate the 
procedure. In these cases, CTC can serve as an alternative for investigating the large bowel 
(Section 1.1.5 and Section 1.2.5). Published data report that approximately 2% of screened 
patients undergo CTC as their first-line investigation, rising to 9% in some centres (363) 
(364). CTC is a CT-based radiological scan specifically designed to examine the colon and 
rectum and was first introduced in 1994 (Section 1.1.5.1) (105). The test is increasingly used 
as a completion investigation in bowel screening programmes where colonoscopy has failed. 
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Studies have reported that for larger colonic lesions ( ≥1cm) and CRC, the sensitivity of 
CTC is comparable to colonoscopy (106). Nonetheless, a key consideration of CTC is the 
inadvertent detection of an incidental extracolonic finding (ECF); the advantage of this being 
the potential to encounter important abdominal, pelvic or lung base abnormalities that 
otherwise would have been undetected. However, these ECFs may trigger further 
investigation, potentially by invasive means, and may ultimately be found to be benign. This 
can result in additional resourcing costs and trigger unnecessary patient anxiety. 
Several studies have examined the prevalence and monetary cost of ECFs at CTC. These 
mainly considered symptomatic patients undergoing CTC in Korea (365), Australia (366, 
367) and the USA (368), but similar studies on asymptomatic patient populations have been 
carried out in the USA (108, 171, 369). However, in the UK, to our knowledge, only one 
study reports the prevalence and cost impact of ECFs at CTC (169). This study was 
published in 2006 prior to the rollout of the bowel screening programme. It examined a 
symptomatic population from a fast track bowel cancer clinic (169).  
Within the bowel screening population, patient characteristics such as age, sex, social 
deprivation, obesity and measures of body composition may be linked to extracolonic 
pathology. As such, the present study is the first to report the incidence, implication and risk 
factors for ECFs at CTC in patients undergoing CTC within the SBoSP.
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6.2 Methods 
Subjects, inclusion and exclusion criteria and data collection 
All patients who underwent CTC between July 2009 and February 2016 as part of the SBoSP 
in NHS GGC were eligible for inclusion. CTC was performed in screening patients deemed 
unfit for colonoscopy and in patients who had already undergone an incomplete or 
suboptimal colonoscopy. Data were collected from medical records including age, sex, BMI, 
smoking status, indication for CTC and socioeconomic deprivation. Socioeconomic 
deprivation was assessed using the SIMD system described previously (Chapter 3) (268). 
Measures of body composition were calculated as described previously (Chapter 5). 
CTC reports were scrutinised, and both colorectal findings (CRF) and ECFs from CTC 
colonoscopy (incomplete or otherwise) were recorded. Incidental ECFs were only included 
if they were documented in the official radiological report. CRFs were included as relevant 
only if they were subsequently clarified by colonoscopy. Patient medical notes and previous 
scans were examined in order to ensure only new, previously undocumented ECFs were 
included. Colonoscopy reports were matched to the CTC findings. 
Classification of CRFs and ECFs 
CRFs and ECFs were recorded using the CT Colonography Reporting and Data System (C-
RADS) (171, 370). The C-RADS system classes CRFs and ECFs simultaneously (171); 
CRFs are classed as C0 to C4 and ECFs are classed E0 to E4 by C-RADS using a hierarchical 
system. The C-RADS classification system with clinical examples are displayed in Table 
6.1 and Table 6.2. In patients where multiple ECFs were identified, a hierarchical system 
was used where the only most significant finding was included in the analysis.  
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CRFs follow-up 
CRFs C2–4 were investigated by colonoscopy if clinically feasible and appropriate according 
to the C-RADS criteria [Table 6.1]. The subsequent colonoscopy and corresponding 
pathology reports were examined to confirm the presence and nature of any significant 
CRFs. 
ECFs follow-up 
According to the C-RADS classification for ECFs [Table 6.2], only E3-4 findings require 
follow-up. However, some clinicians exercised clinical judgement by choosing to investigate 
some E2 and E1 on a case by case basis. For this reason, patient medical notes, pertaining to 
ECF-based follow-up, were examined for every patient regardless of the C-RADS 
classification. The following clinical encounters were recorded as follow-up. 
1. Outpatient appointment 
a. Consultant clinic 
b. Nurse-led clinic 
2. Further radiological procedure 
a. CT scan 
b. Ultrasound (US) scan 
c. MRI scan 
3. Invasive procedure 
a. Endoscopy 
b. Biopsy 
c. Blood sampling 
4. Other tests 
a. Bone scan or other non-specific tests 
5. Day surgery procedures 
a. Operative  
b. Endoscopic 
6. Inpatient stay 
a. Either surgical or non-surgical treatment 
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Specific exclusion criteria 
Patients with ECFs on CTC but without documented follow-up were identified and excluded. 
There were no other specific exclusion criteria. 
Cost analysis of benign disease 
The monetary cost of investigating subsequent benign disease was calculated. A previous 
UK study in 2006 reported on the NHS costs with regards to CTC in symptomatic patients 
(169). The researchers estimated the cost based on the NHS reference costs manual for 2004 
(now archived) (371). Since matters of healthcare budgeting in Scotland are devolved to the 
Scottish Government, the present study reports on costs (in British Pounds; £) specific to the 
NHS in Scotland. Public Health Scotland, and specifically the Information Services 
Division, hold and maintains data relating to health finance (372). This includes the Scottish 
health service costs manual, referred to as the “cost book”. The data are collated annually 
and are the only source of published NHS costs for Scotland (372). The cost book for the 
year ending 31st March 2017, published on the 21st November 2017, was the most up-to-date 
report available at the time of writing. Costs were calculated based on those published for 
the GGC health board, and where costs were only published for specific hospitals rather than 
on a regional level, Glasgow Royal Infirmary (GRI) was chosen as the base hospital. In the 
interests of transparency, a detailed description of how monetary costs were calculated is 
outlined below.  
Specific methodology for costing of services and investigations 
In determining the cost of a radiological investigation, the cost book for radiology services 
was accessed (373). The total gross expenditure per modality was divided by the total 
number of examinations in the year to provide an estimated cost per procedure, with the cost 
of a consultant or nurse-led outpatient appointment determined on a “per attendance” basis 
(374). Patients allocated an appointment that did not attend were included in the cost analysis 
since the cost is still incurred by the health service in these cases. Inpatient and day-case 
 215 
 
surgery costings were available and were grouped by speciality (374). Inpatient costs were 
calculated as the total cost per speciality per year and divided by the number of inpatients. 
Direct costing for endoscopy was not available; thus, endoscopy was classed as a 
gastroenterology day-case procedure (374). Direct laboratory service costs were available 
for pathological reports, clinical genetics and medical physics (375). Other laboratory works 
were not available on an itemised basis; therefore the cost of one blood test or non-itemised 
laboratory work was estimated as the cost for laboratory tests for a single day as an inpatient 
in GGC, with all specialities considered equal (374). The costs estimated in the present study 
reflect those incurred in hospital care settings only. It was not possible to accurately 
determine the number, if any, of primary care consultations in relation to ECFs.  
Statistical analyses  
Statistical analyses were carried out to assess the relationship between patient characteristics 
and the likelihood of detecting ECFs. Standard WHO categories for BMI were used for 
grouping. Age thresholds were selected based on established and validated age ranges used 
to stratify risk in CRC patients. A χ2 test was performed to determine statistical significance, 
and ORs were calculated to estimate risk. A p-value was calculated using a linear by linear 
approach where more than two groups were analysed from a single independent variable. In 
order to obtain ORs, binary logistic regression was used to compare categorical variables 
with two or more groups against a reference group. Any variables with p<0.1 on univariable 
analysis were included in the multivariable model. In all analyses, a two-tailed p-value <0.05 
was considered statistically significant. All statistical analyses were carried out using IBM® 
SPSS® Statistics version 22 (SPSS Inc., Chicago, IL, USA). 
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6.3 Results 
Study population 
400 patients underwent CTC during the study period and were eligible for inclusion. 6 
patients were lost to follow-up and were excluded leaving 394 patients in the analysis. The 
study group comprised of 146 (37%) males, the median age was 65 years [IQ range 59–71], 
and median follow-up time was 72 months [IQ range 46–86]. The indications for CTC in the 
present study are shown in Table 6.3. 92 (23%) patients underwent CTC as their first-line 
investigation, and 302 (77%) proceeded to CTC after failed colonoscopy.  
CRFs by patient 
Outcomes are shown in [Figure 6.1] Based on CTC findings confirmed by colonoscopy, 45 
(11%) patients had significant CRFs (C-RADS C2–4); of these patients, 36 (9%) were 
diagnosed with an adenoma and 9 (2%) with CRC. 
ECFs by patient  
Outcomes are shown in [Figure 6.2] In considering the whole study group, 244 (62%) 
patients were found to have a total of 368 ECFs. A breakdown of all 368 ECFs by severity 
are shown in Table 6.4. Considering only the 244 patients with ECFs, 179 (73%) patients 
had low significance C-RADS E2 findings, 33 (14%) had moderately significant C-RADS 
E3 findings, and 32 (13%) had highly significant C-RADS E4 findings [Figure 6.2]. In the 
overall study group (n=394), 179 (45%) patients had low significance C-RADS E2 findings, 
33 (8%) had moderately significant C-RADS E3 findings, and 32 (8%) had highly significant 
C-RADS E4 findings.
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Figure 6.1: Outcomes from CTC in relation to CRFs 
CTC as first-line 
investigation 
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CTC carried out 
(n=394) 
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(no follow up data) 
(n=6) 
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Significant CRFs requiring colonoscopy for 
clarification C-RADS C2-4 
(n=98) (25%) 
No significant CRFs 
(n=296) (75%) 
No neoplastic 
pathology 
(n=53) (54%) 
Invasive  
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(n=9) (9%) 
Non-advanced 
adenoma  
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Colonoscopy as first 
line investigation 
successful 
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Figure 6.2: Outcomes from CTC in relation to ECFs 
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Outcomes, investigations and treatments related to incidental ECFs 
In considering the study group as a whole (n=394), 59 (15%) patients required further 
investigation for incidental ECFs [Figure 6.2]. This represented 24% of the 244 patients 
with ECFs. 17 (29%) patients required endpoint treatment as a direct result of ECFs, and 5 
(9%) were entered into radiological surveillance programmes. Of the 5 patients entered into 
surveillance programmes, 3 were entered into a programme of regular abdominal aortic 
aneurysm (AAA) surveillance, 1 underwent regular review of a common iliac artery stenosis, 
and 1 was entered into CT surveillance for lung nodules. Of the 17 (29%) patients requiring 
endpoint treatment, 10 required major surgery. There were 3 AAA repairs, 2 pulmonary 
lobectomies, 1 small bowel resection, 1 colonic resection (non-neoplastic colovaginal 
fistula), 1 de-functioning colostomy (non-neoplastic colovesical fistula), 1 nephrectomy and 
1 hysterectomy. 3 patients began chemotherapy or radiotherapy for metastatic malignancy 
(breast, gastric, lung), 2 underwent endoscopic therapy including ERCP, while 2 patients (1 
with Crohn’s disease and 1 with benign prostatic hyperplasia) began lifelong medications. 
Cost analysis relating to benign ECFs 
37 (63%) patients who had further investigations for ECF were subsequently found have 
benign disease [Figure 6.2], and these patients required a combined total of 112 clinical 
encounters [Table 6.5]. These included 46 outpatient appointments at the cost of £8,441, 5 
invasive procedures (1 inpatient surgery, 1 day case surgery and 3 endoscopies) at the cost 
of £5,301, 43 radiological investigations at a cost of £3,405 and 18 laboratory tests at a cost 
of £442. The total estimated cost of investigating was ultimately benign disease over the 
study period was £17,589. 
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Host characteristics and the risk of ECFs 
Table 6.6 displays the relationship between host characteristics and the risk of finding ECFs 
at CTC. Older patients were more likely to have ECFs (p<0.05). There was a linear 
relationship between advancing age and the risk of ECFs with OR 1.90 [95% CI; 1.03–3.52, 
p<0.05] and 2.49 [95% CI; 1.00–6.17, p<0.05] for those aged 65–74 years and ≥75 years 
respectively, when compared with those aged <55 years. There were no associations between 
other host characteristics and the risk of finding ECFs at CTC.
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6.4 Discussion 
The present study is the first to report the prevalence, cost and potential risks factors for 
incidental ECFs at CTC as part of a UK bowel screening programme. The results suggest 
that incidental ECFs are common and more frequently diagnosed in older patients. 
Moreover, although the majority of ECFs are of little clinical significance, a proportion 
require further investigation at a cost to the healthcare service. Furthermore, the likelihood 
of detecting important colorectal pathology by CTC as part of a bowel screening programme 
is lower than the likelihood of detecting ECFs. 
CTC use is expected to increase 
CTC remains an important adjunct to, or in some cases as an alternative to colonoscopy 
when performed as part of a bowel screening programme. The use of CTC continues to 
increase as it becomes more accessible  and in the future patients may be allowed to choose 
this investigation modality following positive bowel screening (376). This would only be 
feasible if the patient was adequately counselled with regards to the risks and benefits of 
each procedure. In England and Wales, current guidelines do not recommend that patient 
choice should be considered a valid reason to refer for CTC (377). Furthermore, in England 
and Wales, bowel screening now begins at 50 years as opposed to the 60 years cut-off used 
previously, bringing the guidelines in line with Scotland (378). This will draw many more 
patients into screening and potentially CTC. For this reason, considering the implications of 
this test as part of screening is becoming more significant. 
The advantages and disadvantages of CTC within a bowel screening population 
CTC offers a number of advantages over colonoscopy. The examination is quicker, does not 
require the use of sedation and is generally well-tolerated. Generally, bowel preparation is 
milder, and there is no absolute requirement for intravenous contrast, thus reducing the risk 
of anaphylaxis (376). Many patients report CTC as more comfortable than colonoscopy 
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(105). The required dose of radiation for CTC is significantly lower than that used in 
standard CT scanning because of the high contrast between the air-filled colonic lumen and 
soft tissue (105). In addition, the risk of colonic perforation is low based on high volume 
studies (379, 380). Any test used for screening purposes must carry a low risk of returning 
false negative results since it is crucial not to miss pathology. A recent systematic review 
suggested that CTC is less sensitive for the overall detection of colonic lesions compared 
with colonoscopy (66.8% vs. 80.3% respectively) (106). Nonetheless, when considering 
larger polyps (≥1cm), sensitivity is comparable (91.2% vs. 92.9% for CTC and colonoscopy, 
respectively). When considering CRC only, large studies have reported a sensitivity of 
96.1% [95% CI; 93.8%–97.7%] for CTC vs. 94.7% [95% CI; 90.4%–97.2%] for 
colonoscopy (381). The above studies would suggest that, when required, CTC can serve as 
an attractive substitute for colonoscopy in a bowel screening programme as larger polyps 
and cancer are unlikely to be missed. 
The prevalence of ECFs 
A consequence of CTC is the high prevalence of incidental ECFs and the subsequent costs 
to the patient and healthcare service. In the present study, ECFs were detected in a significant 
proportion of patients (62%), which is similar to the data in previously published reports 
where ECF detection rates range from 46–69% (108, 169, 368, 382). In the present study, 
59 (15%) patients proceeded to further investigation as a result of ECF detection. Previous 
reports of potentially significant ECFs have ranged from 10–37%, while outlying studies 
have reported this to be as high as 45% (108, 171, 368, 369, 383-386) (365). The present 
study found that 32 (8%) patients had highly significant (C-RADS E4) findings [Figure 6.2], 
including malignancy and arterial aneurysmal disease which mirrors previous reports of 2–
10% (108, 171, 383, 384, 386). The finding that 32 (8%) patients in the present study were 
found to have highly significant ECFs could form an argument in favour of CTC. However, 
this should be conducted with care since closer inspection determined that only around half 
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(4% of the entire cohort) of these patients went on to require treatment as a result. Therefore, 
although it appeared that the yield of important ECFs overall was relatively low, it is 
accepted that the value allocated to this finding is subjective. Furthermore, several of the 
more significant ECFs included metastatic malignancy that was unsuitable for curative intent 
treatment. It is questionable whether the finding of late-stage metastatic malignancy is of 
any physical or psychological benefit to the patient. Another consideration are the 5 (1%) 
patients who, as a result of ECFs, were entered into long-term surveillance programmes for 
lung nodules and vascular disease. The cost-effectiveness of surveillance programmes, 
outside of national screening, which is usually local-guideline driven, remains unclear. 
The prevalence of ECFs vs. useful CRFs 
Another key consideration when offering a patient CTC is to balance any potential 
disadvantages of detecting ECFs with the likelihood of yielding important CRFs, specifically 
colorectal neoplasia. This is especially important when a CTC is conducted as a completion 
test after a colonoscope may have been used to visualise as far as the splenic flexure, thus 
covering the region where 70% of colorectal malignancies are usually found. It follows that 
in this situation, the likelihood of finding additional colorectal pathology with a completion 
CTC is likely to be low at the outset. This is supported by the findings of the present study. 
Within a bowel screening cohort, the primary aim is to examine the colon and rectum. As 
such, any test should be justified with respect to the potential yield of useful pathology. The 
present study showed that in the overall cohort, 45 (11%) patients had significant CRF 
(neoplastic) detected by CTC and confirmed by colonoscopy. This is broadly similar to 
previous reports of 14% for low-risk symptomatic patients (387), but substantially lower 
than the 32% of symptomatic high-risk (for CRC) patients (382). Crucially, it is also much 
lower than the combined standard colonoscopy yield for adenomas and cancer 
(approximately 40% in the SBoSP; (375). This indicates that any additional yield of useful 
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CRF from a completion CTC in asymptomatic screening patients is low when compared 
with symptomatic and standard bowel screening patients. 
CRF yield vs. ECF and patient consent 
In the present study, the relatively low colorectal pathology yield of 11% mentioned above 
can be compared to the 15% of patients who required additional investigation for ECFs, the 
majority (63%) of which were subsequently benign. Therefore, the likelihood of significant 
ECFs is higher than useful CRFs in this bowel screening cohort and must be considered 
when consenting patients for a CTC. It should be made clear to patients that they are subject 
to a 15% chance of ECFs which may cause anxiety and require further investigation versus 
the 11% chance of finding colonic neoplastic pathology, the majority of which are benign. 
Despite this, several patients may be willing to accept the risks, given that 4% of the present 
study group had significant ECFs that required endpoint treatment. 
In terms of consenting a patient for CTC, the above information amounts to a significant 
volume for a layperson as it is reasonably complex information. A significant number of 
patients in a screening cohort are elderly with comorbid disease. They may struggle to grasp 
or fully understand the implications of what they are consenting to. In this scenario, a 
significant responsibility remains with the clinician ordering the test who must use a 
balanced judgment to assess the risk: benefit ratio of that test for the specific patient on a 
case by case basis. Of particular interest in the present study was the finding that almost a 
quarter of patients (23%) had CTC as a first-line investigation, and the most common 
indication in these patients was a lack of fitness for colonoscopy. Thus, it is important to 
justify sending patients who are unfit for a colonoscopy, and therefore unlikely to be 
surgically fit, for a CTC whose primary aim is to detect colorectal malignancy but may, 
detect more ECFs. 
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Symptomatic vs. asymptomatic patients 
Another key consideration for the care provider ordering a CTC relates specifically to the 
population for its intended use. In symptomatic patients, where clinical manifestations are 
largely non-specific (e.g. abdominal pain, a minor rectal bleed or change in bowel habit), the 
decision for CTC is easier to justify given its added benefit as a diagnostic test for the 
extracolonic organs. In fact, in a large study of 10,000 participants, the rate of extracolonic 
cancers diagnosed by CTC was higher than that of CRC at 0.35% vs. 0.21%, respectively 
(388). Furthermore, a UK study mentioned previously investigated the prevalence of ECFs 
and CRFs in high-risk symptomatic patients referred for CTC and reported that 32% had 
significant CRFs (14% CRC, 19% adenoma(382). In this situation, any additional ECF 
detected would be acceptable, given the prevalence of useful CRF. This patient group differs 
from the asymptomatic bowel screening cohort in the present study, where the likelihood of 
ECFs should be balanced more cautiously with the lower likelihood of CRFs. 
The additional monetary cost of ECFs 
Colonoscopy is the investigation of choice in the SBoSP, although it is accepted that CTC 
is a safe and suitable alternative (389). Nonetheless, the present study calculated the 
additional cost to the NHS from the investigation of benign ECFs to be £17,589, or an 
additional £45 per CTC. This reflects only a modest increase in cost, but may underestimate 
the true figure as discussed later. This is the first study to our knowledge that reports 
specifically on the additional costs of investigating subsequently benign disease. Previous 
studies in the USA have reported the additional cost of investigating ECFs as approximately 
$34–50 per CTC (108, 368). However, both studies considered the cost of additional, ECF-
related, radiological tests only. Moreover, both studies calculated the cost of investigating 
any significant ECF regardless of whether they were benign or not. As such, it is difficult to 
draw comparisons with the present study, especially considering the differences between the 
private and public-funded healthcare systems of the USA and UK.  
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To date, only one previous study has estimated the cost of ECFs in the UK. Xiong et al., in 
2006, examined the CTC reports for patients referred from a “fast-track” CRC clinic and 
reported a higher estimated ECF-related cost of £153 per CTC (169) than the present study. 
However, their results are not comparable to the present study as the researchers calculated 
the cost to investigate and treat all ECFs, rather than calculating the cost of subsequently 
benign disease only. Nonetheless, it is of interest to compare this with the £45 additional 
cost (per CTC) of investigating only benign findings in the present study. It would seem 
reasonable that the additional £108 be spent on providing treatment for those who require it 
and who may benefit from the ECF findings.  
The additional non-monetary costs of ECFs 
Non-monetary costs of additional investigation related to ECFs include patient anxiety. In 
some cases this can be significant (390). In a publicly-funded health service such as the NHS, 
the undertaking of any voluntary screening test that potentially impacts on cost and patient 
anxiety should be carried out with caution. It should be considered that at the beginning of 
the bowel screening process, a patient is only initially consenting for an investigation of their 
colon and rectum, not their full abdomen and lung bases as would be the case with CTC. 
The present study was unable to capture the cost to patients in terms of anxiety and the 
potential discomfort of further investigations including endoscopy, biopsy, radiological 
investigation and, in some cases, surgical intervention. One patient in the present study 
underwent a laparotomy for what was found later to be benign disease. A diagnosis of ECFs 
that requires further investigation and is ultimately benign is akin to a false-positive result at 
bowel screening. A Scandinavian study by Brasso and co-workers demonstrated that patients 
suffered a similar degree and duration of anxiety when given a false positive bowel screening 
result compared with a true positive result (168). Although normal levels of anxiety returned 
by 12 months, these findings suggest there is a psychological impact as a result of false-
positive results.  
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In contrast to this are the results of a study in 2014 by Plumb and co-workers (391). They 
used face-to-face interviews and interactive laptop presentations to assess the attitude of 50 
healthcare professionals and 79 patients to false-positive ECFs at CTC. The interviews and 
interactive presentations used in the study were designed for participants to consider the 
implications of both false-positive results and subsequent investigations. Interestingly, 
although this was a small study in terms of numbers, the researchers found that patients were 
prepared to accept a high (99.8%) rate of additional imaging or invasive testing after CTC 
to reap the benefits of a potential early diagnosis of extracolonic malignancy (391). These 
results suggest that the impact of ECFs on patient anxiety is less of a concern than previously 
thought, and closer inspection may be of benefit. 
Risk factors for detecting ECFs 
Given that careful consideration must be made regarding the potential implications to the 
healthcare service and patients with ECFs, determining an “at-risk” population would be 
useful to aid decision making. In patients with a high risk of ECFs but a large burden of 
disease, clinicians may decide that the additional burden of potential ECFs would not be 
beneficial to the patient. For this reason, the present study sought to determine an “at-risk” 
patient population. Advancing age was associated with increased risk of ECFs. Those aged 
65 years or older were approximately twice as likely to have ECFs than those younger than 
65 years (p<0.05). This is in agreement with previously published work (367). BMI, visceral 
obesity, sarcopenia, social deprivation and smoking were not associated with a higher 
incidence of ECFs. Therefore, the present study can only suggest advancing age as a risk 
factor for ECFs. Clinicians should take this into account when considering the possible 
burden of ECFs on older patients prior to requesting a CTC.  
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Strengths and limitations 
The present study is the first to report the implications and costs of ECFs as a result of CTC 
in a UK bowel screening population, addressing an important and relevant topic. There were 
minimal patients lost to follow-up, allowing the use of an almost complete data set for 
analysis. The present study benefitted from an extended follow-up period (median 72 
months) thus enabling adequate time for completion of follow-up investigations to 
resolution. 
There are a number of limitations, however. The present study may underestimate the 
monetary cost of post-CTC investigations since data collection was only available from the 
role out of the SBoSP in 2009 to date of censor in August 2018. Some patients, such as those 
undergoing long-term surveillance, may continue on this path lifelong, or at some point 
require invasive investigation (e.g. CT-guided biopsy for indeterminate lung lesions). This 
prolonged follow-up is not captured in the present study. In addition, the retrospective nature 
of the present study meant it was unable to account for any associated primary care 
attendances, additional radiological reporting time, or hidden costs such as administration 
and transport. Furthermore, the present study was unable to quantify the non-monetary costs 
of ECFs to patients such as travel inconvenience, lost working hours, loss of productivity, 
anxiety, and discomfort from investigations. Nor was the present study able to estimate how 
long any anxiety persisted. Finally, patients being investigated by CTC as an alternative or 
adjunct to colonoscopy are likely to have a higher burden of comorbid disease and may be 
less representative of a standard bowel screening cohort. 
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Final conclusions and future work required 
CTC is likely to remain as a commonly utilised test within the UK Bowel Screening 
Programmes. It is feasible that its use will increase, both as technology advances and 
radiological tests improve, and as a result of an ageing population that is increasingly unfit 
for colonoscopy. The present study highlights some of the issues arising from the decision 
to offer CTC to patients in a bowel screening cohort, and in particular, those who are 
asymptomatic. Furthermore, the present study reports that ECFs are very common and more 
likely with advancing age. Within a bowel screening population, the incidence of ECFs may 
be higher than the useful yield of colonic findings at CTC. The implications of this in terms 
of further investigation, should be carefully discussed with the patient as part of the consent 
process. CTC as a test should be used judiciously in screening patients. Clinicians should 
have an awareness of the potential additional cost to both the healthcare service and the 
patient, both in financial terms and in terms of morbidity. 
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Table 6.1: C-RADS classification and examples of CRFs at CTC 
 
 
 
C-RADS classification 
 
Explanation and examples 
  
C0  
Inadequate study 
 
Inadequate preparation, inadequate insufflation 
  
C1  
Normal colon or benign lesion 
 
No polyp >5mm, recommend routine screening with 
CTC or colonoscopy in 5 years 
  
C2  
Intermediate polyp or indeterminate finding 
 
Polyps 6–9mm, <3 in number, recommend CTC 
surveillance or colonoscopy and polypectomy 
  
C3 
Polyp, possibly advanced adenoma 
Polyps ≥1cm, ≥3 polyps with each 6–9mm, 
recommend colonoscopy with polypectomy 
  
C4 
Colorectal mass, likely malignant 
 
Lesion compromises bowel lumen, shows extracolonic 
invasion, recommended surgical review 
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Table 6.2: C-RADS classification and examples of ECFs at CTC 
  
C-RADS classification Explanation and examples 
  
E0  
Limited examination 
 
Excluded scan 
Scan compromised by artefact, evaluation of extracolonic tissues limited 
  
E1  
Normal examination or 
anatomic variant  
No ECFs 
Extracolonic abnormalities visible, no workup indicated 
  
E2  
Clinically unimportant 
finding 
Low significance minor findings 
Benign conditions that do not require further medical therapy or 
additional work-up 
 • Calcifications 
• Granulomas 
• Diverticulosis 
• Simple organ cysts 
• Hernias without strangulation, obstruction or concerning features 
• Pleural thickening 
• Benign prostatic hypertrophy 
• Accessory spleen 
• Benign bony lesion 
• Bony degeneration and osteoarthritis 
• Fatty liver 
• Old renal infarction 
• Uterine fibroids 
• Simple ovarian cysts 
E3 
Likely unimportant, 
incompletely characterised 
Intermediate significance moderate findings 
Conditions not requiring immediate therapy but may require further 
investigation, clarification, monitoring or intervention at a later date 
 • Simple calculi 
• Intermediate cysts 
• Pulmonary fibrosis 
• Pulmonary nodules 
• Inguinal hernia 
• Uterine myoma 
• Endometriosis 
• Pelvic fluid collection 
• Liver cirrhosis 
• Liver haemangioma 
• Bile duct dilatation 
E4 
Potentially important finding 
High significance major findings 
Lesions requiring immediate intervention and/or urgent investigation 
 • A solid organ mass 
• Adrenal mass >3cm 
• Aortic aneurysm >3cm 
• Aortic dissection 
• Lymphadenopathy >1cm 
• Cardiomegaly 
• Pericardial effusion 
• Fistulation 
• Abscess 
• Small bowel infarction 
• Small bowel obstruction 
• Obstructing ureteric calculi 
• Complex ovarian cyst or adnexal mass 
• Lytic bone lesions 
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Table 6.3: Indications for CTC as part of the bowel screening process 
Reason for CTC 
 
n (%) 
  
All patients 394 (100) 
  
CTC after a failed colonoscopy  302 (77) 
  
• Technical failure to complete colonoscopy  190 (63) 
  
• Patient discomfort resulting in the withdrawal of consent 59 (19) 
  
• Poor bowel preparation resulting in inadequate views or failure to progress colonoscopy 45 (15) 
  
• Inadequate views 8 (3) 
  
CTC as the first-line investigation 92 (23) 
  
• Comorbidities resulting in an unreasonable risk of complications or technical difficulty  55 (14) 
  
• Indication for CTC not clear from medical notes 13 (3) 
  
• Patient choice/refusal for standard colonoscopy 12 (3) 
  
• Previous failed optical colonoscopy either due to patient discomfort or technical difficulty 10 (3) 
  
• Serious complication from previous standard colonoscopy (perforation) 1 (0.5) 
  
• Patient unable to tolerate full bowel prep for standard colonoscopy 1 (0.5) 
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Table 6.4: Incidental ECFs on CTC by C-RADS criteria 
C-RADS All ECFs1 
 
n (%) 
 
   
  368 (100) 
   
E4               High significance major findings 
 
 32 (9) 
 • Abdominal aortic aneurysm (AAA) 5 
 • Lung mass, suspected malignancy 4 
 • Complex adnexal mass (suspicious) 4 
 • Bony lesion (possible metastases) 3 
 • Renal mass (suspicious) 3 
 • Organ-to-organ fistula 2 
 • Pancreatic mass (suspicious) 2 
 • Small bowel mass/abnormality (suspicious) 2 
 • Pelvic collection 1 
 • Peri-colic collection 1 
 • Spinal stenosis 1 
 • Stomach mass 1 
 • Abnormal gallbladder 1 
 • Pulmonary arteriovenous malformation (bleeding risk) 1 
 • Hydronephrosis (new/unexplained) 1 
   
E3               Intermediate significance moderate findings 
 
 45 (12) 
 • Adnexal cystic lesion (benign) 9 
 • Biliary duct dilatation (new/unexplained) 7 
 • Osteopenia/osteoporosis 5 
 • Lung nodules (indeterminate) 4 
 • Atypical renal cysts (more likely benign) 3 
 • Bulky uterus (indeterminate cause) 2 
 • Common iliac artery stenosis (new) 2 
 • Thickened endometrium 1 
 • CBD stones 1 
 • Abdominopelvic lymphadenopathy 1 
 • Abnormal appearance of the common bile duct  1 
 • Dermoid cyst 1 
 • Breast tissue density (indeterminate) 1 
 • Gastric polyp 1 
 • Liver hypodense lesions (undefined) 1 
 • Lytic bony lesion (low suspicion) 1 
 • Non-aortic small vascular aneurysm 1 
 • Pancreatic cyst (low suspicion) 1 
 • Prostatic enlargement 1 
 • Splenic artery aneurysm 1 
   
E2               Low significance minor findings 
 
 291 (79) 
 • Liver cysts (benign) 40 
 • Cholelithiasis 39 
 • Renal cysts (benign) 38 
 • Spinal degenerative change (bony or disc) 32 
 • Fatty liver 31 
 • Hiatus hernia 30 
 • Adrenal adenoma 15 
 • Renal calculi 8 
 • Inguinal hernia 9 
 • Uterine fibroids 6 
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 • Ventral abdominal wall hernia 7 
 • Spinal wedge fracture 6 
 • Renal cortical scarring 5 
 • Spondylolisthesis 5 
 • Chronic pancreatitis 3 
 • Pleural plaques (chronic) 3 
 • Benign prostatic enlargement 2 
 • Haemangioma of liver 2 
 • Small bowel diverticulum 2 
 • Duodenal lipoma 1 
 • Renal atrophy 1 
 • Splenic atrophy 1 
 • Rib fracture 1 
 • Duplex kidney 1 
 • Neurofibroma 1 
 • Meckel’s diverticulum 1 
 • Gastric diverticulum 1 
 
 
1244 patients had a total of 368 ECFs 
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Table 6.5: Itemised cost of the clinical workup for subsequently benign ECFs 
Clinical encounter 
 
n  Method / coding used to calculate cost Per 
item 
(£) 
 
Total 
(£) 
     
All clinical encounters 112   17,589 
     
Outpatient appointment 46   8,441 
     
Gynaecology 19 Consultant outpatient clinic per visit NHS GGC 201 3,819 
General Surgery 15 Consultant outpatient clinic per visit NHS GGC 162 2,430 
Urology 5 Consultant outpatient clinic per visit NHS GGC 145 725 
Radiology1 2 Consultant outpatient clinic per visit NHS GGC 199 398 
Haematology 2 Consultant outpatient clinic per visit NHS GGC 266 532 
Neurosurgery 1 Consultant outpatient clinic per visit NHS GGC 200 200 
Vascular Surgery 1 Consultant outpatient clinic per visit NHS GGC 175 175 
Breast 1 Consultant outpatient clinic per visit NHS GGC 162 162 
     
Invasive test/treatment 5   5,301 
     
Endoscopy2 3 Day case gastroenterology per case NHS GGC 654 1,962 
Inpatient surgery3 1 Inpatient gynaecology per case NHS GGC 2,549 2,549 
Day case surgery4 1 Day surgery general surgery per case NHS GGC 790 790 
     
Radiology investigation 43   3,405 
     
US5 Scan 20 US scan Glasgow Royal Infirmary 48 960 
CT5 Scan 12 CT scan Glasgow Royal Infirmary 77 924 
MRI5 Scan 6 MRI Glasgow Royal Infirmary 180 1,080 
Isotope bone scan 2 Gamma camera Glasgow Royal Infirmary 150 300 
Plain x-ray/mammogram 2 Classed as “other radiology” NHS GGC 47 94 
DEXA Scan6 
 
1 Classed as “other radiology” NHS GGC 47 47 
Laboratory tests 18   442 
     
Blood tests 14 Laboratory cost per day as inpatient NHS GGC 25 350 
Tissue biopsy7 
 
4 Cost per examination of specimen NHS GGC 23 92 
 
1Classed as “medical other” outpatient clinic in costing book 
2Included diagnostic and therapeutic endoscopy 
3Laparotomy and ovarian cystectomy 
4Open lymph node biopsy 
5Abbreviations as previously defined 
6Dual energy x-ray absorptiometry (DEXA) 
7Cost to examine the specimen does not include the cost of collecting the specimen 
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Table 6.6: The relationship between host characteristics and the incidence of ECFs at CTC 
Baseline characteristics All 
patients 
(%) 
No ECFs 
(%) 
ECFs 
(%) 
OR 
(univariable) 
p-value 
      
All patients 394 (100) 244 (62) 150 (38)   
      
Age (years)      
     <55 55 (14) 28 (19) 27 (11) 1.0 - 
      55–64 135 (34) 52 (35) 83 (34) 1.66 [0.88–3.11] - 
      65–74 170 (43) 60 (40) 110 (45) 1.90 [1.03–3.52] - 
      75+ 34 (9) 10 (6) 24 (10) 2.49 [1.00–6.17] 0.03 
      
Sex      
     Female 248 (63) 92 (61) 156 (64) - - 
     Male 146 (37) 58 (39) 88 (36) 0.89 [0.59–1.36] 0.60 
      
BMI1 (kg/m2) groups       
      20–24.9 (normal weight) 75 (24) 30 (25) 45 (23) 1.0 - 
      <20        (underweight) 22 (7) 9 (7) 13 (7) 0.96 [0.37–2.53] - 
      25–29    (overweight) 90 (29) 40 (33) 50 (26) 0.83 [0.45–1.55] - 
      30+        (obese) 127 (40) 43 (35) 84 (44) 1.30 [0.72–2.35] 0.41 
      
Visceral obesity (all sexes)      
      No 79 (23) 30 (24) 49 (22) - - 
      Yes 272 (77) 95 (76) 177 (78) 1.14 [0.68–1.92] 0.62 
      
High SFI2      
      No 38 (13) 16 (16) 22 (12) - - 
      Yes 246 (87) 87 (84) 159 (88) 1.33 [0.66–2.66] 0.42 
      
Sarcopenia2      
      No 131 (46) 50 (49) 81 (45) - - 
      Yes 153 (54) 53 (51) 100 (55) 1.17 [0.72–1.89] 0.54 
      
Social deprivation quintile      
      5 (least deprived) 68 (18) 22 (15) 46 (19) 1.0 - 
      4  45 (12) 15 (10) 30 (13) 0.96 [0.43–2.13] - 
      3 60 (15) 22 (15) 38 (16) 0.83 [0.39–1.72] - 
      2 79 (20) 35 (23) 44 (18) 0.60 [0.31–1.18] - 
      1 (most deprived) 137 (35) 56 (37) 81 (34) 0.69 [0.38–1.28] 0.13 
      
Smoking status      
     Never smoked 133 (35) 46 (31) 87 (37) - - 
     Ever smoked 249 (65) 101 (69) 148 (63) 0.78 [0.50–1.20] 0.25 
      
CTC first-line test2      
     No 302 (77) 193 (71) 109 (73) - - 
     Yes 92 (23) 51 (21) 41 (27) 1.42 [0.89–2.29] 0.14 
      
Intracolonic findings      
      Nil 349 (89) 132 (88) 217 (89) 1.0 - 
      Adenoma 36 (9) 17 (11) 19 (8) 0.68 [0.34–1.35] - 
      Cancer 9 (2) 1 (1) 8 (3) 4.87 [0.60–39.35] 0.13 
 
 1Data available for 314 patients 
 2Data reliant on height measurement. Available for 284 patients 
 3CTC first-line in those who went straight to CTC without a prior colonoscopy 
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7 CONCLUSIONS AND FUTURE WORK 
7.1 Overview of thesis 
Colorectal cancer has been associated with a number of risk factors. Some of these risk 
factors are modifiable, while others are not. In order to minimise CRC incidence, an 
understanding of the risk factors themselves and how they might be modified is of high 
importance. From the outset of this research project, it was clear that colorectal adenomas, 
as pre-malignant entities, are modifiable risk factor for CRC.  
Logic dictates there are two ways in which this risk factor can be modified. Firstly, by 
reducing primary adenoma incidence and secondly, by reducing recurrence in those who 
have undergone polypectomy. Identifying risk factors for adenoma incidence and recurrence 
and setting out to modify and mitigate them is likely to be of benefit in reducing subsequent 
CRC incidence. 
Although previous work has been conducted examining the influence of various risk factors 
for incident and recurrent colorectal adenomas, there is significant heterogeneity between 
study designs. At the time of writing this thesis, there was a lack of uniform agreement on 
which risk factors are most relevant, the magnitude of their effect, the interaction between 
them, and the applicability of the results to different populations. This explains why post-
polypectomy guidelines are in constant evolution and may demonstrate why those from the 
UK, EU and USA differ. Therefore, contributing to the knowledge base in this important 
and costly topic was of value.  
In Scotland, adenomas are most commonly identified as a result of the bowel screening 
programme. Post-polypectomy surveillance is costly to both the patient and to healthcare 
services. Screening was still largely in its infancy in Scotland at the start of this research 
period having been rolled out in 2009. Examining the factors associated with adenoma 
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incidence and recurrence in this specific group; the better to target finite resources, was 
desirable. The literature was notable in that a sizeable body of work examining adenoma risk 
factors originated in the USA and Southeast Asia. There are clear social, demographic, 
physical and racial differences between patients from Southeast Asia and the UK, and more 
specifically, the Scottish population. As such, the validity of these studies as a guide to 
adenoma risk factors, their modification, and post-polypectomy surveillance, within a West 
of Scotland bowel screening population is questionable. 
At the beginning of this period of research, the current BSG guidelines for post-polypectomy 
surveillance recommended follow-up colonoscopy based solely on the size and multiplicity 
of colorectal adenomas found at the index colonoscopy (15). It was unclear to what extent it 
was possible to detach the host from the adenoma; therefore, an examination of the 
association between adenoma incidence and recurrence, and non-adenoma host factors such 
as age, sex, BMI, social deprivation and body composition was of interest.  
Chapter 1 provided an overview of CRC, summarising the implicated risk factors, 
treatment, and prognostic indicators. CRC screening was discussed, including the rationale, 
outcomes and risks of screening. Moreover, a detailed overview of the classification, natural 
history, suspected risk factors and management of adenomatous polyps of the colon and 
rectum was outlined. 
Chapter 2 explored the relationship between host factors and their influence on colorectal 
adenoma recurrence after polypectomy; the aim of which was to quantify the association 
between age, sex, BMI and adenoma recurrence. These three variables were selected as they 
represent host characteristics that are quantifiable and could be used to group patients for a 
personalised screening and post-polypectomy surveillance schedule. An attempt was made 
to identify an “at-risk” group which would allow optimal utilisation of surveillance 
colonoscopy in a selected group of individuals with the highest risk of developing future 
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adenomas, advanced adenomas, or cancer. The results are presented as a systematic review 
and meta-analysis, which pooled raw data available in the published literature. The meta-
analysis suggested that worldwide, advancing age, male sex and higher BMI were risk 
factors for adenoma recurrence. However, there were limitations with significant 
heterogeneity between study design, sample population and reporting of results. This 
questioned the validity of the results in a West of Scotland population. Nonetheless, the 
findings did present an argument for host factors to be considered in future surveillance 
guidelines. 
With this in mind, the work presented in Chapter 3 was designed to examine the role of host 
characteristics in identifying a high-risk group for adenoma and advanced adenoma 
recurrence in a representative UK screening population. This was conducted by collecting 
original data from the first round of the West of Scotland Bowel Screening Programme, the 
benefit of which was an extended median follow-up time of >6 years. In addition, Chapter 3 
also explored the association between adenoma-specific factors and the risk of recurrence, 
since adenoma size and multiplicity are included in UK post-polypectomy guidelines. The 
analysis suggested that a higher adenoma number was associated with recurrence at 
surveillance but not advanced adenoma recurrence. In addition, the presence of advanced 
adenomas at baseline was associated with subsequent advanced adenomas at follow-up. 
However, the analysis did not support the incorporation of host factors into existing 
surveillance guidelines with the results supporting the current BSG guidelines. Nonetheless, 
the research did suggest that patients with advanced adenomas, in addition to those with 
multiple and large adenomas, should be considered as high-risk for surveillance purposes. 
Importantly, the results support the new inclusion and definition of “advanced adenomas” in 
the latest 2020 BSG surveillance guidelines  that were published during the latter stages of 
thesis preparation (392). Finally, although the present study did not find an association 
between BMI and adenoma recurrence, there was evidence of a weak association between 
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BMI and the development of subsequent advanced adenomas. Based on this, and given the 
modifiable nature of BMI as well as other measures of body composition, further evaluation 
of this relationship was warranted, which formed the basis of Chapters 4 and 5. 
The main aim of Chapter 4 was to gain insight into the determinants of initial colorectal 
neoplasia formation as opposed to recurrence. Of particular interest was the SIR. It is well 
established that systemic inflammation is associated with poor prognosis and survival in 
established CRC. However, the stage at which this systemic inflammation can modify the 
cancer development pathway, and the mechanisms that underpin it, are complex and not 
fully understood. This chapter examined the relationship between host characteristics, 
colorectal neoplastic incidence, and the SIR, with a focus on pre-malignant disease. A 
prospective cross-sectional study was designed to gather data over a two-year period to 
determine these relationships. The study found evidence for an association between 
advancing age and colorectal neoplasia. In addition, when adjusting for age, smoking and 
CRP, subjects taking aspirin were less likely to have neoplasia, a finding which has 
previously been reported in a wide-ranging systematic review (393). A link between 
clinically detectable systemic inflammation and neoplasia incidence was not found. It is 
likely that the level of inflammation during the pre-malignant disease stage is at a low level 
and may not be detected clinically. However, it is plausible that this low-grade inflammation 
contributes to genetic damage in the pre-malignant stage and thereafter, a tumour promoting 
effect leading to established cancer. In the initial stages of this project, there was 
consideration given to host characteristics strongly associated with CRC (e.g. advanced age, 
male sex and higher BMI). Logic suggests there was a linking mechanism between these 
host factors, the development and progression of neoplastic lesions, and the SIR appeared to 
be a plausible link. The results demonstrated that systemic inflammation at a clinically 
detectable level was significantly associated with higher BMI, smoking and possibly with 
increased socioeconomic deprivation. There was no demonstrable evidence for a direct link 
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between host factors, systemic inflammation and neoplasia. The use of a cross-sectional 
study design to examine systemic inflammation may be suboptimal, and further work could 
be considered to explore this. 
Chapter 5 examined the relationship between CT-derived body composition and colorectal 
neoplasia in a bowel screening population. The results of the meta-analysis in Chapter 2 
suggested higher BMI was associated with colorectal neoplasia in the form of adenoma 
recurrence, yet work in Chapter 3, and Chapter 4 failed to replicate this finding in a bowel 
screening population, potentially as a result of varying patient demographics, as mentioned 
previously. However, having noted that higher BMI was associated with systemic 
inflammation in Chapter 4, and given the known links between inflammation and cancer, it 
was considered that adiposity might still be associated with early neoplastic formation and 
that BMI was not the optimal measurement. Accordingly, work to explore the relationship 
between adiposity in different body compartments and colorectal neoplasia was undertaken. 
The results presented in Chapter 5 showed that visceral obesity was associated with 
increased colorectal neoplasia incidence, even when the data were adjusted for age and sex. 
VAT is known to be associated with metabolic disturbance and cardiovascular disease. It is 
therefore likely that hormones synthesised in this tissue play a part in early genetic damage 
and neoplasia formation. In addition, sarcopenia is a feature of established CRC and cancer 
cachexia. The results did not support an appreciable association between sarcopenia and 
colorectal neoplasia in this population. The study group however, were largely patients with 
pre-malignant adenomas rather than established neoplasia. It is likely that this feature 
becomes more evident during the transition from the pre-malignant disease to established 
cancer. 
In conducting research for Chapter 5, the resource burden of the bowel screening 
programme was noted. Despite the benefits of screening, there are risks involved, and the 
question arose as to what extent screening should be pursued at all costs? During the analysis 
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of CTC scans for Chapter 5 it was noted that the patient being deemed unfit for colonoscopy 
was often an indication for the utilisation of CTC. Patients deemed unfit, or borderline, for 
colonoscopy would not likely be fit for subsequent curative intent cancer treatment. This 
raised the question as to whether investigating these patients was the most efficient use of 
limited resources. 
Chapter 6 sought to estimate the prevalence, outcomes, and costs of ECFs in an 
asymptomatic bowel screening population, the first study of its kind in the UK. The detection 
of a significant number of ECFs is a problem of particular note in a bowel screening 
population where the aim is to examine the colon and rectum specifically. When 
volunteering for screening, a patient is only consenting to have their colon and rectum 
investigated at the outset. However, although 11% of patients were found to have significant 
colorectal findings, 15% were actually found to have significant ECFs that required 
additional workup. The majority of these were subsequently found to be benign. This chapter 
concluded that careful consideration and consenting is important when offering a patient any 
test to screen the colon and rectum that will also screen the entire abdomen and lung bases, 
with a higher chance of detecting non-colorectal, indeterminate disease. Patients must be 
made aware of the disadvantages of this approach and the potential useful yield, while 
clinicians need to be aware of the potential burdens on both healthcare resources and their 
patients before proceeding to CTC as a screening test, in a largely unfit population. 
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7.2 Future work 
This thesis is an examination of the interplay between the pre-malignant neoplasm and the 
host, the better to prevent neoplastic formation and recurrence. Chapter 3 indicated that 
adenoma factors seemed to be stronger predictors of future risk than host factors and, 
therefore, future work should focus more specifically on the adenoma. The consideration of 
this has, in part, led to the launch of the Integrated Technologies for Improved Polyp 
Surveillance (INCISE) project; a multi-million-pound project, led by the University of 
Glasgow and NHS GGC. The aim of the project is to combine the latest developments in 
digital pathology with genomic and transcriptomic analyses of excised polyps. The INCISE 
project will utilise machine learning to develop a risk-stratification tool to better determine 
the need for follow-up colonoscopy after polypectomy. During the period of thesis 
preparation, the BSG released their updated 2020 guidelines on post-polypectomy 
surveillance. For the first time, as a marked deviation from the 2010 guidelines, it is notable 
that specific adenoma features (e.g. HGD) are included in the definition of an advanced 
adenoma for risk stratification (392). This further highlights the need for ongoing 
examination of the pre-malignant polyp and how it may aid prediction of future risk (394).  
Moreover, UK guidelines for post-polypectomy surveillance have historically considered all 
adenomas of the colon and rectum as one entity for screening, risk stratification and 
surveillance purposes. This is unchanged in the most recent guidelines. However, it is known 
that the acquisition of mutations appear to vary between tumours of the colon and rectum. 
Their management differs substantially, especially with regards to neoadjuvant and adjuvant 
treatment. Although data were not available to examine this during the present study period, 
future work may consider colon and rectal adenomas as separate entities. This may enable 
the separate study of their behaviour both in isolation and in combination with host 
characteristics. It may be that rectal adenomas and colonic adenomas should be treated 
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separately, given the disparity in incidence between CRCs of the proximal and distal portions 
of the colon or rectum. 
The relationship between the SIR and early, largely pre-malignant disease was explored in 
Chapter 4. No association was found between systemic inflammation and the presence of 
colorectal neoplasia. Nonetheless, during thesis preparation, a well-conducted study was 
published in 2020, suggesting that elevated CRP was associated with colorectal adenomas 
incidence (395). The researchers report the OR of finding a colorectal adenoma as 1.71 [95% 
CI; 1.12–2.62, p<0.05] in males and 2.86 [95% CI; 1.26–6.49, p>0.05] in females when 
comparing the highest quartile CRP group to the lowest. The results were even more 
pronounced when considering advanced adenomas. The researchers used 23,000 patients 
with laboratory CRP measurements to validate a predicted CRP model based on patient 
characteristics. They achieved consistent results when using either laboratory or predicted 
CRP measurements.  
Therefore, further examination of the relationship between systemic inflammation and pre-
malignant disease is warranted. Ethical approval for an extension of the study time frame in 
the prospective study reported in Chapter 4 was granted during the writing of this thesis. 
Ongoing data are being collected on CRP, BMI, host characteristics and bowel screening 
outcomes. This will enable further detailed analyses with enhanced study numbers and 
follow-up. Additional data are also being collected regarding dietary habits, and faecal 
samples for calprotectin have been requested. These data will enable future expansion of the 
work presented in Chapter 4 to include a more in-depth analysis of the association between 
systemic inflammation, local intra-colonic inflammation, dietary habits and early colorectal 
neoplasia. 
Building on the results of Chapter 5 which examined the relationship between body 
composition and colorectal neoplasia, it would be useful to compare the characteristics of 
 245 
 
this screening group who are largely pre-malignant, with those who have established cancer. 
Exploring body composition differences between patients with pre-malignant disease and 
established cancer could enable a further understanding of the changes that take place during 
this transition, paving the way for further studies to evaluate the precise mechanisms that 
underpin this relationship.  
The clear association between visceral obesity and colorectal neoplasia reported in Chapter 
5, indicates that there may be a “teachable moment” for bowel screening patients. The 
relationship between visceral obesity and metabolic syndrome is well known. A recent large 
epidemiological study in South Korea suggested that metabolic syndrome is associated with 
CRC development independently from sex, HR 1.22 [95% CI; 1.20–1.24] (396). The 
researchers note that the association is stronger in males than in females and that abdominal 
obesity, according to WC using an Asia-Pacific cut-off, is a leading risk factor (397). 
However, it is not clear to what extent abdominal obesity is associated with or reflects 
visceral obesity in this population. Further studies examining this relationship would be 
useful.  
In addition, the well-established links between visceral obesity and metabolic syndrome, 
non-insulin dependent diabetes and cardiovascular disease suggest that targeted diet and 
exercise regimes to reduce visceral obesity specifically may be a worthwhile interventional 
option(398). Indeed, this is an area of active research where the potential benefits may extend 
beyond CRC prevention to other comorbid diseases. Of interest, a recent report discussed 
the elevated incidence of major cardiovascular events (MACE) in survivors of CRC (399). 
The increased prevalence of MACE may limit the ongoing improvement in overall survival. 
The researchers examined a cohort of 2,839 CRC survivors, within 10 years of diagnosis. 
They determined that while BMI was of limited use in predicting MACE, visceral adiposity 
and muscle radiodensity were predictors of risk. Further work in this field and development 
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of a cancer-specific MACE scoring system could allow physicians to refine risk management 
for this growing population of cancer survivors.  
The fight against colorectal cancer is an ongoing one, however it is encouraging to observe 
the extensive effort and resources that are dedicated to reducing incidence and mortality 
from this disease. It is hoped that the work carried out in this thesis, its continuation, and the 
recent extensive funding secured by the University of Glasgow will contribute positively to 
the improvement of colorectal cancer services for patients in the future. 
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